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Executive Summary  
Introduction 
The International Diabetes Federation’s Life for a Child Program (IDF-LFAC) was 
established in 2001 with support from the Australian Diabetes Council and HOPE 
worldwide. Its purpose is to increase access to life-saving insulin and diagnostic 
tools for children and young people with type 1 diabetes (T1D) under the age of 
25 in low and middle-income countries, many of whom die within one year of 
diagnosis. The program uses a simple formula whereby monetary and in-kind 
donations are given to established diabetes centers and associations, enabling 
them to provide the ongoing clinical care and diabetes education children need 
to stay alive. The recipients in turn provide comprehensive clinical and financial 
feedback to the IDAF-LFAC management team in Sydney, Australia. 
IDF-LFAC aims to provide: (1) insulin and syringes; (2) blood glucose monitoring 
(BGM) equipment; (3) appropriate clinical care; (4) HbA1c testing; (5) diabetes 
education; and (6) technical support and training for health professionals, as 
well as 7) facilitating relevant clinical research, and where possible 8) assisting 
with capacity building. IDF-LFAC receives financial and in-kind support from 
private foundations, individuals, and corporations. Insulin and blood glucose 
monitoring equipment distribution is made possible by donations of insulin and 
the purchase of blood glucose monitors and strips at a reduced price from large 
pharmaceutical companies.  
Evaluation Goals 
The goal of this evaluation is to assess IDF-LFAC’s organizational structure, 
strategic framework, processes, program impact, and potential to catalyze long-
term sustainable improvements to T1D care delivery systems in its partner 
countries. LSHTM were commissioned to undertake the evaluation in 2014 when 
IDF-LFAC had active programs in 45 countries. 
Methods 
In order to carry out this evaluation, a multi-faceted approach was adopted. This 
consisted of: 
a) In depth interviews with key informants from IDF-LFAC and others with 
knowledge of its work 
b) Review of documentation on the operation of IDF-LFAC  
c) Field visits to five countries, to assess the IDF-LFAC operation on the 
ground. The countries were identified in consultation with IDF-LFAC and 
chosen on the basis of geography (at least three continents), length of 
IDF-LFAC presence in a country, number of children served by IDF-LFAC 
programs, overall state of T1D care in the country, strength of the 
country’s health system and size of health budget, economic development 
(low and middle income countries), and ability to coordinate travel with 
IDF-LFAC staff, volunteers, and evaluation team members.  
The countries visited were Rwanda, Jamaica, Mexico, the Philippines and 
India (Nagpur).   
d) An electronic survey of all recipient countries receiving IDF-LFAC 
support, designed to provide sufficient information to capture the 
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diabetes environment in each country and to situate the work of IDF-
LFAC within it.  
Findings 
The review covers five themes: 
• IDF-LFAC structure and organization 
• Optimal strategic framework for high impact sustainable results 
• Changes to polices that could improve quality, quantity, efficiency and 
effectiveness 
• Impacts on countries, systems and children 
• Impact on long term sustainability in T1D care delivery systems 
This review overall shows that it is a strong program that is delivered well and is 
highly valued by the countries and the children young people and their families 
who are supported by the program. It is clear that the program enables children 
and young people with T1D to survive and as the program and country policies 
strengthen enables them also to thrive. 
The IDF-LFAC program already does many things right and the team, albeit 
small, are extremely dedicated and enthusiastic and deliver the program well. 
Many aspects are to be applauded and continued.  
The review identifies IDF-LFAC’s strengths and challenges. It focuses particularly 
on their engagement in-country and on how they develop a strategic direction 
for care and treatment of T1D. It identifies a need for developing country 
leadership and building local capacity, implementing approaches that catalyze 
systemic improvements in T1D care delivery systems.  
The ultimate goal must be for people with T1D to be able to get good treatment 
and care within their country’s health system. Unfortunately this does not 
appear to be a realistic goal in the short term in most countries. Nevertheless, 
there is a need for a higher priority to be given to the medium and long term 
sustainability of the support provided for children with T1D, making full use of 
the experiences gathered by IDF-LFAC and the information that it has gathered 
on burden of disease, health needs, and barriers to be overcome in obtaining 
effective care by people with T1D. 
The five themes are explored in depth and recommendations made in relation to 
each and in relation to the specific countries visited.  
Recommendations 
The main recommendations identify a number of key issues:  
• Strengthening the initial process when deciding to start an IDF-LFAC 
program in a country, both in terms of needs assessment, so that the program 
is focused on children in most need, and with a clear strategy to embed IDF-
LFAC within the health system of the country and to gain ‘buy in’, for the 
longer term from the Ministry of Health, ideally with a MOU and an exit 
strategy. This will require leadership from IDF. Mechanisms to strengthen 
leadership within country are also recommended, which again will require 
leadership from IDF but also specific external expertise for leadership skill 
development.  
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• Further enabling countries to be self-sufficient, by encouraging peer to peer 
development, enhancing expert input, utilizing the IDF-LFAC website for 
supportive resources and developing a newsletter. Whilst these may require 
initial focus and resource they should in time streamline the work of the LFC 
team.  
• Education and training has been identified as a recurring theme and all the 
countries surveyed recognize the need both for further training of health care 
personnel and of children and families and awareness raising in the general 
population. Many of the existing educational materials developed by IDF-
LFAC are excellent and welcomed but some require translation in terms of 
both language and culture.   
• Education, vocational training and support to children and young people to 
enable them to be self-sufficient when they reach adulthood has been 
developed in a number of countries and needs further focus to expand to 
other countries.   
• Enhancing the robustness of data collection from the program, both in terms 
of systems and in terms of requiring feedback from countries, to build into a 
powerful database across 45 countries and use the data to demonstrate the 
burden of disease. This should include outcome measures both throughout 
the program and when young people ’age out’. 
• Finally we identified that there is much experience and a wealth of 
knowledge held in the heads of the IDF-LFAC team and suggest this should be 
captured by commissioning an oral historian.  
 
This report seeks to enable the IDF-LFAC program to take stock of its activities, 
enhance the elements that are already working well, and refocus on the areas 
that have been identified that, we believe, will enhance its effectiveness and 
sustainability. However, it is recognized that this will require specific funding for 
‘start-up’ of some elements and will also require some specific external expertise 
and for IDF to take a greater leadership role.  
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Introduction 
The International Diabetes Federation’s Life for a Child Program (IDF-LFAC) was 
established in 2001 with support from the Australian Diabetes Council and HOPE 
Worldwide. Its purpose is to increase access to life-saving insulin and diagnostic 
tools for children and young people with type 1 diabetes (T1D) under the age of 
25 in low and middle-income countries, many of whom die within one year of 
diagnosis. The program has adopted a simple formula whereby monetary and in-
kind donations are given to established diabetes centers and associations, 
enabling them to provide the ongoing clinical care and diabetes education 
children need to stay alive. The recipients in turn provide comprehensive clinical 
and financial feedback to the IDAF-LFAC management team in Sydney, Australia. 
IDF-LFAC aims to provide: (1) insulin and syringes; (2) blood glucose monitoring 
(BGM) equipment; (3) appropriate clinical care; (4) HbA1c testing; (5) diabetes 
education; and (6) technical support and training for health professionals, as 
well as 7) facilitating relevant clinical research, and where possible 8) assisting 
with capacity building. IDF-LFAC receives financial and in-kind support from 
private foundations, individuals, and corporations. Distribution of insulin and 
blood glucose monitoring equipment is made possible by donations of insulin 
and the purchase of blood glucose monitors and strips at a reduced price from 
large pharmaceutical companies. These are then shipped to recipient countries. 
According to its website, IDF-LFAC currently has a presence in 48 countries, 
reaching 15,000 children and has plans for further expansion.  
From 2011-2014, the Leona M. and Harry B. Helmsley Charitable Trust’s Type 1 
Diabetes Program provided approximately US$700,000 annually to IDF-LFAC, 
representing half to three quarters of IDF-LFAC’s total annual revenue during 
that time.  The Helmsley Charitable Trust commissioned the London School of 
Hygiene and Tropical Medicine (LSHTM) to undertake an independent 
assessment of the impact and organizational capacity of IDF-LFAC. The results of 
this evaluation are intended to guide any future funding to IDF-LFAC and inform 
the Helmsley Charitable Trust’s Type 1 Diabetes Program strategy development 
overall. 
Evaluation Goals 
The goal of this evaluation is to assess IDF-LFAC’s organizational structure, 
strategic framework, processes, program impact, and potential to catalyze long-
term sustainable improvements to T1D care delivery systems in its partner 
countries. In carrying out this evaluation program, materials have been reviewed 
and a wide array of stakeholders have been consulted to identify IDF-LFAC’s 
strengths and challenges, with a particular focus on discerning the extent to 
which IDF-LFAC’s engagement in-country is developing, or could develop 
country leadership and catalyze systemic improvements and local capacity 
building of T1D care delivery systems.  
Terms of reference 
Before work began on the evaluation, the Helmsley Charitable Trust met with the 
LSHTM evaluators and agreed on a series of questions with which to frame the 
structure of the report. The findings and recommendations have been fed back 
and discussed with staff of the Helmsley Charitable Trust and with the IDF-LFAC 
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team as well as with senior IDF staff. Based on these discussions, proposals are 
made for taking the findings forward in the work of all the parties involved.  
This report describes the evaluation, including the methodologies used and 
findings and makes recommendations in relation to the evaluation goals. 
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Methods 
In order to carry out this evaluation, a multi-faceted approach was adopted. This 
consisted of: 
a) In depth interviews with key informants from IDF-LFAC and others with 
knowledge of its work 
b) Review of documentation on the operation of IDF-LFAC  
c) Field visits to five countries to assess the IDF-LFAC operations on the 
ground. The countries were identified in consultation with IDF-LFAC and 
chosen on the basis of geography (at least three continents), sufficient 
duration of IDF-LFAC presence in a country, number of children served by 
IDF-LFAC programs, overall state of T1D care in the country, strength of 
the country’s health system and size of health budget, economic 
development (low and middle income countries), and ability to coordinate 
travel with IDF-LFAC staff, volunteers, and evaluation team members.  
d) An electronic survey of all recipient countries receiving IDF-LFAC support, 
designed to provide sufficient information to capture the diabetes 
environment in each country and to situate the work of IDF-LFAC within it.  
 
The evaluation was undertaken by a 
team comprising Dr Sue Atkinson 
(SA), Ms Miranda Eeles (ME), Ms Zoe 
Atkinson (ZA), and Dr Louise Sigfrid 
(LS), under the overall direction of 
Professor Martin McKee (MM), 
Professor of European Public Health, 
LSHTM. PHAST (Public Health Action 
Support Team), a not for profit, 
Community Interest Company, 
supported the work by identifying 
some team members and translation 
support. 
Interviews with key informants: 
Interviews were conducted with members of staff from IDF-LFAC, IDF head 
office, and others who have knowledge of the program. Interviews were 
conducted with an array of stakeholders, including beneficiaries of the IDF-LFAC 
program and their families during the country visits. A full list of interviewees is 
in appendix 1 
Review of documentation: A comprehensive portfolio documenting its 
operation was provided by IDF-LFAC and reviewed with staff during a meeting 
with MM in Sydney in September 2014. 
Field visits: Field visits, each lasting between five and ten days, were conducted 
to the following countries: 
• Rwanda (8th – 14th May 2014)  
• Jamaica (21st – 26th July 2014) 
• Mexico (25th October – 3rd November 2014) 
• Philippines (10th -17th December 2014) 
• India (3rd - 11th January 2015) 
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The field visits were arranged through 
IDF-LFAC and the relevant national 
diabetes association. The team 
consisted of SA, (all 5 countries) ME 
(Rwanda and Jamaica), ZA (Jamaica, 
Philippines and India) and Dr John 
Shanks (Mexico) with support from 
London by LS and MM. The team, with 
support from LS and together with the 
local diabetes association/lead 
coordinator in each country visited, 
and with advice from IDF-LFAC, 
arranged to meet a series of people 
involved with the delivery of IDF-LFAC 
and with health services delivery 
within the country.  
As well as the ‘country’ questionnaire, 
which was completed during the visit, 
a series of interview schedules 
(appendix 8b) were developed for discussion with various categories of people 
within the country—including health workers in clinics and health centers 
treating children and young people with diabetes; Ministry of Health personnel; 
WHO country staff; partner organizations including NGOs such as Oxfam and 
commercial entities; children, young people and their families; experts and 
mentors. The full list of people 
interviewed is in appendix 1. Most of 
the visits and interviews were 
undertaken face to face, while most of 
the children and families were 
interviewed in their own homes, 
which provided a picture of their local 
circumstances. In many countries the 
staff of the diabetic association 
described the areas where the 
beneficiaries lived as ‘slums’. A few 
interviews were undertaken via Skype 
or telephone, depending on 
availability of interviewee and 
geography. Consent was given by all interviewees in the field visits (consent 
form appendix 9). Most interviews were conducted in English, but some required 
interpretation into French (Rwanda), Spanish (Mexico) and some local languages 
(e.g. India, Philippines). The visit team themselves provided French and Spanish 
interpreting, but for local languages the local diabetic association staff acted as 
interpreters.  
The first visit undertaken was to Rwanda. This was arranged to ‘piggy back’ on 
an already arranged visit including key IDF-LFAC personnel (Graham Ogle (GO)), 
partner organizations (Marjorie’s Fund and Team Type One), together with 
external experts and researchers who are undertaking work and support in 
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Rwanda.  The Ministry of Health arranged a meeting with partners to discuss 
their ongoing involvement and strategy and facilitated a meeting with the 
Minister of Health. This provided an excellent overall introduction to IDF-LFAC 
and related health service issues for the visit team, who added further meetings 
to the visit, for example with WHO and Oxfam.  
Summaries of the country visits and recommendations in relation to specific 
countries are at Appendices 3 to 7.  
Survey: Following discussions with the Helmsley Charitable Trust and IDF-LFAC, 
an electronic survey (appendix 8) was designed, piloted, and translated from 
English into French and Spanish (for use as appropriate) before being sent to 38 
recipients of IDF-LFAC support not 
receiving a field visit. Responses 
were obtained from 35. The non-
responders were Burkina Faso, 
Iraq and Uganda. In addition there 
were the five surveys from the 
country visits, so a total of 43 
countries were surveyed with 40 
responses (response rate of 93%). 
The survey was not sent to two 
countries with established 
programs. In Morocco the program 
was on hold because of illness of a 
key individual and in Papua New 
Guinea the IDF-LFAC program 
supports only 1 child.  
In passing, it should be noted that several respondents welcomed the survey, 
noting how, as one said, completing it had been an ‘eye-opener’, making them 
consider how they might influence government and support sustainable health 
services in a way that they had not previously considered 
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Findings 
We begin by describing the IDF-LFAC’s structure and mode of operation, where 
appropriate commenting on issues that arise that are relevant to its ongoing 
operations. 
IDF-LFAC’s organizational structure; strengths, weaknesses, and implications 
The IDF-LFAC Program was established in 2000 with support from the then 
Australian Diabetes Council (now Diabetes NSW) and HOPE worldwide. It is 
managed by Diabetes NSW, on behalf of the IDF. Day to day management is 
undertaken by the general manager, Dr Graham Ogle, who is accountable to a 
Steering Committee and also, via the IDF Chief Executive Officer (supported by 
the Director of Policies  and Programmes, Director of Partnerships and Director 
of Communications and Advocacy) to the IDF Board. Figure 1 shows the 
organizational structure and lines of formal accountability.  
Figure 1 IDF-LFAC organizational structure 
 
 
The IDF and IDF-LFAC program are geographically separate, with the former 
based in Brussels and the latter in Sydney. However, despite the distance and 
time zones that separate them, relationships between the IDF-LFAC staff and the 
IDF headquarters are good, and appear to have been so for some time, although 
we came to understand that, in the past, while IDF was pleased to be associated 
with IDF-LFAC, it was largely left to its own devices. Over the past two years the 
links between the two bodies seem to have become closer, following extensive 
changes in management at IDF headquarters, so that IDF is now taking a much 
greater interest in the work of IDF-LFAC than was the case in the past. Inevitably, 
however, the geographical distance involved between IDF and IDF-LFAC is a 
barrier to closer engagement, although key staff typically meet several times a 
year at various diabetes-related meetings.  
We understand that these arrangements may change in the near future. On 10th 
March 2015 the IDF General Assembly adopted new Articles of Association that 
provide a legal basis for creating subsidiaries. The IDF Board will now decide on 
the next steps, which may include creating a subsidiary in Australia for IDF-LFAC 
as well as a 501(c ) (3) ‘friends of’ in the USA that would manage donations from 
the USA in support of IDF-LFAC. This would be a so-called “Friends of” 
organization but would be governed by a separate board, with three out of five 
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members being US citizens, and would be organizationally independent of both 
IDF-LFAC and IDF. If these changes take place, it has been suggested that IDF-
LFAC staff transfer to that subsidiary, but their work would be supplemented, by 
additional staff in IDF, who could develop future work on strengthening health 
systems.  
The model adopted by IDF-LFAC since its inception has been one of rapid 
growth, extending coverage to approximately 5 new countries per year and 
exiting from very few. As a consequence, it is now supporting partners in 48 
countries, with five started in 2014 and several new candidates under 
consideration, including some that are among the most difficult countries in the 
world to work in, such as North Korea, Syria, and the Central African Republic. 
IDF-LFAC staff are strongly supportive of this approach, citing the many 
achievements that it has delivered and the openness of the program to any 
country wishing to participate.  
The core staff number fewer than five full time equivalents. IDF-LFAC justifies 
this as it is, in effect, operating a franchise, IDF-LFAC is managed in each country 
by a diabetes association, or similar, and with considerable outsourcing of 
practical arrangements. Thus, most insulin is shipped by UTI, a pharmaceutical 
distribution company based in Johannesburg (which has the advantage that, as 
the insulin is sourced in South Africa, it is labeled in English and Afrikaans, so if it 
did appear on the market in countries it is being supplied to, it would be 
instantly recognizable). Strips are distributed by Fedex. The national diabetes 
associations are responsible for making arrangements with customs authorities 
to import insulin and other materials, where necessary arranging for duty to be 
paid (see later). In some countries, such as the Philippines, insulin and other 
supplies are sourced locally but funded by IDF-LFAC.  
 IDF-LFAC selects countries in an ad hoc way, based mostly on requests from 
local diabetes associations or medical professionals (Table 1), although some 
requests come from other organizations working in the field of diabetes or child 
health, such as Insulin for Life and Operation Mercy. IDF-LFAC has established 
informal criteria for accepting new partner countries. Most, but not all, are 
members of the IDF. There have been some proactive attempts to identify local 
partners where IDF-LFAC had not previously operated, such as in Malawi. On 
several occasions, those seeking support have been declined, primarily because 
of concerns about their organizational capacity and, in particular, the absence of 
an identifiable local champion. 
Table 1 Organizations initiating discussions about receiving IDF-LFAC 
support 
Organization/representative Percentage 
(number) of 
respondents 
 
National Diabetes Organization 30.6 % (n=11) 
Senior Medical Professionals 19.4 % (n=7) 
Ministry of Health 2.8% (n=1) 
Patient(s) with Type 1 Diabetes 8.3% (n=3) 
Other (please specify) 38.9% (n=14) 
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IDF-LFAC staff confirm that they do undertake an initial questionnaire/ needs 
assessment in each country they work in, often conducted by an external ‘expert’, 
but  only 50% of respondents to the survey reported that the IDF-LFAC support 
was informed by a formal needs assessment, while 22% reported that it was not 
and 28% did not know. The ‘needs assessment’ comprises a questionnaire 
concerning such issues as the number of children with T1D and numbers that do 
not have access to insulin etc. Other mechanisms for ‘needs assessment’ in 
relation to diabetes have been developed, notably the RAPIA (Rapid Assessment 
Protocol for Insulin Access)(Beran, Yudkin et al. 2006). A modified RAPIA was 
undertaken in the Philippines in 2008 but it does not appear to have been used 
by IDF-LFAC, nor by local endocrinologists, who, somewhat surprisingly, seemed 
unaware of the RAPIA research. Overall, the survey showed low awareness of 
number of children with T1D in the country; only one respondent seemed aware 
of the IDF Atlas (Patterson, Guariguata et al. 2014), an invaluable resource that 
has synthesized data on numbers of children and young people with T1D 
worldwide, with a major input from IDF-LFAC. Where the RAPIA has been 
undertaken, it afforded useful links between NGOs and IDF-LFAC. Consideration 
needs to be given as to how to develop a more robust ‘needs assessment’ 
approach, which could ensure that the children most in need, are being 
supported by IDF-LFAC and local diabetes associations. For example, in Mexico 
the IDF-LFAC program is delivered through state-based diabetes associations, 
involving those who already have the capacity to manage the IDF-LFAC program 
effectively. However these are not in the poorest states and IDF-LFAC is aware 
that they are not therefore reaching the children most in need.  
Certain issues arise from this overview of IDF-LFAC’s structure and processes, all 
raising important questions about its resilience to unexpected events.  
First, its funding base is highly concentrated. At present about 50% comes from 
the Helmsley Charitable Trust, and 25% from a BNP Paribas foundation, 
Fondation de l’Orangerie. The program would be very vulnerable if it lost either. 
IDF and IDF-LFAC recognize the importance of diversifying its sources of funding 
(appendix 10). 
Second, its operations are highly dependent on one individual, GO. Although he 
has seemingly boundless zeal and energy, there are inevitable questions about 
the ability of IDF-LFAC to cope should circumstances lead to his absence from 
the program. Given the number of children whose lives depend on its continuity, 
this must be a matter of great concern. We were advised that IDF-LFAC has 
discussed such a situation but there are no clearly articulated contingency plans. 
We were told that, at least in the short term, Martin Silink (chair of the Steering 
Committee) would assume some day to day responsibility, with support from the 
program manager (once someone is appointed to replace Robyn Short-Hobbs, 
who has recently departed), with some ad hoc support from a community of 
local pediatric endocrinologists. While not doubting the commitment of these 
individuals, we are not fully convinced that this could be more than a very 
temporary solution. A longer term, but related issue is the leadership of IDF-
LFAC following the retirement of GO. GO plans to continue for another 10 years 
and anticipates the successor will be appointed during this period. However, 
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there would be clear advantages to allowing a potential successor to grow into 
the post, becoming familiar with its activities and progressively taking over 
responsibility. Though nothing would need to be done in this respect for a few 
years yet, we recommend that IDF-LFAC take time now to develop an explicit 
plan that can address both contingencies related to GO’s work and, in the longer 
term, succession planning. 
We have been impressed by the wealth of knowledge about IDF-LFAC and its 
recipients that GO has accumulated. We believe that it is important that this 
knowledge be institutionalized within IDF-LFAC, as well as ensuring that the 
lessons that have been learned are available to other organizations involved in 
similar activities. For this reason, we recommend that IDF commission an oral 
historian to document the experience with IDF-LFAC. We also explored the 
related issue of security and resilience of managerial information necessary for 
the sustainability of operations. We were reassured that there are robust 
arrangements for remote backup of documentary material and data. 
A third concern relates to the very small core staff. As the organogram (Figure 1) 
shows, it has fewer than 5 FTE staff. Although the staff are all highly motivated, 
and they can draw on other volunteers for visits to countries, this does seem a 
remarkably small complement, given the workload. IDF-LFAC staff concede that 
the staff are spread extremely thin. Given the immediate needs of getting insulin 
and supplies to partners, it was reported that it was fundraising activities that 
tended to be displaced (although this raises questions about the balance of 
activity with respect to fundraising between IDF and IDF-LFAC). We recommend 
that the core staff be strengthened by the appointment of an additional 
administrator in Sydney. We believe that this should be considered a higher 
priority for available funding than expansion to additional countries. 
Fourth, while the franchising model has many advantages, it places 
responsibilities on the recipients that they are not always able to accomplish. 
Thus, IDF-LFAC distributes diabetes education materials in different languages. 
It was apparent from the country visits that these materials are very well liked 
and seem to be effective both with children and young people and their families 
and with professionals. However, they do need to be translated into local 
languages and be produced in ways that are culturally appropriate. For example, 
in Jamaica families would have liked more ‘visual’ materials such as comic books, 
cartoons as they regard themselves as not a ‘reading’ nation. Some educational 
materials have been translated into various languages and some are available via 
the IDF-LFAC website. Consequently, we recommend that national associations 
be required to take more responsibility, building upon the work of IDF-LFAC in 
their countries but going beyond it, including adapting educational materials by 
means of ‘in country’ translations and adaptations. 
Finally, IDF-LFAC has expanded rapidly into a large number of countries. 
However, in some the number of children being supported was extremely small 
(1 in Papua New Guinea) and although we were advised that type 1 diabetes is 
extremely rare in Melanesian populations, it seems implausible that there were 
not many more that were being missed. There is clearly a question of whether 
support on such a small scale is viable. Although we were reassured that the 
additional workload was extremely small, clearly it is finite. A different issue 
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arises in some countries where the need for IDF-LFAC support is clearly very 
large, but where they were only able to reach a very small proportion of the 
population, such as India, Pakistan, and Mexico. We recommend that IDF-LFAC 
review their criteria for working in countries where either they can support only 
a very small number of children or where the contribution is minimal in relation 
to the total disease burden, thereby giving them limited leverage in advocating 
for the structural reforms that will be needed to create a sustainable model of 
care. 
How can IDF-LFAC achieve high-impact, sustainable results in partner 
countries? 
Measuring success 
We explored the question of how IDF-LFAC defines and measure the success of 
its work in each country. IDF-LFAC was able to articulate a clearly defined and 
appropriate vision, “that no child should die from diabetes” and a mission 
statement (Box 1). However, it was less clear that these words, which do not 
appear on their website, have been clearly communicated to their partners. 
Box 1 IDF-LFAC Mission Statement 
To support provision of the best possible health care, given local circumstances, 
to all children and youth (under 26 years of age) with diabetes in developing 
countries, through strengthening the services in these countries. 
Conduct clinical research and international advocacy so as to improve diabetes 
care for children and youth, and where possible help both adults and also 
recipient countries with achieving sustainability. 
Success is, first and foremost, defined by IDF-LFAC as evidence that care is 
improving. IDF-LFAC has operationalized this under three headings: stop deaths 
from occurring; provide “standard care” for all eligible children (adequate 
insulin, self-monitoring with at least 2 strips per day, regular HbA1c tests, and 
diabetes education); and reduce and prevent complications.  
This can, in theory, be monitored using data supplied to IDF-LFAC on a range of 
process measures (e.g. increased diagnosis, children treated, spread throughout 
the country, improved data collection systems) and outcome measures (survival, 
fewer admissions with diabetic ketoacidosis, HbA1c levels). However, although 
IDF-LFAC has developed a web interface to support data collection, in English, 
French, Spanish and Russian (http://database.lifeforachild.org/lifeforachild/) 
only a few countries are using it and there is limited capacity to analyze the 
results of what is actually a major data monitoring exercise. The issues of data 
and monitoring are discussed further below. Two practical obstacles were noted. 
One is that the University of Sydney, consistent with common practice in high- 
income countries, requires evidence of approval by a local ethics committee 
before it will permit analysis of data on individual children. This is a very 
complex and expensive procedure in some countries. The second is that the 
database is internet based and some countries have difficulty with consistent 
connectivity and are not therefore able to input data successfully. This is being 
addressed by IDF-LFAC, which is exploring various alternative options.  
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The survey of national associations provided mixed evidence of progress in 
changing the management of diabetes in the countries (Table 2). Although 83% 
believed that the management and control of those children known to have 
diabetes had improved, only 42.5% believed that there had been an increase in 
the numbers of children correctly diagnosed. 48% believed that services now 
covered a wider geographical area than before IDF-LFAC partnered with them 
and 38% believed that staff training had improved. Less than half thought there 
was greater awareness of diabetes among the population. Of course, it is clearly 
not possible to attribute these changes specifically or with certainty to the work 
of IDF-LFAC but it is noteworthy that the respondents did believe that IDF-LFAC 
had played some role. From the country visits there was a strong view that IDF-
LFAC had made a profound difference to children and young people with T1D in 
those countries. Most identified increases in diagnoses, better management, 
fewer hospitalizations (especially for diabetic ketoacidosis (DKA)) and gradually 
improving HbA1c levels.  
Table 2 Positive impacts of the IDF-LFAC program, as identified by survey 
respondents 
 Yes No Missing/ don’t 
know 
Numbers being correctly diagnosed 17 (42.5%) 7 (17.5%) 16 (40%) 
Diabetes management and control 33 (83%) 1 (3%) 6 (15%) 
Wider geographical coverage in 
diagnosis, treatment and care 
19 (48%) 10 (25%) 11 (27%) 
Staff training 15 (38%) 17 (42%) 8 (20%) 
General awareness in the wider 
population about Type 1 diabetes 
17 (42%) 14 (35%) 9 (23%) 
 
Some specific examples were cited, such as how “We have also engaged with the 
media and patients have explained the symptoms they had at the beginning on 
national TV” (Kenya) and how “LFAC has built hope. We lost one child but the 
other 6 would have surely died. Thanks to IDF-LFAC we have been operating for 4 
years and the children are relatively well, coming to the ‘clinic’ every two weeks 
from far away distances. They are glad to come” (Liberia). There were also 
broader benefits for children and their families: “Parents economy has improved - 
when they don’t have to buy strips, so they can buy better food instead” (Mexico). 
Other impacts mentioned included:“Progress is real but very slow; in former years 
children and youth died, now they survive longer” (Democratic Republic of Congo), 
“Training during camps from IDF-LFAC staff help families and local staff update 
knowledge, and share information” (Fiji), and “None of our children has presented 
with severe ketoacidosis nor needed hospitalization for several years” (Bolivia). 
Respondents provided many positive examples of differences to the health and 
wellbeing of the children receiving support that partners attributed to the work 
of IDF-LFAC (Table 3). 
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Table 3 Examples of ways that IDF-LFAC has impacted on the lives of children  
Bangladesh 
LFAC is reducing the huge burden of Social welfare department of 
BIRDEM by providing care to these children. 
Bolivia 
We have now the satisfaction of providing insulin and supplies to ALL 
children or young person diagnosed with Diabetes, the IDF-LFAC 
program makes a big difference Before it was very difficult for many 
families to buy Insulin and they often reduced the doses needed to 
make the insulin bottle last longer or let the kids get worse and die.  
Most children and youth diagnosed in recent years have not reached 
the point of ketoacidosis, as parents or paediatricians have directly 
identified diabetes as a cause of the symptoms presented and have 
taken proper and effective measures securing them endocrinologist 
specialist or paediatric endocrinologist care. 
Burundi 
Currently, children with diabetes are well followed up as they benefit 
from receiving insulin, glucometers and syringes, whereas previously 
they were almost abandoned. 
Cambodia 
The cost of testing regularly is about $30 per month which is far 
beyond the means of most people in Cambodia, so the provision of 
glucometers and test strips is a huge benefit for our patients. 
Congo 
The positive difference in terms of glycaemic self-monitoring. Before 
the program the majority of children did not have glucometer and 
controlled blood glucose once a month, now they are 2 per day or 60 
day blood glucose. 
Democratic 
Republic of 
Congo 
We started in 2000 and got support from IDF-LFAC in 2003. So 
improvement was from nothing to something. Progresses are slow. 
Before, most of the patients died after a few months of diagnosis: 
usually lack of insulin and DKA. Now they survive, some of them for 
more than 10 or 15 years. I am working in diabetes since 40 years and 
this program is the best and most respectful I ever worked with. They 
accept our failures and shortcomings with patience. Other programs 
are more demanding and refuse assistance if we cannot comply with 
their requirements.  
Now at least in Kinshasa most people or doctors know where to go for 
treatment when a young patient has diabetes 
Dominican 
Republic 
Helping us with as little as the supply of an A1C Machine has been a 
good help to provide something we don’t have. 
Ecuador 
The difference is positive, because the children that receive the insulin 
from IDF-LFAC would not have the chance to survive without it; it has 
brought them the possibility to improve their quality of life. 
 If we wouldn’t have the IDF-LFAC support we could not attend the 
children with type 1, because we opened the “programa de 
apadrinamiento” since we receive their insulin support. 
Ethiopia 
Lack of insulin was our major concern and through IDF-LFAC children 
are able to stay alive but a lot has to be done since this is a big country 
with focus on communicable diseases, hence we still need to work 
hard to put diabetes on the front.  
Through the program we were able to do posters and distribute 
educational materials and the diagnosis rate has improved as the 
number of children reported from each centre increases. 
Fiji Establishment of local guidelines to manage DKA, other situations 
such as sick days, surgery etc. 
Guatemala We already have 105 children and youth that are likely to be self-
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monitoring and for 42 of them access to free insulin is thus helping to 
better manage their diabetes. 
Guyana 
The training that was done in March I was personally able to work 
with a private physician on a newly diagnosed 7 year old boy. Once 
this program is properly implemented it can make a big change and 
work wonders for Type 1. 
Haiti 
The most important thing is that children and young adults stay alive. 
Before, as the parent cannot afford the insulin, they had to leave the 
child die 
With the availability of the insulin and materials, children and young 
adults can stay alive and try to avoid complications. Children and 
young adults living outside of the capital of Port-au-Prince can receive 
the materials and insulin at the affiliated center of FHADIMAC where 
they are followed for their diabetes 
India 
LFAC is saving many lives in resource poor communities in India. 
Where no child had survived prior to IDF-LFAC we now have 56 
children leading a normal life. However due to limited resources has 
not been able to provide long acting insulin, training of health care 
professionals and partner with local organizations to start a dialog 
for national policy for children with type one diabetes. 
Kenya 
The negative is the children have to check blood sugars, which they 
couldn’t afford and now they think it is a lot of work. The positive is we 
are able to manage them with blood sugar controls. The HbA1c has 
gone down because now they understand. 
Liberia 
It may not be perfect, but we are going to buy time until the 
technology on IDM gets better. We know this way of blood sugars 
averaging 200 is not good enough but it is a step in the right direction.  
LFAC has built hope. We lost one child but the other 6 would have 
surely died. Thanks to IDF-LFAC we have been operating for 4 years 
and the children are relatively well, coming to the “clinic” every two 
weeks from far away distances. They are glad to come. They come 
with their coolers and pack of ice for check-up and insulin 
Mali 
It’s just an amazing impact on Mali from 14 children with type 1 
diabetes few years ago with life expectancy less than 1 year after 
diagnosis to 300 children with type 1 managed in six regions of Mali 
with diabetes clinics equipped for this and health professionals 
trained 
Nigeria With the availability of insulin fewer are dying, the insulin is 
distributed to all over the country 
Pakistan 
My patients cannot afford insulin or the strips. Now they know how to 
control their sugars. It is an amazing difference in their lives.  
One of my patients has had leg cramps for the past 3 years. In the book 
they recommend Amitriptyline. When we started that she immediately 
improved. She is grateful not to have the leg cramps any more. 
Tajikistan Insulin shortages have been a major problem in the past, particularly 
as the type 2 population has grown and taken precedence. IDF-LFAC 
provision of insulin has reduced the stress felt by families who wonder 
whether there will be insulin for their children. Glucometers have 
allowed some endocrinologists to train their patients in daily blood 
glucose testing, which has assisted with the adjustment of insulin and 
improvement in blood glucose control The glucometers have the 
potential to really improve the blood glucose control of children, but 
need to be accompanied by education for both the families and 
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endocrinologists. The provision of supplies is at this point keeping the 
children alive - but because of low education the insulin and 
glucometers are not being used to their full potential. Since 
distributing IDF-LFAC insulin and glucometers, the wider 
endocrinology community has seemed to be more aware and 
interested in type 1 diabetes. 
Uzbekistan 
Provision with self-control tools, constant monitoring improved “team 
work” of “patient-parents-doctor” team (within Life for a child 
program) resulting in more tight control of glycaemia and, as a result, 
in decrease of acute and chronic complications and mortality among 
children and teenagers with type 1 diabetes 
Vietnam Helping patients monitor their complications better 
Source: respondents to the survey of country organizations (verbatim comments) 
 
While these examples provide evidence that the program is very well received at 
country level, it is widely accepted that, ultimately, countries should become self-
sufficient with regard to the management of children with diabetes. Thus, a key 
measure of success is the ability of IDF-LFAC to exit from a country, leaving a 
sustainable model of care in place. Progress in this regard has been much less. So 
far, IDF-LFAC has only succeeded in exiting from two countries (Romania, 
Montenegro), where the government took over responsibility. In a few other 
cases, governments have expanded their role but gaps remain (e.g. Azerbaijan, 
an oil rich country now supplies each diabetic with a far from adequate 50 strips 
per year) and IDF-LFAC remains engaged. In discussions during the course of the 
evaluation, some other countries were identified where, it was agreed, exit 
should be possible in the short term such as the Cayman Islands and Fiji. In fact, 
exit from Fiji took place during the evaluation, offering lessons that can be used 
to develop a generic policy for exit strategy, which should be codified for use 
elsewhere. There is also a strong argument for having, however tentative, a plan 
for ‘exit’ at the commencement of the IDF-LFAC program in each country. Such 
an exit strategy needs to be part of the overall model of care showing the 
‘evolution’ of progress of IDF-LFAC.  
Exit strategies can benefit from the momentum provided by the almost certain 
inclusion of universal health care in the post 2015 development agenda. We 
explored IDF-LFAC’s goals at the international and the national level. Staff 
accepted completely the need for much stronger advocacy in the international 
arena, linking access to insulin with wider movements for access to essential 
medicines and universal health care, while taking advantage of the post-2015 
development agenda. However, while the evidence that IDF-LFAC collects could 
be used to support such an advocacy strategy, including stories from those 
children being supported, it was recognized that there was insufficient capacity 
to engage meaningfully in this process at present. This is, however, an area 
where IDF could play a much greater role in association with the NCD Alliance 
and its members, where IDF already plays an active role, as well as organizations 
such as Health Action International, with their focus on access to essential 
medicines. 
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Making a difference 
We explored IDF-LFAC’s theory of change that they use to achieve their goals. 
This has several components: 
• Working through existing organizations, already recognized as centers of 
excellence in provision of care; 
• Working with and supporting local champions; 
• Incremental improvements in care, progressively introducing new elements 
and not overwhelming local implementation capacity; 
• Transfer of expertise through advice and mentoring; 
• Flexibility and complementarity in working with partner organizations 
 
Additional elements, undertaken where feasible, include support for clinical 
research, vocational training and related measures to support youth 
transitioning off the program (see later), and working towards sustainability of 
the program in each country. Different elements of the program may be 
appropriate to different countries, both depending on the health status and 
services in the country and on the evolution of the IDF-LFAC program.  
From a health systems perspective, there is a potential danger that IDF-LFAC, 
with its model of care based largely on doctors working from hospitals, could 
replicate the worst of both vertical disease control programs traditionally 
adopted in low income countries to address challenges such as malaria and over 
reliance on hospitals as settings for care. There is now a widespread consensus 
that, other than in a very few situations, such a model is inappropriate and, 
instead, services should be integrated horizontally with mainstream health 
services (Oliveira-Cruz, Kurowski et al. 2003). Of 31 respondents to a question 
on this issue in the survey, 61% (n=19) thought that the IDF-LFAC program 
could be better integrated into the national health system but 39% (n=12) 
thought that this would not be possible. However, those that thought IDF-LFAC 
could be better integrated recognized that this would require better financing 
and strengthening of health systems, more stability, and prioritization by 
politicians.  
This issue was explored with IDF-LFAC staff who, while accepting the 
desirability of a horizontal model, with services embedded in primary care, 
expressed concern about the virtual absence, in many countries of pediatric 
endocrinologists and the extremely low skills level of many doctors and other 
health workers in primary care settings. Moreover, they noted how, even in 
many high income countries, pediatric diabetes is rarely managed in primary 
care. The possibility of enhancing the skills of general pediatricians was also 
explored but, again, in many countries, they tend to be inexperienced. Indeed, 
this was part of a wider problem, well recognized in the international literature, 
of the severe shortage of skilled health workers in many countries. The only 
exception, in the experience of the IDF-LFAC staff, was the availability of nurse 
educators in most countries. It seems, therefore, that while far from ideal, the 
current model is probably the only viable one in most countries at present. 
Experience from the country visits supports this. Even in some of the more 
developed countries there may be none, only one or a few pediatric 
endocrinologists in the country. Care of T1D children is provided by general 
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pediatricians and sometimes by adult endocrinologists, and the expertise of 
‘local’ primary care doctors is not adequate to treat T1D children properly. 
Repeatedly, children were referred on to ‘hospital’ or ‘diabetologists’. Whilst the 
direction of travel in many countries is to more horizontal programs and 
primary care based delivery, this was not a likely possibility in the near future.  
In all the countries visited there is a NCD (non-communicable diseases) or 
similar national strategy covering diabetes, hypertension, cardiovascular 
disease, stroke but the focus is on obesity and Type 2 diabetes (T2D) and related 
issues. It rarely addresses T1D and often does not address the needs of children 
and young people at all. Likewise whilst there may be specific programs and 
strategies for child health, many of these are still focused on infectious disease 
and immunization and have not yet made the shift to chronic diseases such as 
T1D. Hence children and young people with T1D was not an owned 
responsibility or a priority in either strategy. As one Ministry of Health 
interviewee noted, “type one diabetes is not a priority” and another commented 
“no one speaks up for type 1 diabetes” 
In discussions about the ‘context’ of the country, as described by WHO 
representatives, it was seen that there may be more appropriate ‘linkages’ that 
can be made, such as with maternal and child health programs. Finding the right 
place and level to integrate activities supported by IDF-LFAC into mainstream 
health programs is not without difficulty and will vary from country to country. 
However, explicit consideration of what approach should be undertaken at an 
early stage of IDF-LFAC engagement, as part of the development of a plan for 
integration with health services and eventual exit. This approach needs to be 
agreed with the local diabetic association and local champions and leaders, while 
recognizing that their existing networks may not extend to all possible 
collaborators in the different parts of the health system.  
IDF-LFAC works very closely with pharmaceutical companies and is 
substantially dependent on donations in kind, from Lilly for insulin, Nipro 
Diagnostics for test strips, and Lifescan for meters and strips, along with some 
financial support from Sanofi. However, if countries are to become self-sufficient, 
they will have to develop effective procurement systems that can deliver these 
products at low costs, including, potentially, preferential pricing. In some of the 
more developed countries visited, the model is already based on local 
procurement and it was reported that this was at ‘preferential pricing’. For 
example, in the Philippines the senior doctor procures insulin and other supplies 
locally and IDF-LFAC provides funding. Given a range of factors, including 
parallel trade, it is likely that the manufacturers may prefer to maintain tightly 
controlled donations and small scale preferential pricing rather than preferential 
pricing on a large, and potentially national, scale, given the risk of leakage back 
to high income countries. This is an obvious target for advocacy but we recognise 
that IDF, as a major recipient of funding from the pharmaceutical industry, may 
find this difficult to do. We note that IDF-LFAC staff report never having 
experienced any inappropriate pressure from industry, although this may reflect 
an unwillingness to confront the interests of some of its industrial sponsors. A 
further concern is the drive by manufacturers to increase market share of more 
profitable analogue modifications of insulin. However, we noted with approval 
that IDF-LFAC only accepts donations of non-analogue human insulin.  
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A further benefit of local procurement was seen in Nagpur in India, where this 
model enabled the local diabetologist to purchase a range of different insulins, 
including some pens, to ensure children were able to give themselves their 
afternoon dosage in schools. It was noted that there have been problems in 
schools when children tried to use syringes. (India country visit, Appendix 7)  
The IDF-LFAC program contrasts with a competing program, run by Novo 
Nordisk, in seven countries (India, Ethiopia, Bangladesh, Tanzania, Kenya, 
Uganda, Guinea Conakry, Cameroon, and DRC). It supplies insulin, 2 test strips/ 
day, and some education and there is some overlap with IDF-LFAC. We heard 
that it has faced problems in Kenya and Uganda. The Novo program involves a 
separate vertical system and prioritizes links with government (which has the 
obvious benefit to Novo of obtaining preferential access to policy makers) 
whereas IDF-LFAC emphasizes work within the existing health system. We were, 
however, told by the Ministry of Health in the Philippines, that while they were 
willing to accept donations from the pharmaceutical industry, they did not allow 
them to exert any influence on policies. We were not, however, in a position to 
evaluate this independently. A further limitation of the Novo program is that it 
only enrolls people up to age 18.   
The type of agreements that are reached between IDF-LFAC before entering into 
a partnership with the Diabetes Association in a country, were explored, and 
particularly whether there is any expectation of or conversation with the 
government about taking on responsibility for caring for its own T1D patients, 
perhaps with IDF-LFAC technical assistance. IDF-LFAC staff report that they do 
not insist upon governmental approval to work in a country but they welcome it 
where this can be arranged. In practice, they rarely sign memoranda of 
understanding with governments and their formal agreements are with diabetes 
associations, other similar organizations (e.g. Hope Worldwide in the 
Philippines) or major teaching hospitals. This was borne out by the visits and 
respondents to the survey. 73% reported that there was no formal, written 
agreement with their government on the provision of T1D care and management 
in children and young people, while 24% did have one and (3%) did not know.  
The visit team enquired whether the presence of IDF-LFAC and the implication 
that the country needed ‘charity’ to provide services was either an actual or 
potential source of leverage to persuade or ‘shame’ the country into providing 
insulin and better services for children and young people with T1D. Most 
diabetic associations had not considered this and nor had they developed strong 
relationships with the Ministry of Health to influence decisions. Some recognized 
that IDF-LFAC’s presence could be influential but they had not used it in such a 
way. Some thought that their government was content to receive ‘charity’ and 
that pressure on governments came from more ’political’ influences, such as in 
Mexico where one senior doctor considered that the fact that Columbia had 
recently taken the decision to provide treatment for people with T1D was more 
likely to influence their own government. However, as noted above, the 
government of Azerbaijan has been influenced by IDF-LFAC and is now 
providing 50 strips per year free to each diabetic. This demonstrates that IDF-
LFAC may be able to exert influence on government policies but also that it does 
so relatively infrequently.  
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Supplies and importation 
 In many countries arduous and complex customs procedures and high import 
duties are critical obstacles to progress (Box 2 and Table 4). In a third of 
countries responding, they reported that taxes and duties are charged on 
imported insulin and other supplies (although a further third did not know or 
did not respond to this question). A third had experienced delays and over one in 
five had experienced insulin expiring while held in customs.  
Box 2 Customs and import duties: a major challenge  
Partners in both Nigeria and Kenya face seemingly intractable customs issues. 
The problems in Nigeria are well-recognised, with many far from transparent 
rules and widespread corruption. As a consequence, it has not been possible to 
import insulin which is, instead, bought locally at much higher prices. It is also 
impossible to import the cheap Nipro strips but instead it is necessary to 
purchase more expensive ACON strips because the manufacturer has developed 
a means to clear customs. The local champion and the Diabetes Association of 
Nigeria have tried very hard to overcome these problems but without success. 
An additional problem is the ongoing conflict in the north of the country, which 
makes it almost impossible to work there. Similar problems arise in Kenya, 
where the partner at the Kenyatta National Hospital has been unable to negotiate 
customs clearance, so that one insulin shipment expired, having languished in 
customs for over 15 months. A subsequent one cleared customs easily but the 
next one, despite using exactly the same procedure and engaging support from 
the CEO of the hospital and a government minister, also expired before it could 
be cleared. This means that it has been impossible to extend the program beyond 
Nairobi.  
 
Table 4 Number and percentage of countries who identified problems with 
customs and importation processes.  
 Yes No Missing/ 
don’t know 
Taxes and duties have to be paid 13 (32.5%) 14 (35%) 13 (32.5%) 
Delays in delivery of medicines and 
supplies 
15 (37.5%) 10 (25%) 15 (37.5%) 
Medicines and supplies going out of date 9 (22.5%) 14 (35%) 17 (42.5%) 
 
We asked the national associations for details of other specific problems that 
they faced (Table 5). The situation was extremely variable, but frequently 
difficult. Thus, they simply replied “We don’t know what to do” (Ecuador) but 
others had no problems, as in the Maldives “Supplies are coming through 
WHO/MOH without any obstacles”. 
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Table 5 Specific challenges related to importing insulin and supplies 
Ethiopia Although we try to get the items out as soon as possible, we need items 
that have long shelf life. 
Zimbabwe Negotiating with government authorities to waive these charges. This 
time we are going to engage the parliament portfolio committee on 
health. 
Haiti The administration paperwork is very heavy in Haiti. Even if we start 
working on it way before we receive them, to avid the delay, we should 
take the merchandise (par anticipation: French) and therefore give a 
check upfront; money that FHADIMAC does have sometimes. 
Tanzania Clearance of goods from the customs can sometimes take long time due 
to many procedural steps that have to be fulfilled which in the end cause 
a lot of delays and inconvenience. These can be avoided in the future 
when the documentation is sent earlier before the goods arrive so that 
clearance procedures could be initiated in advance. 
Bolivia For the current government regulations, we cannot improve or change 
these procedures, but we pay much lower costs by demonstrating that 
they are donated products, but we can’t stop paying the formalities and 
they are not as slow as before. 
Guatemala For us in the Association it would be a great help if we could persuade 
Congress to exempt us from taxes and duties but, not only is this a highly 
complex and lengthy procedure, it would require the mediation of a 
member of Congress. For this reason we have opted instead to request 
that the receipts and documentation for donations which we are sent 
should display the lowest possible sums, trying (also) to get 
advance clearance on all the necessary licences before the donation 
reaches Customs. 
Congo Since its beginning, the program is now known and benefited from 
support by the customs service with a fixed price of 25 USD for receipt of 
package. 
Tajikistan We have to submit all shipping paperwork (translated) to the 
government 2 weeks prior to receiving shipments. If the paperwork 
comes in on time and can be translated, the process is usually fine. 
Nigeria If funds are made available to pay or other NGO in the country could be 
involved or appeal made to government for waiver.  
 
We were able to confirm how, in the countries visited, the processes for 
importing insulin and supplies were complex and time consuming. In Jamaica, 
for example, the Director of the Diabetes Association considered it a major part 
of her participation in the IDF-LFAC program to ensure that importation was 
undertaken correctly and in a timely fashion, in order to ensure delivery. 
However, as noted above, in some countries, such as the Philippines and in 
Nagpur in India, they had moved to ‘local procurement’ using funding from IDF-
LFAC. This model should be considered where possible, to overcome ‘import’ 
problems, but of course is only feasible in more developed countries where 
insulin is regularly available and where there are adequate safeguards to avoid 
diversion of supplies, a risk that is, to some extent, mitigated where insulin is 
supplied by IDF-LFAC because of the ease of identification of vials labelled in 
both English and Afrikaans, as noted earlier. Also there must be a consideration 
about the costs of locally procured materials. We do however recommend that 
IDF-LFAC include discussions on ways in which health ministries and other parts 
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of government can facilitate the import of supplies when negotiating IDF-LFAC’s 
entry to a country or renewing agreements to operate there. 
Other organizations providing support for Type 1 Diabetes 
In each country there may be a number of organizations that either take, or could 
be encouraged to take an interest in children with diabetes. We asked 
respondents to the survey about other organizations that are engaged with this 
issue and how they relate to IDF-LFAC. 51% of respondents reported that there 
are other organizations besides IDF-LFAC that provide support to children and 
young people with T1D in their country. 34% reported that they were the only 
organization active in this field. Other organizations mentioned included: Novo 
Nordisk (n=6), Insulin for Life (n=2), the WDF, ISPAD, AYUDA, FUVIDA, CLAN, 
ISDFI, insurance schemes, other diabetes organizations and sponsorship of 
children by prominent business persons. Thus, in Tajikistan it was reported that 
“Operation Mercy has created educational materials in Tajik and distributed these 
with the IDF-LFAC aid materials. Their main role is to support the NREC (Ministry 
of Health) in its efforts to improve the care of children with diabetes.”  
37% of respondents reported that IDF-LFAC partnered with other organizations 
to deliver support in their country, including Novo Nordisk, Insulin for Life, 
Operation Mercy, Eli Lilly, Nipro diagnostics, universities and other diabetes 
organizations. In the countries visited, it was a demonstrable strength of IDF-
LFAC that they were flexible and collaborative in working with other such 
organizations. They were willing to adapt their ‘model’ to accommodate other 
partners. One partner in Rwanda commented that IDF-LFAC had a ‘generosity of 
spirit’ in their working with partners.  
Building capacity 
The day to day operations of IDF-LFAC focus on the distribution of insulin, strips 
and related material and of educational materials. However, IDF-LFAC cannot 
hope to take the place of a strengthened national health system and nor should 
it. Moreover, it cannot provide support indefinitely and, as noted above, should 
be exploring opportunities to exit countries, leaving an effective program to 
support children with diabetes. There are other examples of where this has been 
done, and local capacity has been developed, such as the World Heart 
Federation’s Emerging Leaders program. This recruits young cardiologists 
displaying qualities of leadership and brings them together into a learning 
network in which they can acquire skills not only in cardiology but also in health 
systems, policy analysis, and advocacy.  
IDF-LFAC does, however, provide support for training, on request and subject to 
availability of staff. In the survey, 35% (n=14) of countries reported that IDF-
LFAC had provided training for health professionals, 30% (n=12) reported that 
IDF-LFAC delivered training to children/young people and 17.5% (11/33) that 
IDF-LFAC delivered training to families. 
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Table 6   Positive improvement of the training provided by IDF-LFAC on 
service delivery, control, management, training and awareness 
Has the training had positive impact 
on any of these issues: 
Yes No No 
response/ 
don’t know 
Clinical Services 13 (32.5%) 1 (2.5%) 26 (65%) 
Changes to insulin regimes 13 (32.5%) 2 (5%) 25 (62.5%) 
Patient outcomes 12 (30%) 1 (2.5%) 27 (67.5%) 
HbA1c testing 11 (27.5%) 4 (10%) 25 (62.5%) 
Patients’ self-help/management of their own 
conditions 
15 (37.5%) 0 25 (62.5%) 
Patients’ better glucose control 14 (35%) 0 26 (65%) 
Reduction in severe episodes such as DKA 
requiring hospitalization  
13 (32.5%) 1 (2.5%) 26 (65%) 
Reduced mortality from diabetes in children 
and young people 
10 (25%) 1 (2.5%) 29 (72.5%) 
Increase in regular reviews to prevent 
complications e.g. eye examinations, foot 
examinations 
11 (27.5%) 0 29 (72.5%) 
A reduction in complications 9 (22.5%) 1 (2.5%) 30 (75%) 
Delays in onset of complications 10 (25%) 0 30 (75%) 
Wider awareness of diabetes 12 (30%) 1 (2.5%) 27 (67.5%) 
Yours or other partners (e.g. health 
professionals) skills in advocacy lobbying to 
support from the government 
8 (20%) 5 (12.5%) 27 (67.5%) 
 
Additional training  
All respondents expressed a need for more training of health care professionals, 
families and young people. The priorities identified were as follows: 
• Seminars for general health care professionals 
• Training of professional diabetes educators 
• Training for families with diabetic children on how to manage their children 
• Continued training for young adults with T1D 
• General T1D education for the general public and media 
• Diabetes education camps for children and families 
• Training in how to give information to TV, medical journals and newspapers 
 
Specific examples of needs identified in selected countries are shown in Table 7. 
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Table 7 Expressed needs for training in selected countries 
Bangladesh Training of Health Care professionals by ISPAD experts 
Bolivia We urgently need to train all members of our team in the management of 
people with type 1 diabetes 
Kenya Most health care professionals think Type 1 Diabetes is the same as Type 2 
DKA management. Training in insulin therapy and social skills in handling 
diabetic children 
Liberia Management of blood sugar in children whose food options are 
inconsistent; carbohydrate counting of local foods 
Dominican 
Republic 
Train new people to serve as Diabetes Coaches will be a great program in 
DR 
Ethiopia Robust training of health care professionals at all levels, empowering 
those living with diabetes and their families as well through the right 
education and information 
Guatemala Physicians in our country are unaware of the management of diabetes and 
give erroneous treatments and zero education in diabetes. Family 
education needs to be strengthen too 
India We urgently need training for professional Diabetes Educators who can 
empower patients in diabetes self- management education. Education of 
physicians in early diagnosis and management. Community awareness 
Tajikistan Endocrinologists require training on correct diagnosis and treatment of 
type 1 diabetes. Rural doctors (general practitioners) require training on 
the signs of diabetes in children. Families require basic diabetes education 
- most do not receive any training except the instruction of how much and 
when to inject insulin. 
Tanzania Additional training is required for the following: - parents and families for 
them to understand the condition and how to cope with it and support 
their affected child - microfinance skills and vocational training to ensure 
long term sustainability - training of school teachers to make them aware 
of the condition and how to cope with students having type 1 diabetes - 
peer educators for better control of blood glucose 
 
Much of this continued need for training is focused on clinical treatment of T1D, 
which may require more input from IDF and ISPAD, supported by additional 
experts and mentors. However, there is also a need for education of children and 
families and for greater awareness raising and advocacy development. Some of 
these aspects could be addressed by peer to peer country support and by 
increased use of the IDF-LFAC website and the development of a newsletter, 
which could provide support to countries through examples from elsewhere and 
sharing of templates and documents. The Mexican diabetes association in 
particular noted that country to country support would be helpful “especially at 
the beginning – practical support from other countries who have an LFAC program 
up and running on ‘how to do it’ “ 
Into adulthood 
As noted above, the support offered by IDF-LFAC only continues until the 
individual is 25. In the survey we asked about the challenges that those with 
diabetes face at this time of transition. The responses were largely what might be 
expected. Thus, having diabetes places a major financial burden on individuals 
and families, for several reasons. These include limited employment 
opportunities, the cost of insulin and strips, the often very high cost of specialist 
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care, with few physicians having adequate experience in the management of the 
often small numbers of children with Type 1 diabetes who survive to adulthood, 
and the ability to maintain appropriate lifestyle modifications. There are also 
many ‘social’ issues for the ‘graduates’ of the IDF-LFAC program which impact on 
their lifestyle. For example, in India young women with T1D were very unlikely 
to marry as their condition was still highly stigmatized, although this did not 
seem to be the case for young men with T1D. In effect the young women with 
T1D therefore need to be self-sufficient. One married woman (aged 40) in India 
(Nagpur) told us that she had kept her diabetes a secret from her husband, for 16 
years. She thought he would divorce her if he knew. Another young woman was 
about to marry but her and her fiancé had not told the fiancé’s parents that she 
has diabetes as they would have opposed the marriage. While it is beyond the 
mandate of IDF-LFAC to support such individuals indefinitely, respondents from 
31 countries (77.5%) reported that they did not have the ability to support 
affected individuals through this transition. IDF-LFAC should consider how they 
can best prepare countries to support young people as they transition off the 
IDF-LFAC program when ‘aged out’.  
In some countries, such individuals can benefit from the Insulin for Life program 
but we also identified some innovative ideas that might be emulated elsewhere. 
These included the development of a micro-credit program in Tanzania, 
designed to help people with diabetes establish their own businesses, offering 
them startup capital and training, as 
well as links with local business 
people. India (Nagpur) had developed 
a series of special support 
mechanisms, some simple, such as 
bicycles to support girls accessing and 
staying in schools in rural areas, some 
more complex such as educational 
grants to encourage the young people 
to stay in education so that they could 
develop skills to get jobs and support 
themselves, and a ‘rehabilitation’ 
program to provide support for them 
to set up their own businesses. These 
ranged from a water buffalo, 
developing into a yoghurt and cheese 
business, to sewing machines for 
seamstresses, as well as support with 
startup capital, business mentoring 
and advice and training to set up 
businesses such as selling Saris. 
(Country visit report Appendix 7) 
In Rwanda, IDF-LFAC supported the education center where the young people 
learned new skills equipping them for employment as barbers, tailors, 
beauticians, and chefs in order to become self-sufficient (country visit reports, 
Appendix 3 - 7).  
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IDF-LFAC has supported these initiatives and, with relatively little funding, these 
approaches are life-changing for the young people. Drawing lessons from these 
examples and sharing them more widely can offer a road to self-sufficiency for 
the young people and should be considered an important aspect of developing 
sustainable health programs for young people with T1D.  
In some countries the IDF-LFAC program does not continue until age 25. For 
example, in Mexico and the Philippines it effectively finished at age 18. By that 
time the diabetes associations expected the children to either be in full time 
education or jobs. In Jamaica the transition from ‘children’s health services’ to 
‘adult services’ was at age 12, although some pediatricians continued to offer 
informal support until about age 16. Some of the children and families were 
unaware that the IDF-LFAC support finished at age 25, reinforcing our 
perception that many diabetes associations were ill equipped to manage the 
transition. Crucially, we found no evidence that information was being collected 
on the fate of those who age out of the program.  
Whilst many young people and families seemed unaware that support from IDF-
LFAC would cease at age 25 or had not considered it, some ‘hoped’ that there 
would be other support available and some knew that they were likely to have to 
pay for insulin and care. The mother of one 14 year old we interviewed said “he 
has started saving from his allowance so that he can buy insulin when there are no 
support services”. Others were more innovative or fanciful, one 15 year old in 
Mexico hoped for ‘a cure’, another for ‘sniffable’ insulin to become available and 
a 16 year old in the Philippines was optimistic that a ‘pancreas transplant’ would 
be available at some stage in the future. Some were more pragmatic, one young 
woman in India said that her future husband would support her.  
 
The survey (table 8) showed that in less than half the countries, young people 
would get some support, insulin and medical care, 50% would have to pay for 
insulin and over 50% would have to pay for glucose testing, medical care and 
diabetes check-ups. This reinforces the importance of finding means to enable 
young people to become self-sufficient.  
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Table 8 Support received when people ‘age out’ of the IDF-LFAC program  
(> 26 years old), and any associated costs 
Support received > 26 years old 
 Yes No No response/ don’t 
know 
Insulin 
 
15 (37.5%) 12 (30%) 13 (32.5%) 
Glucose testing 
 
6 (15%) 18 (45%) 16 (40%) 
Medical care 
 
14 (35%) 12 (30%) 14 (35%) 
Diabetes check-ups 
 
15 (37.5%) 11 (27.5%) 14 (35%) 
Does the young person have to pay? 
 Yes  No  
Insulin 20 (50%) 8 (20%) 12 (30%) 
Glucose testing 22 (55%) 4 (10% 14 (35%) 
Medical care 20 (50%) 5 (12.5%) 15 (37.5%) 
Diabetes check-ups 22 (55%) 4 (10%) 14 (35%) 
 
Achieving Success 
We asked IDF-LFAC staff where they felt they had achieved the greatest and least 
success. The most successful countries were named as Rwanda, Tanzania, Mali, 
Mauritania, and Azerbaijan. In each of these countries activities began in the 
capital city but rapidly expanded to other parts of the country, initially to regional 
centres and subsequently beyond. The least successful were Nigeria, Kenya, 
Guyana and Guatemala. The reasons are revealing, although not entirely 
surprising. As noted previously, one of the main issues in those countries that 
are less successful is the inability to bring insulin and related products through 
customs. The main determinant of success is seen as the commitment, 
organizational ability, and connectedness with the authorities of the local 
partner country. Importantly, it seems less important what type of partner is 
involved. Thus, in Rwanda, Tanzania and Mauritania the partner is the national 
diabetes association, in Mali it is a French-Malian diabetes NGO, and in 
Azerbaijan a senior doctor.  
What could improve the quality, quantity, efficiency, or effectiveness of the 
work of IDF-LFAC?  
Many of the issues covered in the previous sections relate to improving quality, 
efficiency and effectiveness. One issue not covered so far is the role of volunteer 
experts, on which IDF-LFAC relies extensively, to conduct site visits, conduct 
training and serve as mentors. We explored how they train and prepare 
volunteers to represent the program and ensure consistency in appropriate 
clinical standards and other issues given the challenging circumstances after the 
volunteer leaves. IDF-LFAC staff concurred that it can be a challenge to find 
skilled and motivated volunteers for site visits, especially now that they are 
promoting a South-South model, now widely used by many civil society 
organizations. They recognize the importance of the volunteer having adequate 
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experience and appropriate people skills. Shared language and culture are not a 
guarantee of success; an Azerbaijan - Tajikistan link was successful whereas a Sri 
Lanka - Maldives one was not. IDF-LFAC takes considerable care when screening 
potential expert volunteers to assess whether they are appropriate for 
participation, including review of their CV and, especially, references from 
trusted sources. They have turned people down. 
Working relationship with IDF-LFAC 
Only 32 countries rated their working relationship with IDF-LFAC but of those 
that did, 78% rated it as excellent and 22% as good. When asked how it could be 
improved some suggested by more regular communication and visits, more 
training and/or additional resources. 
What impacts are IDF-LFAC’s programs having on the countries, systems, 
and children with whom it works?  
Coverage of diagnosis and support for children and young people with T1D 
IDF-LFAC reports that it reaches 12,000 children a year. 37.5% of country 
respondents (n=15) believed that most children and young people with T1D in 
their country were being correctly diagnosed while 16 (40%) did not believe all 
were being diagnosed but 9 (22.5%) did not know or did not respond to this 
question.  
55% of respondents (n=22) stated that children not supported through the IDF-
LFAC program, were not adequately supported by other organizations, 30% that 
some of them were adequately supported through others and 15% thought that 
all children with T1D in their country were adequately supported by IDF-LFAC 
or through some other organization. This picture was reinforced by the country 
visits; it seemed unlikely, in any of the countries visited, that children across the 
whole country were being diagnosed and adequately supported. Even in 
Rwanda, which has an IDF-LFAC program that reaches across the whole country, 
through its district hospitals, it still recognized that capacity of local health care 
workers was inadequate to treat children with T1D. In other countries, e.g. 
Mexico, the IDF-LFAC program is well aware that it does not address the poorest 
areas and in the Philippines the main IDF-LFAC program has only operated in 
Manila and is just now being extended to a few children on one of the other 
7,000 islands.  
Support provided by IDF-LFAC  
The support provided by IDF-LFAC varies among countries. This, in part, reflects 
their ability to obtain materials from other sources. Thus, there are a number of 
other sources of insulin, including the government and other donors, so that IDF-
LFAC only supplies it to three-quarters of countries. On the other hand, there are 
few alternative sources of glucometers and test strips, so these are provided to 
almost all countries. A few countries only receive educational materials and 
three (Azerbaijan, Tanzania, and Zimbabwe) reported receiving the entire 
package of possible support (table 9). “Other support” listed by individual 
countries included; financing for a diabetes camp; glycosylated hemoglobin 
reagents; fridges for storing of insulin; one-off economic support for HbA1c tests; 
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translation of information for children; a Diabetes Education Centre (Rwanda); 
and research (Sudan, Tanzania). 
Table 9 Support provided by IDF-LFAC: Number (%) of countries receiving 
specific support from IDF-LFAC  
Insulin 29 (76.3%) 
Glucometers & strips 36 (94.7%) 
Syringes 23 (60.5%) 
HbA1c testing equipment 21 (55.2%) 
Educational materials 26 (68.4%) 
Training of health professionals 8 (21.1%) 
Support from experts from abroad 9 (23.7%) 
Other 12 (31.6%) 
Total (countries responding to this question) n=38 
 
Clearly, despite its considerable reach, there are many children who could 
benefit from access to insulin but are unable to do so. The survey and the visits 
explored the barriers that exist to extending the reach of the program.  
The following issues were commonly identified.  
• Access: A majority of respondents reported that access in reaching children 
in rural areas and cost of transportation for children/families from rural 
areas to access support as a major barrier. This was also raised as a major 
difficulty in the countries visited. In Rwanda, some children had to walk 
anything from 2 to 6 hours to attend clinic and this was despite the IDF-LFAC 
program operating across the country in ‘district’ hospitals.  These sort of 
distances were not unusual elsewhere. In India (Nagpur) the geographical 
coverage required up to 6 – 8 hours travel for some children, often by several 
buses and on foot. Recognizing this, and to encourage attendance, the local 
champion offers travel payments and has established an excellent robust 
system of repaying on production of tickets/receipts.  
In the Philippines they were trying to expand the IDF-LFAC program beyond 
Manila, at the request of the IDF-LFAC team, and had recently started clinics 
on one of the islands, but were finding it difficult to coordinate reliable 
insulin supplies. In Mexico, the delivery of IDF-LFAC programs is through 
those state based diabetes associations where there is capacity to manage the 
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program. However there is recognition by IDF-LFAC that this does not reach 
the most ‘needy’ children in rural areas, where there is the greatest poverty 
but no diabetes associations. Mechanisms to develop capacity to deliver IDF-
LFAC programs to the most needy should be considered and stimulated. This 
issue was particularly pertinent in Mexico, where the diabetic associations in 
the most impoverished states lacked adequate capacity to work with IDF-
LFAC. (See country visit report Appendix 5) 
• Awareness and education: Many countries reported a lack of general 
awareness and understanding of diabetes in the population and amongst 
health care staff as barriers, e.g. awareness of early symptoms, management 
and treatment and knowledge about the disease in general. From the 
interviews with children and families in country visits there often appeared 
to be a difficulty with some families and schools and teachers not 
‘understanding’ how to deal with children with T1D. Schools may 
‘overprotect’ (such as not allowing them to participate in physical education), 
or not allow syringes into school, as they were associated with HIV and drugs, 
hence preventing children with T1D from giving themselves ‘afternoon’ doses 
of insulin. In India (Nagpur) the clinic had decided to provide insulin ‘pens’ 
for some of these children in order to overcome this problem.  
• From other children and families it was apparent that the majority were 
unaware of T1D before diagnosis or that diabetes can affect children and 
there remain many ‘misunderstandings’ and ‘myths’ about T1D. Some 
children and young people had virtually stopped attending school once they 
were diagnosed. The diabetic associations usually worked hard to 
demonstrate that this was an inappropriate response and to encourage 
children to remain in education as long as possible.  
• Poverty: Those with T1D face many cost pressures, which are often beyond 
the means of those living in poverty. Costs of medicines and of transport to 
access medicines are high and there are additional costs of parents having to 
take time off work to travel to diabetes centers or sit all day in clinics waiting 
to be seen and to get medication. This was a very common theme in all the 
country visits. Even in countries which, in theory, made insulin available, in 
practice it was often not available or there were major barriers to its delivery 
to poor children and families. (country reports in appendices 3-7)  
• Parent support and stigma: Stigma was reported as a major barrier by 
many of the countries to providing effective support, especially with regard 
to diabetes management and in continuing education or gaining employment. 
Stigma also led to parents not accepting the diagnosis in their child and not 
providing adequate support. In Rwanda, one of the young people interviewed 
was a young woman in her late teens who was working as a cook in a private 
house. She said of her biological family that they “think of me as already a 
dead person”.  
• Adherence: This is often a consequence of limited access to care, but also 
reflects lack of education and acceptance of the diagnosis. 
• Access to affordable syringes, blood glucose monitoring and strips: This 
is reported as a barrier by countries in most regions. 
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• Insulin storage: Some countries in Africa and Western Pacific and elsewhere 
identified the lack of fridges or electricity to power them as a barrier to 
storing insulin. Many of the children and families interviewed on country 
visits reported that they stored their insulin in relatives’, neighbors’ or 
friends’ fridges. The doctor in 
Nagpur had invented a double-
layered terracotta pot for 
storage of insulin. Water is 
added to one compartment 
and it cools by the principle of 
‘cooling by evaporation’. This 
is provided to children and 
families who have no access to 
fridges. Such innovations could 
be shared with other 
countries, via IDF-LFAC’s 
website or through a 
newsletter.  
• Customs delays and/or charges: Customs was reported as a barrier by four 
countries in different regions (Uzbekistan, Nigeria, Haiti and Ecuador). Some 
reported custom delays as the main issue and two reported customs charges 
as a major barrier. 
• Transition to adult services: One country also mentioned the transition 
from children to adult services as a barrier. The visit to Jamaica revealed that 
the transition age there is 12. For many of the pediatricians treating children 
with T1D this appeared very young, and several revealed that they informally 
continued to treat children beyond this age as they were not confident of the 
treatment they would get otherwise. This seemed to be less of a problem in 
rural areas where there may be a smaller number and ‘closer’ community of 
doctors and the pediatricians knew the ‘adult’ doctor who would take over 
the child’s care. However such a young transition age meant that the IDF-
LFAC program did not usually continue to age 25 and that these children and 
young people were ’lost’ to follow-up, long before age 25.  
The comments received elaborated on these issues. Thus, in Cambodia, it was 
noted that “Awareness of symptoms of type 1 diabetes is extremely poor in 
Cambodia. As around 80% of the population live in rural areas, their first point of 
contact when they are sick is the local health centre which is usually staffed by a 
midwife and one or two nurses. They have no knowledge of type 1 symptoms and 
children usually present when almost in a coma. Children are often misdiagnosed 
as having dengue or similar diseases. When the child’s condition doesn’t change 
and if parents have enough money to pay for transport, they will take them to the 
district hospital where, again, staff have little or no knowledge about type 1 
symptoms. In Siem Reap there are two free children’s hospitals so if the child is 
lucky it may be diagnosed in one of these hospitals. CDA is working in collaboration 
with one of these hospitals and when the child is discharged we do follow-up care 
and support. The situation is better in the capital, Phnom Penh where there are 
more doctors with higher training.” 
The Ethiopian respondent noted how “The lack of human power at the association 
made it difficult to do monitoring and evaluation, hence we rely on hospitals for the 
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report and for confirming that the supplies reach children. In rural areas it is 
difficult to work since most of the hospitals are found in urban areas, hence 
children from rural areas have to walk long distances to reach hospitals and get 
their supplies.” 
The Nigerian respondent emphasized the problems with customs, discussed 
above, but also certain other problems “Custom charges and duty clearance, No 
money for clearance. Children do not have money to come to clinic to collect 
insulin. Lack of proper storage facility for insulin at home.” (Nigeria) 
The complexity of the challenges was apparent in the Democratic Republic of 
Congo where the mix of problems differed in urban and rural areas, thus “Rural: 
distances, lack of communication, poverty, illiteracy, lack of cold storage of insulin 
and HbA1c reagent, lack of proper training or capacity building of healthcare 
providers. Urban: (in a city of 10 million people) Poverty, illiteracy (50% cannot 
read or write properly) poor transportation, general health system deficient, health 
workers badly paid” DRC. These same rural/ urban differences were also seen in 
the country visits. 
Even in the more prosperous countries, such as Fiji, there are many problems 
even if on a smaller scale than elsewhere “a) sourcing cheap supply of syringes 
and needles is a challenge. We buy our supplies from government bulk purchasing 
scheme. Retail is too expensive. b) Adherence to treatment is difficult. Most families 
struggle to cope with their child’s diabetes c) Lack of awareness on Type 1 DM in 
both public and among health workers who tend to approach type 1 DM as type 2. 
d) Transition of care to adult team. Young person can easily get lost in the system.”  
Support provided by the government 
Ultimately, if IDF-LFAC is to exit countries, it will be necessary for governments 
to assume responsibility for the support that IDF-LFAC now provides. Yet, as the 
survey revealed, there is still some way to go (Table 10). Only 6 countries 
reported that the government supplied glucometers and strips, and of these, only 
two reported that they were offered to everyone under 26 years old. 
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Table 10 Numbers (percentage of total, including don’t knows and no 
responses) of countries where specific support from the government is 
available, or not, and whether it is free to children and young people, or not 
Support  Is it provided? Is it available to all < 
26 years old? 
Is it free to all < 
26years old? 
 Yes No Yes No Yes No 
Insulin 15 (37.5% 4 (10%) 7 (17.5%) 11 (27.5% 9 (22.5%) 9 (22.5%) 
Blood glucose 
monitoring 
(meters and 
strips) 
6 (15%) 14 (35%) 1 (2.5%) 16 (40%) 2 (5%) 13 (32.5%) 
Syringes 10 (25%) 8 (20%) 2 (5%) 13 (32.5% 4 (10%) 10 (25%) 
HbA1c testing 
equipment 
6 (15%) 13 (32.5%) 3 (7.5%) 15 37.5%) 4 (10%) 11 (27.5%) 
Educational 
material for 
children and 
families 
3 (7.5%) 16 (40%) 2 (5%) 13(32.5%) 2 (5%) 11 (27.5%) 
Training for 
children and 
families 
5 (12.5%) 14 (35%) 1 (2.5%) 15 (37.5%) 1(2.5%) 13 (32.5%) 
Specialist 
diabetes 
training for 
health 
professionals 
8 (20%) 11 (27.5%) 1 (2.5%) 12 (30%) 1 (2.5%) 11 (27.5%) 
 
Given the extremely weak health systems in many of the countries receiving 
support from IDF-LFAC, as well as the interational development context that 
prioritises infectious disease (Geneau, Stuckler et al. 2010), it is not entirely 
unexpected that there is little support for children and young people with 
diabetes. In these circumstances, it may be as important to consider the direction 
of travel. Yet, unfortunately, 62.5% (n=25) of respondents reported that 
government support for children with T1D had not improved since IDF-LFAC 
had begun to operate in the country. Where positive changes had occurred, they 
primarily involved a greater awareness of the burden of disease associated with 
Type 1 diabetes. Thus, the respondent from Azerbaijan noted that there was 
“More attention to children” while, in Tanzania, “The MoHSW is now aware of the 
burden of the disease, the challenges faced in managing these children and its 
responsibility to ensure long term sustainability of the program after donors have 
left”. In Rwanda the program had helped forge links with the government “There 
is a close collaboration between the government institution NCD’s (RBC) and 
Association Rwandaise des Diabetiques in the actions of the national policy and 
activities on diabetes”. There was also some evidence of greater awareness 
among other donors, as in Burundi “Other donors are aware, beginning 
integration of the management of diabetes in primary health care in two pilot 
provinces, but with no age distinction”. 
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In several of the countries visited there was a difference between the 
‘theoretical’ availability of insulin and other support and what appeared to be 
available in practice.  
In Jamaica, Philippines, Mexico and India, discussions with the Ministry of Health 
indicated that Insulin was either on an ‘essential medicines’ list (hence available 
from the government), or available through either insurance, public health 
systems or special ‘poorest of the poor’ mechanisms. In most cases, glucometers, 
strips and syringes etc. were not included in these packages or were available 
intermittently. In many cases insulin supplies are only available following an 
appointment at a public hospital, which might entail long queues and repeated 
visits, through an insurance scheme which required registration, that was often 
difficult or impossible for the very poor as they often did not have the right 
paperwork. In Jamaica, for example, the family had to register for the “National 
Health Fund”, which required various paperwork and a tax number. Many of the 
poorest families were single parents and either not working or scraping a living 
in the black economy, so unable to produce tax numbers and the like. In India, 
insulin was said to be available through the public health system, provided by 
each state. In practice it was only available if the child was hospitalized. Some 
years previously, insulin had been available at outpatient clinics but a supply of 
only 15 days was given, after which the child and family would have to return to 
the hospital for another appointment, which usually took all day. It appeared 
that now, even this short supply of insulin was not available at outpatient clinics. 
Thus, in some of the more prosperous countries surveyed (e.g. Mexico, India) 
there is an intention by the government to supply insulin to those who cannot 
afford it, but the practice does not meet the theory. (country visit reports 
appendices 3 – 7)  
Most countries do not supply glucometers and test strips, even though these are 
necessary for the child to monitor and manage their T1D, and in most countries 
the test strips are the single most expensive item to the family, more expensive 
than insulin. In Mexico, we were told by the ministry of health that there was a 
‘safety net’ where glucometers were ‘available’ to the poorest 10% of the 
population. This appeared to be news to the local diabetic association and when 
quizzed as to how they could be accessed, the somewhat oblique reply indicated 
that they may have got lost in the community clinics and would have to be found. 
Even where glucometers are available there are multiple different makes and the 
test strips are unique to each make and not interchangeable. Families are often 
not able to access the right strips, or can only afford to buy a few strips to test 
blood glucose maybe once or twice a week or month. Hence it is often in these 
scenarios where in practice the family has to ‘pay’ for insulin and supplies that 
IDF-LFAC is providing support.  
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In some of the more prosperous countries, such as Mexico, the focus of the 
diabetic associations is on the education of children and their families and on 
good management of their T1D and reducing Hba1c. Hence, IDF-LFAC is 
supporting by providing (in conjunction with NIPRO) glucometers and enough 
strips for children to test up to seven times a day. The diabetic association has a 
‘co-responsibility’ approach, requiring the child and family to ‘sign up’ to attend 
educational sessions every month to learn how to manage their T1D, and they 
expect to see results in reducing Hba1c levels. If the child and family default then 
their IDF-LFAC support may be transferred to another child. However, we 
pointed out that this could potentially disadvantage the most vulnerable 
children, maybe with dysfunctional or unsupportive families. The diabetic 
association appreciated this point and probably in practice their staff recognized 
and continued to support 
such children. In several 
cases we witnessed personal 
financial support, for 
example for travel money, 
being given to needy children 
by clinic or diabetic 
association staff. In one case 
in Mexico we made a two 
hour car journey detour and 
walked up mountain tracks 
to visit a teenage boy who 
lived with his grandmother in 
very poor circumstances. He 
had not attended the last 
clinic or educational session. The diabetic association coordinator wanted to 
deliver his insulin supplies and encourage him to attend the next clinic session. 
On leaving she slipped him some ‘bus money’, from her own pocket, to ensure he 
could afford to attend. Unfortunately he did not attend the session the following 
day, but the coordinator was confident he would return. We repeatedly saw this 
level of personal care, concern and support from the diabetic association and 
clinic staff in all the countries visited (country reports appendices 3 -7). 
  
Accountability 
Given the volume of goods provided by IDF-LFAC, it is essential that there is 
accountability for their use. 33 (82.5%) countries reported confidence that all 
IDF-LFAC supplies reached the intended beneficiaries. In two countries 
(Burundi, Kenya) it was believed that there was a problem and two respondents 
(Guyana, Solomon Islands) explicitly said they did not know (others failed to 
respond to this question). The explanations were the same as those identified as 
barriers to greater uptake. Thus in Kenya they believed that insulin had 
purposefully been destroyed at least twice. Most countries work hard to make 
sure the supplies get to the intended beneficiaries.  “We do our very best and 
amount stolen or lost is really minimal. Control is really strict.” DRC. In India 
(Nagpur) they ask the children to return the used vials, to ensure they are not 
being sold on. 
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82.5% (n=33) stated that children and young people received their IDF-LFAC 
provided support free of charge, 8% that they did not (Sudan, Guyana, 
Cambodia). This was due, in Sudan, to patients having to pay for strips and lab 
tests while in Cambodia the strips were free but they have to pay for the insulin 
to cover shipping costs from Insulin for Life and Guyana stated that they did not 
know how to answer the question. Tajikistan noted that: “they only have control 
of distributing the insulin to the endocrinologists, based on the number of clinical 
data sheets completed. But the endocrinologists themselves are in charge of 
distributing the insulin to their patients, and so we can never be 100% sure that it 
is free of charge. Of course the NREC instructs that it must be given for free; we 
believe that most endocrinologists follow this instruction, but we have never 
audited”. 
80% (n=32) stated that medicines and equipment were stored appropriately so 
they would not go off or expire before reaching the children/young people, 7.5% 
(3/37) stated that they were not all stored appropriately (Burundi, Solomon 
Islands and Tajikistan) and 5% (n=2) that they did not know if they were. 
In all the counties visited, the main insulin supplies were kept in fridges, usually 
dedicated to IDF-LFAC supplies, but some in hospital pharmacy fridges. Some 
fridges had been provided by IDF-LFAC.   
In the survey the following are examples of 
reasons for not all medicines being stored 
appropriately or reaching people before 
expiry date:  
• “There is a problem with recurring 
electricity cuts in the pilot center. We 
moved the main stock to the vaccination 
program site for safe keeping as it has a 
powerful generator. In addition the 
expiration dates are often short” Burundi 
• “In Kinshasa no problem (cold storage is 
correct), in rural areas: power supply is 
absent or erratic. Solar equipment is very 
expensive and not easy to maintain and 
not available everywhere. Also transport 
to different provinces is complicated” 
DRC 
• “There are problems with electricity, access to fridges” Jamaica 
• “But we need insulin fridges specifically for the donated insulin” Kenya 
38 
 
• “Refrigerator space in the capital 
city is limited, and the NREC does not 
have its own cold storage space. 
They attempt to keep it properly 
stored until distribution, but 
occasionally other medicines come in 
(i.e. vaccines) and the insulin is de-
prioritized. Also, due to this lack of 
storage space (in the capital and 
also in each endocrinologists’ office 
throughout the country), the insulin 
is distributed annually to the 
children. And since many children do 
not have refrigerators in their homes 
(or no electricity) in rural areas, it 
may become too warm. This is an 
ongoing problem. Most children 
know to try and keep it in a cool 
place” Tajikistan 
 
 
Collecting and sharing data  
The IDF-LFAC program requests that 
each program (country) maintains at 
least annual records on each child and 
shares these with IDF-LFAC 
(submitting an annual IDF-LFAC data 
sheet). This and other data collection 
methods were explored in the survey 
and during the county visits. Ideally 
data are provided when the child is 
diagnosed/ recruited to the IDF-LFAC 
program, annually whilst they are 
being supported by IDF-LFAC and 
when they cease to be supported by 
IDF-LFAC at maximum age 26. (Fig 2) 
Unfortunately very few countries have 
systems to collect ‘outcome’ data after 
the young person has left the IDF-LFAC 
program, which is a major weakness.  
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Figure 2 Countries collecting data at different time-frames 
The potential value of the dataset is great, for both ‘in country’, as it provides an 
indicator of ‘burden of disease’ and the scale of support being provided, and this 
could be used in advocacy with Ministers of Health and others to increase 
support for people with T1D, but also as a global public good, as a dataset 
covering 45 (or more) countries can provide an extremely valuable resource to 
examine progress in managing T1D, relating this information to the performance 
of the health system and the economic development of the countries. 
Unfortunately this ambition is not yet realized.  
Not all countries replied to this question in the survey, but of those that did, over 
90% reported having data sets on all the children and young people supported 
through the IDF-LFAC program. About 50 – 75% reported collecting more 
detailed data about management, control and complications. 8% reported that 
they did not have data about all the children.  
Table 11 Numbers (percentages) of countries collecting or not collecting 
different types of data on the children supported by the IDF-LFAC program 
 
 
Yes No Missing/ don't 
know 
Age 35 (88%) 1 (3%) 4 (10%) 
Sex 36 (90%) 1 (3%) 3 (8%) 
Address/ village 32 (80%) 2 (5%) 6 (15%) 
Education 29 (73%) 6 (15%) 5 (13%) 
Diabetes management and 
control 
31 (78%) 5 (13%) 4 (10%) 
Diabetes complications 29 (73%) 6 (15%) 5 (13%) 
Other medical complications 22 (55%) 8 (20%) 10 (25%) 
 
40 
 
 
Other data collected by individual countries included: lipids/cholesterol, family 
history of diabetes, history of smoking, BP; eye exam, blood test, creatinine, 3 
daily blood glucose, glycosylated hemoglobin every 3 months, complete 
laboratory analysis once a year, ophthalmological control, annual foot review, 
weight and height, BMI, number of educational diabetes sessions attended, 
education, school grades. In India (Nagpur), as part of their initial assessment of 
a child being considered for the IDF-LFAC program they also collected some 
economic and related data about the family’s circumstances, e.g. whether parents 
were working and average daily wage, home circumstances and room numbers 
etc., whether and how they had previously paid for insulin. This information 
helped the clinic to decide whether the patient was suitable for IDF-LFAC 
support.  
70% (n=28) reported sharing the data collected with IDF-LFAC. 62.5% (n=25) 
reported that the IDF-LFAC program had improved data collection in their 
country. Yet while some countries clearly recognize the importance of data 
collection and using information, and the importance of monitoring in relation to 
the IDF-LFAC program, many do not. In the survey only 24 countries reported 
that they completed an IDF-LFAC data sheet every year on each child. This is not 
an onerous task but is only completed by 60% of countries.  
In the countries visited there were excellent and very poor examples. Rwanda 
has developed an excellent data capture and information system, but this has 
been heavily supported by the ‘research’ support that they have from external 
experts. Lessons can be learned from this data set and system for other 
countries, and even if it is not immediately transferable then the principles 
involved should be shared.  
At the other extreme, Jamaica was extremely poor at collecting data from the 
clinics. It was apparent that although the diabetic association has a responsibility 
to collect the annual datasheets for return to IDF-LFAC it does not do so. The 
doctors themselves in the clinics visited were, when reminded, aware of the 
annual datasheets but had not completed them as they had not been ‘chased’ for 
them. A suggestion that the diabetic association should use some ‘leverage’ as a 
quid pro quo for providing insulin and supplies, was not well received. However a 
more forceful way of IDF-LFAC ensuring they are collecting this data needs to be 
found.  
In the Philippines the PSEDM (Philippines Society of Endocrinology and Diabetes 
Metabolism), one of the clinic bases for the IDF-LFAC program have just 
developed a database for their own delivery. This could possibly have benefitted 
from Rwanda experience and/or could be shared with others especially in the 
Philippines. The Philippines originally decided that the doctors in the three main 
clinics could be responsible for data collection and annual returns to IDF-LFAC 
but this has not worked out well and they have just appointed someone to collate 
the data, from the whole IDF-LFAC program. They have a backlog of data from 
2013.  
IDF-FAC has set up an internet based database which countries can use to supply 
data back to IDF-LFAC and also to monitor children in their own programs. 
Whilst this seems a good solution, it requires ethical approval in each country, 
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which in some countries is both cumbersome and expensive, and it also requires 
robust internet connectivity, something that is not always available in all 
countries. IDF-LFAC is exploring options to make this system more readily 
available and useful, as only nine countries are using it.  
It is clear that, in many countries (62.5%), IDF-LFAC has been instrumental in 
improving the data that are collected. However, some countries already had good 
clinical systems so there was little scope for IDF-LFAC to bring further benefits. It 
is, however, clear that the real benefits of this potentially huge data set have not 
yet been realized, given its scope to provide unique data on impact and outcomes 
of the program, suggesting the potential value that would accrue if IDF-LFAC 
could forge links with health service researchers, for example, engaging with 
academic networks such as Health Systems Global. The resulting outputs could 
be extremely valuable in advocacy.  
Impact on diabetes management 
The survey enquired what impact the IDF-LFAC program had on diagnostics, 
management and control, coverage, training and awareness 
Whilst only about 74% of the survey recipients responded overall, the vast 
majority (83%) identified improved management and control of T1D as the 
major impact of IDF-LFAC and this was reinforced in the visits where all the 
countries identified the fact that children were surviving and there were fewer 
hospital episodes and fewer complications. Table 12 shows the impact of the 
IDF-LFAC program on diagnosis, treatment, care, training and awareness of T1D. 
Nearly 50% also identified that there was extended geographical coverage since 
IDF-LFAC and increased general awareness. 
Staff training was another area identified but only 33% thought IDF-LFAC had 
impacted here. This accords with the 100% response that there is a need for 
more training of health care professionals. 
Table 12   Number and percentage of countries reporting a positive impact 
of the IDF-LFAC program on a range of T1D services, including diagnosis, 
management, geographical reach, training and awareness. 
 
Yes No 
Missing/ don't 
know 
Numbers being correctly diagnosed 17 (43%) 7 (18%) 16 (40%) 
Diabetes management and control 33 (83%) 1 (3%) 6 (15%) 
Wider geographical coverage in diagnosis, 
treatment and care 19 (48%) 10 (25%) 11 (28%) 
Staff training 13 (33%) 17 (43%) 10 (25%) 
General awareness in the wider population 17 (43%) 14 (35%) 9 (23%) 
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A number of other IDF-LFAC impacts were also identified, which exemplify the 
range of support that IDF-LFAC gives and how they are having impact in 
different countries.  
• “Parents economy has improved - when they don’t have to buy strips, so they 
can buy better food instead” Mexico 
• “Training of primary care health care professional on how to care for these 
children. We have also engaged with the media and patients have explained the 
symptoms they had at the beginning on national TV” Kenya 
• “LFAC has built hope. We lost one child but the other 6 would have surely died. 
Thanks to IDF-LFAC we have been operating for 4 years and the children are 
relatively well, coming to the “clinic” every two weeks from far away distances. 
They are glad to come. They come with their coolers and pack of ice for check-
up and insulin” Liberia 
• “The book from IDF-LFAC on caring for diabetics in a resource poor setting is 
very helpful” Pakistan 
 
From the country visits, there was repeated reference to how children would 
surely have died without the support of IDF-LFAC. In Rwanda there were 
apparently only 25 children diagnosed with T1D when the IDF-LFAC program 
started there in 2004, whereas by 2014 there were over 1000 children and 
young people who had been supported. Prior to IDF-LFAC they were either not 
diagnosed, or misdiagnosed possibly as AIDS or Malaria and consequently died. 
Similarly in India (Nagpur) the Dream Trust (through which IDF-LFAC is 
delivered) was set up in 1995 as a result of two girls, who had been recently 
diagnosed with T1D, dying. They died due to lack of insulin as it proved too 
expensive for their families. In many of these poor countries, some families, with 
several children, have had to make the heartbreaking decision that the other 
children have to take precedence over the child with T1D in their impoverished 
economic circumstances. The IDF-LFAC program ameliorates these problems. 
Support for advocacy 
LFAC have provided some advocacy training and support to some countries, with 
awareness raising being the most common, but even this was only in just under a 
third of countries. Table 13 shows various types of support received from IDF-
LFAC.  
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Table 13 Support received from IDF-LFAC related to advocacy and 
sustainability 
 
Activity Yes  No 
No response/ 
don’t know  
Awareness raising in the community / 
Information campaigns  
30.0% n=12 37.5% n = 15 32.5% n =13 
T1D advocacy with government 15.0% n=6 57.5% n = 23 27.5% n =11 
T1D advocacy with civil society, professional 
organizations or others 
12.5% n =5 57.5% n =23 30.0% n =12 
Encouraging government to take on the 
responsibility of care for its own Type 1 Diabetes 
patients 
10.0% n =4 55.0% n =22 35.0% n =14 
Vocational training for children and young 
people to be able to be self-sufficient in 
managing their diabetes after leaving the 
program 
12.5% n =5 60.0% n =24 27.5% n =11 
Work with pharmaceutical companies to provide 
medicines and supplies for Type 1 Diabetes at 
reduced costs 
17.5% n =7 47.5% n =19 35.0% n =14 
 
There does seem to be considerable scope for countries to learn from each other, 
consistent with the South-South approach supported by IDF-LFAC.  
Partnership working and peer to peer with other countries 
15 countries (37.5%) reported that they worked in partnership with other 
countries and 17 (42.5%) that they don’t. These partnerships included or were 
described as: “NACR”; providing training in another country; cooperating with 
neighboring countries; one received support from physicians/nurses in Belgium; 
co-operation via Insulin for Life; occasional visits from different countries; 
partnership work through ASPED and ESPED or through PenPal United’s 
network and one through the pediatric endocrinology training center in Kenya.  
Of 31 respondents to the question about whether peer to peer country support 
would be useful, the majority of countries, 90% (n=28) would welcome a 
support program or would like to work with other countries, 10% (n=3) were 
not interested. The country visits identified enthusiastic support for this 
approach.  
How has the support from IDF-LFAC impacted on national policies?  
Many specific examples of the positive impact of IDF-LFAC have been described 
in previous sections. The main themes that emerged from the survey included: 
• Better training provision 
• Expansion of free care  
• More children surviving, improved quality of life and fewer complications 
• Strengthening of health systems involved in T1D care 
There were no negative themes that emerged, but a few individual comments, 
including one respondent saying that now, when the children could test blood 
sugars, which they could not afford in the past, the children found it a lot of work 
and another respondent pointing out that it was a good program but there were 
need for more training for health professionals. A third respondent commented 
that there was also need for more resources for long acting insulin, and 
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partnerships with local organizations to start a dialog for national policy for 
children with type one diabetes. As one Indian interviewee noted: “LFAC is saving 
many lives in resource poor communities in India. However due to limited 
resources has not been able to provide long acting insulin, training of health care 
professionals and partner with local organizations to start a dialog for national 
policy for children with type one diabetes”. (India- Haridwar) 
Sustainability 
The ultimate goal must be for people with T1D to be able to get good treatment 
and care routinely through their country’s health system. This does not appear to 
be a realistic goal in the short term in most countries. Even in the more 
prosperous countries visited, such as Mexico, there were still difficulties with 
meeting such a goal. The survey asked about the integration of the IDF-LFAC 
program into the national health services and the expected timeframe that IDF-
LFAC would need to continue 
in that country.  
Of 31 respondents to the 
question about integration, 
61% (n=19) thought that the 
IDF-LFAC program could be 
better integrated into the 
National Health Service. Most 
recognized that a change in 
public health policy would be 
needed for T1D to become a 
health priority. In practice the 
model IDF-LFAC adopts of 
entry to each country through 
a ‘local champion’, utilizing the 
health service arrangements that exist in the country to deliver care, is designed 
to ensure that the IDF-LFAC program is well placed to become better integrated.  
This approach by IDF-LFAC should be applauded and supported. It differs from 
some other NGOs who ‘arrive’ with a ‘model’ which they impose. Some of the 
experts interviewed recognized the importance of this integrated model that had 
been adopted by IDF-LFAC, but also the importance of ensuring the government/ 
ministry of health was engaged, suggesting that IDF-LFAC should “not take 
another step without the Ministry saying what part they are going to take” and the 
importance of “expanding the engagement of the government” and for “a 
developing country to do things itself” but that it did depend on what sort of 
infrastructure and framework there is to integrate with. Respondents to the 
questionnaire suggested that the IDF-LFAC activities could only be integrated 
with those of the Ministry of Health if there were certain structural or 
organizational changes in the government system, such as greater commitment 
by the government (Ethiopia, Guyana, Kenya); greater decentralization - “We will 
develop general diabetes management protocols and specific protocols for type I 
diabetes. Decentralization of care to other provinces is recommended to reduce the 
distance of the associations for the provision of supplies. Capacity building is 
urgently needed”(Burundi); access to low cost insulin through a government 
program -“If the government finds partners who can provide low-cost insulin and it 
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has a team of management of a specific program of diabetes and other NCD” 
(Republic of Congo); higher prioritization of T1D;  and improved guidelines. 
Other changes included better infrastructure, higher health care expenditure, a 
health system with a social conscience, and freedom from inter-communal 
violence.  
 When asked what was the expected time-frame that IDF-LFAC would need to 
continue, over 80% of countries thought it would take 10 years or more before 
their government would take over the responsibility for treatment and care of 
children and young people with T1D. 
These issues highlight the importance both of early engagement with the 
Ministry of Health when an IDF-LFAC program is starting in a country, and also 
the necessity for a ‘strategy’ for that country specifying how the program should 
evolve over time and what might be the exit strategy. Regular reviews, perhaps 
after 4 or 5 years in a country, should be undertaken to ‘take stock’ and ensure 
that the IDF-LFAC program is delivering support most efficiently and effectively. 
This is also an opportunity to reengage with the Ministry. Appropriate skills are 
needed for this sort of strategic dialogue and IDF and IDF-LFAC need to consider 
how best this can be taken forward. Similarly this approach needs to engage both 
with the ‘local champion’ individual or organization (often the local diabetic 
association) through which the IDF-LFAC program is organized, and with senior 
clinicians and endocrinologists who should be advocates for their patients and 
services. Leadership, advocacy and influencing skills are needed and IDF, 
working with suitable experts, should consider how these skills can be 
developed and enhanced in each country.  
A further group of advocates may be the children and young people themselves, 
who, with appropriate support and skills development could become very 
powerful advocates. One young man, a ‘graduate’ from the IDF-LFAC program 
was already representing a group of people with T1D in Rwanda. Review of the 
‘young leaders’ program and the need for a range of skill development, needs 
consideration and may need specific funding streams. Without this direction 
then there is a risk that IDF-LFAC continues to deliver insulin and care 
management ad infinitum.  
The longer term 
IDF-LFAC does not appear to have a strong advocacy role at a national level but 
several countries recognized that its activities had been instrumental in 
increasing the prominence of T1D within their Ministry of Health. During the 
Rwanda visit, it was apparent that IDF-LFAC played an advocacy role, alongside 
other partners, at an important meeting with the Ministry of Health, about the 
way forward within the framework of the NCD strategy and the continuing 
involvement of NGOs in strategy development and implementation. The Minister 
of Health herself clearly recognized the important role IDF-LFAC was playing.  
The Tanzanian respondent reported how IDF-LFAC contributed to advocacy with 
civil society and professional organizations in collaboration with other 
stakeholders, and the Azerbaijani respondent reported that IDF-LFAC had 
supported their advocacy with a speech on television, newspaper articles, and 
frequent meetings with representatives of the Ministry of Health. This seems to 
have achieved results as the Azerbaijan government has now decided to provide 
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50 free strips per year to people with diabetes (as noted previously). Ethiopia 
and Mauritania both reported that training received by IDF-LFAC had helped 
with advocacy with the Ministry of Health and media programs 
However, as was noted, “The Tanzanian Government is lacking resources to 
support most of IDF-LFAC activities however some steps have been taken within the 
Ministry of Health and Social Welfare NCD unit where now there is sufficient 
manpower and recently hired a pediatrician which in itself is a step in the right 
direction. For long term sustainability there arise a need for an extended advocacy 
campaign that will constantly remind the Government into setting aside funds in 
order to efficiently run IDF-LFAC program.” but “LFAC could support the budget for 
mounting advocacy campaign with the Government”.  
In terms of international advocacy, IDF-LFAC has negotiated with some of the 
main insulin and other goods (glucometers and syringes etc.) suppliers to donate 
their products to the IDF-LFAC program. This is an important part of the 
program delivery but also has some negative effects. For example, there is 
restricted variety of goods available and, as noted previously, there still seems to 
be some problems in some countries with importation and customs. We reiterate 
the importance of IDF-LFAC negotiating, when it initially engages with a 
government or periodically renews its agreements, assistance from the 
government to reduce the costs (both in terms of taxes and duties and in labor) 
of complying with regulations, in regard to customs and importation of these 
‘donated medical’ goods. Whilst this is not usually the province of the Ministry of 
Health, it would be symbolic of ‘government’ support.  
In some countries, India (Nagpur) and the Philippines, the local IDF-LFAC 
program procured insulin and other goods locally, having negotiated a reduced 
price. This had the advantage that there were no importation and customs issues 
and also the local procurer (clinic/ doctor) could purchase a range of insulin 
types.  
A key issue is the supply of test strips. It is apparent that manufacturers have 
adopted a business model, similar to that with printer cartridges and razor 
blades, where the initial equipment is inexpensive but the disposable goods are 
very expensive. This situation is maintained by designing for incompatibility 
with existing products and use of intellectual property laws to prevent 
emergence of competitors. We note that IDF-LFAC has initiated discussions with 
an inventor and manufacturer exploring a printer-based model, to create strips, 
albeit this is still in early stages of development. However, we believe that there 
is an extremely strong case for production of a generic glucometer along with 
facilities, such as adapted ink jet printers, that could produce low cost strips. 
While we recognize that the IDF may find it difficult to campaign on this issue 
given its considerable support from strip manufacturers, we recommend that the 
Helmsley Charitable Trust explore other mechanisms by which this might be 
achieved. 
34 countries responded to the question about national diabetes care guidelines, 
and only 9 countries reported that they have national guidelines available to 
primary care physicians. One country noted that they have national guidelines 
but they are not readily available and not implemented. Guidelines can be an 
extra resource for health care workers, physicians, nurses, especially in 
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countries with limited diabetes training. Resources such as the IDF/ISPAD 
Pocketbook for the “Management of Diabetes in Childhood and Adolescence in 
Under-Resourced Settings” could be promoted to the countries and through the 
LFAC website and newsletters. 
Impact on priorities of governments 
When asked whether there had been any difference to the government’s 
prioritization of providing care to people with Type 1 Diabetes due to IDF-LFAC, 
only a minority of responders (21%) thought IDF-LFAC had made a difference 
and only 9% reported that IDF-LFAC had participated in conversations about 
diabetes-related policy and health budgeting with relevant health decision-
makers in their country. In at least one country, Azerbaijan there has been a clear 
impact, with the government now providing strips, although as noted previously, 
this seems rather modest given the resources available to the Azerbaijani 
government. However, respondents to the survey described many ways in which 
IDF-LFAC had been seen to have a positive impact, as is exemplified by quotes 
such as “…LFAC has been a life saver..” (India), “…with the availability of insulin 
fewer are dying..” (Nigeria), “..LFAC has built hope” (Liberia), and “The 
government began to take an active part in providing diabetes supplies,.. improved 
diagnosis of diabetes, decreased acute and chronic complications of diabetes in 
patients” (Azerbaijan). From the visits a similar picture emerged. In Rwanda, 
IDF-LFAC was clearly an important player, alongside other partners in the 
overall development/ implementation of policy, but in the other countries 
visited this was not apparent. In Rwanda, one of the external experts commented 
that the presence of IDF-LFAC had stimulated the diabetes association to also 
become more of an advocate. 
Respondents made some practical suggestions (below) on what IDF-LFAC could 
do to help the government take over responsibility for treating the 
children/young people. Many point to the importance and necessity of ‘official 
conversations’ and advocacy with policy and decision makers whilst some 
recognize the futility of this given the current state of their government and 
health system.  
• Start official conversation through the association and directly with the 
Ministry of health. (Ethiopia) 
• It is difficult. Maybe train people high up in government on diabetes care first. 
(Kenya) 
• For the moment the government is still involved in programs from the World 
Bank: e.g. malaria, TBC Aids, trypanosomiasis vaccinations (Ebola??). Diabetes 
should be added to those programs (DRC) 
• LFAC could support the budget for mounting advocacy campaign with the 
Government. (Tanzania) 
• Re-engage with Fiji government through meetings with policy makers to assess 
its readiness to take over full funding for all medical related cost for children 
and young people with type 1 diabetes. (Fiji) 
• Leave sufficient funds and necessary equipment for the monitoring of diabetic 
children. (Burundi) 
• Start on coordinating talks with decision makers at Government level. 
(Dominican Republic) 
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• More meetings with authorities. (Sudan) 
• Partner with public health foundation, ministry of health and similar 
organization to have policies towards the needs of children with type one 
diabetes. Patients. They are the forgotten ones. Having policies is one thing and 
enforcing them another thing. Corruption is a big barrier for governance in 
India. (India) 
• Yes they can encourage government for support of free insulin to type 1 
diabetic patients at least after 25 years of age. (Nepal) 
• Better education of endocrinologists would show the impact of proper care and 
treatment. They may advocate their own government once they see the 
difference that proper care makes. (Tajikistan) 
• By engaging government in discussion at the highest level and through 
international agencies. (Nigeria) 
On the other hand, there was some cynicism that anything would help, as this 
quote from Bolivia indicates: “At present I think is not appropriate or desirable to 
help this government as we believe that any help would not reach the 
beneficiaries.” 
Overall Impact of IDF-LFAC 
 Overall there were positive responses to the IDF-LFAC program through all 
aspects of the evaluation. Many of the children and families recognized the 
importance of what they were receiving both in terms of insulin, but also in 
terms of education about T1D and support to manage it. All were appreciative 
and expressed their gratitude spontaneously.  In Nagpur, the mother of a 9 year 
old girl, who was also deaf, said  “she now talks again” following her starting to 
receive support from IDF-LFAC, through the Dream Trust. Many had stories of 
how devastated they were when the child was diagnosed with T1D but also how 
the support from IDF-LFAC had changed their lives. From the survey, countries 
also indicated the positive impacts (Table 14)  
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Table 14 Descriptions of the positive impact of IDF-LFACs support: 
Azerbaijan The government began to take an active part in providing diabetes 
supplies, improved diagnosis of diabetes, decreased acute and chronic 
complications of diabetes in patients 
Ethiopia Through the program we were able to do posters and distribute 
educational materials and the diagnosis rate has improved as the 
number of children reported from each centre increases. 
Haiti With the availability of the insulin and materials, children and young 
adults can stay alive and try to avoid complications. Children and 
young adults living outside of the capital of Port-au-Prince can receive 
the materials and insulin at the affiliated center of FHADIMAC where 
they are followed for their diabetes 
Democratic 
Republic of 
Congo 
Now at least in Kinshasa most people or doctors know where to go for 
treatment when a young patient has diabetes 
Fiji Establishment of local guidelines to manage DKA, other situations 
such as sick days, surgery etc. 
Bolivia Most children and youth diagnosed in recent years have not reached 
the point of ketoacidosis as parents or paediatricians have directly 
identified diabetes as a cause of the symptoms presented and have 
taken proper and effective measures securing them endocrinologist 
specialist or paediatric endocrinologist care. 
Ecuador If we wouldn’t have the IDF-LFAC support we could not attend the 
children with type 1, because we opened the “programa de 
apadrinamiento” since we receive their insulin support. 
Uzbekistan Intensive insulin treatment regimen is implemented at all regions of 
the Republic. 
India In the resource poor communities IDF-LFAC has been a life saver. 
Where no child had survived prior to IDF-LFAC we now have 56 
children leading a normal life. We also have about the same numbers 
following MDI from resource sufficient communities. 
Pakistan One of my patients has had leg cramps for the past 3 years. In the book 
they recommend Amitriptyline. When we started that she immediately 
improved. She is grateful not to have the leg cramps any more. 
Vietnam Helping patients monitor their complications better 
Tajikistan Glucometers have allowed some endocrinologists to train their 
patients in daily blood glucose testing, which has assisted with the 
adjustment of insulin and improvement in blood glucose control. 
Since distributing IDF-LFAC insulin and glucometers, the wider 
endocrinology community has seemed to be more aware and 
interested in type 1 diabetes. 
Nigeria With the availability of insulin fewer are dying, the insulin is 
distributed to all over the country 
Liberia LFAC has built hope. We lost one child but the other 6 would have 
surely died. Thanks to IDF-LFAC we have been operating for 4 years 
and the children are relatively well, coming to the “clinic” every two 
weeks from far away distances. They are glad to come. They come 
with their coolers and pack of ice for check-up and insulin 
 
A final question in the survey asked for any further comments about IDF-LFAC. Many 
expressed again their gratitude and that they were now able to treat disadvantaged 
children and young people with T1D through the program: 
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•  “the actual team of LFAC is very dynamic and very supportive” (Haiti)  
• “Our patients need the LFAC support, please support LFAC that way you 
support our needy diabetic patients. No doubt: it is one of the best program I 
ever experienced (I have seen many in 40 years) (Kenya) 
• “…with limited resources they have made a difference in the lives of children 
with diabetes. More needs to be done” (Ecuador)  
• “I think that many children would not be alive if there was not this program 
that demonstrates the real existence of solidarity between individuals, 
institutions and charitable organizations…..proud and honored to work with 
this program.” (Bolivia)  
• “thank you so much. Please come visit us. See what you are doing for our 
children” (Liberia) 
 
IDF-LFAC is clearly doing good things for children and young people  
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Recommendations  
1. LFAC organizational structure and delivery  
i. IDF-LFAC should maintain its current flexibility of approaches so that 
it can provide what is needed in each country to best effect and most 
efficiently. The ‘context’ in the country in which IDF-LFAC programs are 
delivered is crucially important, with widely varying health system 
infrastructures and potential for sustainability.  
ii. It is essential that there is a clear strategy to embed IDF-LFAC within 
the health system in each country. This is a task that will require 
specialist expertise beyond what can be provided by IDF-LFAC. We 
recommend that IDF identify how best this could be achieved, with one 
option being the creation of a small team based at IDF headquarters but 
with strong links to other academic and civil society organizations 
involved in health systems research and development, such as the 
Helmsley Charitable Trust Type 1 Diabetes Program’s grant to Health 
Action International. We would expect that IDF could raise the 
necessary funds for such activities. 
iii. Review the approach to the initial ‘needs assessment’, which uses a 
questionnaire framework and is often undertaken by an external 
expert. In some countries the children that do receive support from IDF-
LFAC may not be the most disadvantaged in that country. IDF-LFAC 
recognizes this problem, and probably those most in need in any 
particular center are covered. However further consideration needs to 
be given as to how those most in need (across a country) can be 
supported. Review of existing RAPIAs, as in the Philippines, may be 
useful. Combining both information from RAPIA, where this is available, 
and from the IDF-LFAC initial ‘needs assessment’ could be useful in that 
these can be used in combination and can assist making connections 
with relevant NGOs (e.g. as in Mali). Efforts should be made to focus on 
the children in most need. This may entail IDF-LFAC supporting the 
development of capacity in their ‘local champion’ to be able to deliver to 
the poorest parts of the country, as was seen to be a necessity in Mexico. 
Consideration needs to be given as to how this can be achieved and 
whether it requires specific additional funding.  
iv. Consider greater use of expert volunteers to offer support and 
mentoring to countries particularly at ‘start up’. Also consider ‘peer to 
peer’ support and research. (see later).  
v. Develop a formal mechanism/system for ‘review’ of the IDF-LFAC 
input after (say) 4 or 5 years, to ensure ongoing support continues to 
match needs and modify the IDF-LFAC program support as appropriate.  
vi. It is clear that Graham Ogle has accumulated a wealth of knowledge 
about the IDF-LFAC partners. There is a centralized ‘Dropbox’ 
repository of information shared by the IDF-LFAC team but 
consideration should be given as to whether there should be more 
‘summaries’ provided to each country each year. There is also much 
information held in ‘heads’. This is important for two reasons: a) 
succession planning, something that we believe will require attention in 
its own right, not least because many of the partners envisage 
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engagement with IDF-LFAC for more than 10 years in the future and b) 
because it will be important to ensure that IDF/LFAC has an 
institutional memory that goes beyond one individual. We recommend 
that IDF commission an oral historian to work with Graham Ogle to 
document the rich experiences of IDF-LFAC.  
vii. Applaud and capitalize on the excellent work that individuals in IDF-
LFAC bring to the program. Clarify roles and responsibilities between 
IDF-LFAC and IDF, and between IDF-LFAC and IDF and the Australian 
Diabetes Council/ Diabetes New South Wales (same organization but 
recent name change). Consider IDF holding more strategic and 
advocacy roles whilst IDF-LFAC focuses more on delivery of the 
program.  
viii. IDF-LFAC should take time now to develop an explicit plan that can 
address both contingencies related to the Director’s (GO) and the IDF 
team’s work and, in the longer term, succession planning for key IDF-
LFAC personnel. 
ix. We recommend that the core staff be strengthened by the appointment 
of an additional administrator in Sydney. We believe that this should 
be considered a higher priority for available funding than expansion to 
additional countries. 
2. Optimal strategic framework for high impact sustainable results  
i. Continue to use the Diabetic Associations in the country as the 
‘route’ in and for them to use the ‘health system’ in that country for 
delivery. This ensures that the IDF-LFAC support is well ‘grounded’ and 
leads to more sustainable opportunities in the future. In some countries 
there is direct delivery through government (e.g. Burundi). The 
principle should be to use a ‘local champion’ who can make it happen. 
ii. Learn from the countries where data collection and collation is robust 
and ‘require’ this of all countries. IDF-LFAC should ‘demand’ the annual 
information returns and use the leverage of IDF-LFAC support and 
supplies by potentially ‘threatening’ to remove support unless robust 
information is delivered. IDF-LFAC should consider requiring each 
partner to use standardized data entry software, such as that already 
developed in the IDF-LFAC database (see below) or in Rwanda. This 
would ensure that the data were provided in a consistent format. 
iii. We recommend that information be collected on the fate of those 
who ‘age out’ of the program. This would provide powerful outcome 
data both specifically for the IDF-LFAC program but also on the burden 
of disease. 
iv. LFAC have set up an electronic database which is available to all 
countries to input their data. It is currently only used by a small number 
of countries (currently 9 and another has just gained ethical approval). 
There may be difficulties in some countries with internet access and 
with applying for/ obtaining ethical approval. IDF-LFAC are exploring 
‘standalone’ or other formats including delimited Excel sheet or paper. 
We recommend that IDF-LFAC consider how to transfer data most 
efficiently and whether using electronic data systems, as have been 
set up in some countries e.g. Rwanda, Philippines, could be 
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‘transferred‘ to other countries, or at least to adopt similar principles, 
or to use ‘shared data management’ systems. (This may need further 
exploration, possibly with specific funding) 
v. We recommend that IDF-LFAC and countries recognize the 
importance of data/ information to inform the ‘burden of disease’ 
(including diabetic sequelae and complications). This is a powerful tool, 
as a byproduct of the IDF-LFAC program, and can/ should be used to 
greater effect with ministries of health. This contributes towards the 
sustainability of the program. Linkage to the databases (above) needs 
exploration. Special funding may be needed to initiate this. 
vi. LFAC should continue to work in partnership with other 
organizations/ NGOs. The flexible approach adopted by IDF-LFAC, 
working with any reputable sensible group, should remain, including at 
times acting as ‘peacemaker’ between groups. Similarly the approach 
adopted to ensure compatibility with the health system/ context of the 
country should remain, rather than a defined model that is imposed. 
Pilot mechanisms for joint working/ shared funding e.g. by using 
opportunities such as those with Marjorie’s Fund and with Team Type 1 
in Rwanda. And then apply elsewhere. 
vii. IDF-LFAC should capitalize where possible on ‘research’ both to 
document benefits and to learn lessons for IDF-LFAC and other NGO 
delivery, as well as for clinical management. (link to 1.iv) re expert/ 
volunteers. However note that research support may be of limited 
duration and consideration has to be given to ‘handling’ when funding 
ceases. Learn from stellar experience in Rwanda, in Nagpur re care-
giver research, the ‘epi’ study and elsewhere. Also explore if there are 
opportunities for working with public health groups. This may require 
specific funding e.g. to cover expert researchers’ air fares/ subsistence 
for visits etc. 
3. Changes to policies that could improve quality, quantity, efficiency or 
effectiveness 
i. IDF_LFAC continues to balance ‘width and depth’ when deciding who to 
support and both approaches have pros and cons. However on balance 
it appears the current ‘wide’ approach may be appropriate, with 
varying depth of ‘packages’ as appropriate. However, this should 
include agreement on a set of minimum criteria that a country should 
meet for support to be viable, expressed in terms of numbers of 
children and existence of supportive infrastructure. Thus, it is unlikely 
that it will be appropriate to support countries with only a very small 
number of children or where the contribution is minimal in relation to 
the total disease burden, or to initiate support in the midst of ongoing 
conflict, as this should, more appropriately, be a responsibility of other 
organizations with experience in such areas, such as MSF. Caution 
needs to apply even if IDF-LFAC support is only delivered to a relatively 
stable part of a strife torn country (e.g. parts of Syria). More robust 
mechanisms for these criteria and on initial needs assessment and then 
review (see 1iii and 1v), should ensure the right ’package’ is delivered 
in each country. This provides for a tiered approach, which looks at 
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each country in terms of leaving a sustainable legacy both for the 
children and for the country as a whole.  
ii. In some countries there are children on ‘partial’ support (e.g. just 
glucometers and strips) and others on full package (i.e. including insulin 
and syringes etc.). The local clinicians making these decisions against a 
background of overall economic criteria remains sound. Some countries 
did not recognize that they were applying sound criteria, such as 
household space and income, a history of difficulties in access to or 
paying for insulin etc., but they were. These criteria could be more 
formalized but a view has to be taken as to whether this would be 
advantageous. Maybe at ‘start up’ some principles including such 
issues could be shared with newly engaged countries, as part of set up  
guidelines, and for IDF-LFAC to encourage them in this approach. 
However local application is important for realism and for ‘ownership’. 
iii. We see more capacity building and education and training amongst 
health professionals within countries as critical to the delivery of 
quality and effective care for T1D. Nurse capacity, educators as well as 
professional training is needed. 100% of respondents to the 
questionnaire thought there was a need for more training of health care 
professionals. Relationships to ISPAD ‘training’ and IDF capacity 
building needs to be taken into account. Mentoring /expert 
relationships can also help here. More can be done with more 
resources. This may need a specific focus and funding stream. 
iv. We recommend that IDF-LFAC should maintain the current age limits, 
but emphasize methods to support the diabetic associations to prepare 
children (and families) to be self-sufficient by age 25. So far, 
discussions seem to have been dominated by the issue of obtaining 
supplies of free access to those over 25. In part this is because many 
individuals with diabetes are excluded from the labor force. An 
alternative is to provide them with the skills and, where necessary 
capital or equipment to earn money. We have identified several 
promising models of support for ‘self-sufficiency’ in four countries, all 
supported by IDF-LFAC, i.e. in Rwanda (educational center); India 
(Nagpur) educational grants/ rehabilitation/ vocational training; 
microcredit in Tanzania; and mobile phone repair in Bangladesh. 
Another possibility, described in Haiti, is to employ young people with 
diabetes as diabetes educators. We see all these as holding great 
promise and consider that they could be a legitimate area for 
extended support by IDF-LFAC. Draw out lessons and principles and 
apply/support/ fund in other countries. Ethical issues of ‘aged out’ are 
thus diminished. IDF-LFAC may choose to adopt a role of ‘start-up’ 
funding to precipitate such action but encourage the local diabetic 
association to look for local support or funding e.g. from Rotary, Lions 
or from partnership with NGOs focusing on vocational training and 
economic independency (e.g. Oxfam in Rwanda). This may need a 
specific focus and funding.  
v. As well as such support to the young people themselves, the countries 
(diabetic associations/ clinicians) also need to be prepared by IDF-
LFAC as to how to support children through the transition off the 
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IDF-LFAC program. This needs consideration as it was clearly an issue 
‘not addressed’ in many countries.  
vi. IDF-LFAC should consider how it could ‘match’ up countries for ‘peer to 
peer’ support (with suitable agreements from countries to adopt this 
approach). The vast majority of countries (93% of respondents to the 
survey) would welcome this approach. It would likely help with quality 
of care, and could also link to the suggestion of a newsletter and 
enhanced website. An initial peer to peer program could be set up and 
evaluated, building on the success of Mali and Burkina Faso and the less 
successful partnership between Sri Lanka and the Maldives. There may 
also be possibilities within countries e.g. between centers within India. 
This may need specific focus and funding.  
vii. “Co- responsibility” model is being used in Mexico to engage children 
and families in order for them to learn how to control and manage their 
T1D. It uses IDF-LFAC support as ‘leverage’. This model of ‘tied in’ 
engagement should be explored elsewhere. Similarly in the Philippines 
a ‘conditionality’ model is being used. There may be other similar 
models elsewhere. In Nagpur a ‘nominal contribution’ from the 
patient for specific care (e.g. cataract removal) is required.. There needs 
to be caution that the most vulnerable children (maybe with less 
supportive or dysfunctional families) are not excluded, although in 
practice it appears that the diabetic association staff usually recognize 
the children who need particular support.. Develop a set of principles or 
guidelines which may be useful for other countries to adopt such an 
approach. These guidelines could be developed by the countries  who 
use these approaches (e.g. Mexico), with support from IDF-LFAC and 
building on evidence from ‘conditionality research’. Special focus and 
funding may be needed.  
4. Impacts on countries, systems and children  
i. Many countries need help with ‘awareness raising’ about T1D. IDF-
LFAC should identify where this has been undertaken successfully and 
develop guidelines/ principles that could be shared with other 
countries. IDF-LFAC has already developed posters on preventing 
deaths from DKA, but this is focused mainly on health care workers. 
They are available in various languages. Currently there are many 
‘barriers’ to children e.g. in schools where there are misunderstandings 
and fear of children using syringes. Zimbabwe has undertaken a 
‘schools program’ which could inform other countries. AM (for IDF-
LFAC/IDF) has developed a schools pack and resources in various 
languages. There are a number of examples of interventions to reduce 
stigma in diabetes, from countries such as Iran (Irani, Abdoli et al. 
2014). A key message is that they must be culturally appropriate. 
Exploration of new mechanisms, including the use of social media 
approaches, may be worthwhile. This may need a specific piece of 
funded work.  
ii. IDF-LFAC should consider whether it should produce a (say) 2 monthly 
bulletin or newsletter to be circulated to all its partner countries. This 
could provide a good vehicle for sharing ‘good practice’ on such 
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activities as ‘awareness raising’, running diabetic camps etc. Countries 
themselves could contribute articles, debate and dialogue. IDF-LFAC 
could use it as a vehicle to develop/ disseminate ‘guidelines’ etc. and for 
countries learning from each other. They should also explore the use of 
social media, such as Twitter, as a means to communicate within the 
network and beyond it. 
iii. The IDF-LFAC support has to ‘start’ at the right point for each country. 
(This should be achieved by the initial needs assessment process). Some 
countries (lower income, less developed) need to start with ‘basics’ i.e. 
just ensuring children are diagnosed and have access to insulin. This 
will evolve over time to a model where there is less focus on ‘survival’ 
and more on ‘thriving’, which entails better control and management of 
T1D (utilizing glucometers,strips,HbA1c etc.). Initially IDF-LFAC and the 
diabetic associations needs to support education of health professionals 
who are not experts in T1D in order that children can be diagnosed and 
given the right support. Developing a more formalized ‘model of care’ 
to demonstrate this ‘evolution’ through care packages and how this 
relates to benefit for the patient may be helpful to the delivery of the 
IDF-LFAC program. This should build on the table of development IDF-
LFAC already has and also potentially relate to the IDF-LFAC ‘Index’ 
when this is finalized. The model needs to show the development and 
flow into the exit strategy. The model could also be used for liaison and 
advocacy with the country’s Ministry of Health. This may need specific 
funding and to complete the index work.  
iv. IDF-LFAC’s Training and educational resources are recognized as 
excellent. There needs to be capacity to ‘translate’ these into 
appropriate languages and make them culturally appropriate. 
National diabetic associations could be required to take more 
responsibility, building upon the work of IDF-LFAC in their countries, in 
adapting educational materials by means of ‘in country’ translations 
and adaptations. IDF-LFAC could also help by designing visual 
templates that appeal to children globally but in a few different designs, 
so that each country can download the design they prefer and add the 
text locally. Additional funding may be necessary. 
v. ‘Camps’ are recognized by children and families and by professionals as 
hugely beneficial to the children with T1D both in terms of ‘learning’ to 
manage their T1D and in making contact/ friends with other children 
and YP with T1D. (It is often the first time they have met other children 
with T1D). Funding to continue to support these and to enable the IDF-
LFAC educator to contribute to these camps and provide educational 
materials would be beneficial (see iv) above). Other key staff, such as 
psychologists are also recognized as important. Again ‘guidelines’ are 
being drawn up by AM building on countries’ and IDF-LFAC experience 
of ‘camps’. Some children and YP suggested ‘international diabetes 
camps’, which is an interesting idea to explore. Whilst local funding may 
be more appropriate for camps themselves, specific IDF-LFAC funding 
may be needed to catalyze action, develop and disseminate guidelines, 
educate at camps etc.  
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vi. Mechanisms for, and to encourage, children and YP with T1D to be ‘in 
touch’ with each other should be explored, potentially both within 
country and between countries. This should build on experience from 
countries where this approach is accelerating e.g. Rwanda, Bolivia and 
Tanzania and social media should be explored. The newsletter/ bulletin 
could be a vehicle for dissemination. Specific focus and startup funding 
may be needed. 
vii. There has to be a degree of ‘realism’ as to whether T1D is likely to be a 
‘priority’ within each country for the Ministry of Health. Whilst the aim 
may be to provide health care for all, this may not be a realistic goal for 
all countries and they will have other priorities both economic and 
within health services. The burden of disease is an important tool (see 2 
v). Access to insulin as an ‘essential medicine’ (WHO list) may be an 
important step. Steps should be taken by IDF early in the ‘start up’ of 
IDF-LFAC support to explore possibilities with Ministry of Health (see 
below). IDF-LFAC’s ‘exit strategy’ should be part of the startup key 
agreement and the 4/5 year review program (see 1 v) (See also re 
sustainability, leadership and advocacy below) 
viii. Additional materials could be made available to countries by additions 
to the IDF-LFAC website. Whilst some guidelines and linkages are 
already available, further materials could be added and regularly 
updated, such as the IDF/ISPAD guidelines on managing T1D in food 
resource poor settings, advocacy tools such as examples of press 
releases, poster templates, videos, instructions for holding camps, 
setting up registers , stories from children supported by LFAC etc, and 
other materials added as they are developed.  
5. Impact on long term sustainability in T1D care delivery systems 
This section relates to action by IDF as well as IDF-LFAC 
i. IDF as the ‘parent body’ of IDF-LFAC and/or IDF through its respective 
Regional Offices, in concert with the national diabetic association 
should instigate discussions with Minister/ Ministry of Health at 
startup of IDF-LFAC support. Ascertainment of where T1D and insulin 
availability are placed in health priorities is important early on. 
Utilizing T1D ‘leaders’, including local diabetologists/ professionals/ 
IDF Regional Offices and diabetic association, to hold robust 
conversations with Ministry of Health and aim to draw up an MOU, 
with suggested time frame for IDF-LFAC support and for government 
‘pick up’. This should include specific support to exempt “donated 
goods” from import duties or, if this is not possible, to reduce the 
costs of payment and complying with regulations. (Although this is not 
usually the province of the Ministry of Health, it would be symbolic of 
government support). Whilst this and the MOU may not be realized, it is 
a baseline for discussion and can be looked at in the 4/5 year review 
program. Thus, the exit strategy should be explored at the time of 
entry into a country, even though T1D may not be high on the country’s 
agenda at this time. It needs to be recognized that there will be a large 
backlog of countries already participating. The burden of disease 
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information developed/collated in the country from the IDF-LFAC 
program is a useful tool for later discussions. (See 2 v).  
ii. The recent development of the exit strategy from Fiji, with its 
definition of achievement and standard of care should be formalized 
/codified and applied elsewhere.  
iii. Whilst in theory in some countries there is access to insulin and T1D 
care, through the government systems, this may not be the case in 
practice. Diplomatic handling is necessary in these circumstances. 
There is a possibility of gradual wean down of the amount of insulin 
provided by IDF-LFAC in some countries. 
iv. IDF/ISPAD/LFAC should at ‘start up’, ‘mobilize’ leaders within the 
country to act as advocates within the country with politicians/MoH. 
These will typically be drawn from mid-career health professionals who 
are recognized as future leaders. There is much to learn from the World 
Heart Federation Emerging Leaders program. Support to identify key 
players, develop advocacy and leadership and influencing skills 
etc. should be provided by IDF. Leadership, advocacy and influencing 
skills are needed and IDF, with suitable experts, should consider how 
these skills can be developed. This role needs exploring in more detail 
and may need specific funding stream for IDF and suitable ‘leaders’ and 
experts in leadership to take it forward.  
v. IDF to consider the inclusion of a specific stream on health systems 
within the World Diabetes Congress (WDC), as is being done in the 
World Cardiology Congress, encompassing awareness raising and skills 
building, drawing extensively on presenters with expertise in these 
fields who may not so far be engaged with diabetes. This is different to a 
stream on global challenges in health, which already exists. 
vi. The IDF-LFAC presentations at the WDC could focus on specific 
common aspects of the IDF-LFAC program, for example on stigma or 
on awareness raising and thus make ‘linkages’ both between countries 
and to diabetologists with particular interests/ research experience in 
some of the IDF-LFAC key issues. Potential links to new research 
support may be a possibility. 
vii. Key individuals  should also be identified and given suitable support to 
develop advocacy, leadership and influencing skills to promote T1D 
and its treatment and care. They should actively identify  champions, 
such as politicians with an interest in T1D (or who may have T1D 
themselves or in a close family member) who could also, with support, 
act as advocates.  While this is quite different from the role played by 
the existing IDF Young Leaders Program, it may be that some 
participants in it could play an enhanced role as advocates in the future.  
viii. Seeking ‘opportunities’ where IDF-LFAC can demonstrate its 
contribution and ‘worth’ may be important in influencing the Ministry 
of Health e.g. their contribution/experience to developing diabetic 
registers, and/or from research findings. Identifying current examples 
may be worthwhile. Again specific funding may be needed or experts 
identified to contribute.  
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ix. The knowledge held by the IDF-LFAC team is vast but not accessible. 
Mechanisms need to be found to capture and utilize this knowledge and 
to share experiences between countries. (See 1vi). 
x. There is a need for much stronger advocacy in the international 
arena, linking access to insulin with wider movements for access to 
essential medicines and universal health care, while taking advantage of 
the post-2015 development agenda. However, while the evidence that 
IDF-LFAC collects could be used to support such an advocacy strategy, 
including stories from those children being supported, it was 
recognized that there was insufficient capacity to engage meaningfully 
in this process at present. This is, however, an area where IDF could 
play a much greater role in association with the NCD Alliance and its 
members, where IDF already plays an active role, also organizations 
such as Health Action International, with their focus on access to 
essential medicines.  
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Conclusions  
 
This review of the IDF-LFAC program has shown that it is a strong program that 
is delivered well and is extremely valued by the countries and the children, 
young people and their families who are the beneficiaries of the program. It is 
clear that the program enables children and young people with T1D to survive 
and as the program and country policies strengthen enables them also to thrive. 
The IDF-LFAC program already does many things right and the team, albeit 
small, are extremely dedicated and enthusiastic and deliver the program well. 
Many aspects are to be applauded and continued.  
The evaluation was undertaken using review of documentation, interviews with 
key stakeholders, and a survey to 43 countries where the program is active 
including visits to five countries. The country visits were especially powerful for 
examining the IDF-LFAC program in situ and in detail.  A summary of each 
country visit – Rwanda, Jamaica, Mexico, the Philippines and India (Nagpur) - 
and specific recommendations in relation to each country are at Appendices 3 to 
7.  
 The review covers five themes: 
• IDF-LFAC structure and organization 
• Optimal strategic framework for high impact sustainable results 
• Changes to polices that could improve quality, quantity, efficiency and 
effectiveness 
• Impacts on countries, systems and children 
• Impact on long term sustainability in T1D care delivery systems 
  
From this review it is clear that the aim must be to enable and encourage the 
country itself to provide the support necessary for children and young people 
with T1D, but recognizing that this may not be possible immediately in some of 
the poorest countries and hence IDF-LFAC can provide temporary support and 
development to a more sustainable state. From the evaluation we are able to 
make recommendations that would improve the program and may act as a focus 
for the next steps and further funding applications. The full list of 
recommendations, in relation to the five themes, are listed in the previous 
section, and a brief summary of key issues from the recommendations below. 
The main recommendations identify a number of key issues:  
• Strengthening the initial process when deciding to start an IDF-LFAC 
program in a country, both in terms of needs assessment, so that the program 
is focused on children in most need, and with a clear strategy to embed IDF-
LFAC within the health system of the country and to gain ‘buy in’, for the 
longer term from the Ministry of Health, ideally with a MOU and an exit 
strategy. This will require leadership from IDF. Mechanisms to strengthen 
leadership within country are also recommended, which again will require 
leadership from IDF but also specific external expertise for leadership skill 
development.  
• Further enabling countries to be self-sufficient, by encouraging peer to peer 
development, enhancing expert input, utilizing the IDF-LFAC website for 
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supportive resources and developing a newsletter. Whilst these may require 
initial focus and resources they should in time streamline the work of the 
IDF-LFAC team.  
• Education and training has been identified as a recurring theme and all the 
countries surveyed recognize the need both for further training of health care 
personnel and of children and families and for awareness raising in the 
general population. Many of the existing educational materials developed by 
IDF-LFAC are excellent and welcomed but some require translation in terms 
of both language and culture.   
• Education, vocational training and support to children and young people to 
enable them to be self-sufficient when they reach adulthood has been 
developed in a number of countries and needs further focus to expand to 
other countries.   
• Enhance the robustness of data collection from the program, both in terms of 
systems and in terms of requiring feedback from countries, to build into a 
powerful database across 45 (or more) countries and use the data to 
demonstrate the burden of disease. This should include outcome measures 
both throughout the program and when and after young people ’age out’. 
• Finally we identified that there is much experience and a wealth of 
knowledge held in the heads of the IDF-LFAC team and suggest this should be 
captured by commissioning an oral historian.  
 
The aim of this report is to enable the IDF-LFAC program to take stock of the 
program and enhance the elements that are already working well and refocus on 
the areas which have been identified to enhance the program. It is recognized 
that this will require specific funding for ‘start-up’ of some elements and will also 
require some specific external expertise and for IDF to take a greater leadership 
role. 
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Appendix 1 List of interviewees 
IDF-LFAC (Sydney):  
Dr Graham Ogle, General Manager 
Robyn Short-Hobbs, Program Manager 
Angie Middlehurst, Education manager 
Diabetes NSW:  
Stuart Eastwood (CEO) 
IDF (Brussels):  
Dr Petra Wilson (CEO)  
Sir Michael Hirst (President) 
Dr David Cavan (Director of Policies and Programs) 
ACADEMICS/EXPERTS: 
Professor David Beran, University of Geneva (RAPIA) 
Professor John Yudkin, Institute Research Information Service, University 
College London 
Dr Michiyo Higuchi, Chairperson & Senior researcher, Bridges in Public Health 
(Incorporated Association),Mizuho, Nagoya, Japan. (RAPIA in Philippines) 
Professor Trevor Orchard, Professor of Epidemiology, Paediatrics and Medicine, 
University of Pittsburgh, (expert/research in Rwanda)    
Dr Deborah Edidin, Asst Professor Paediatrics, Feinberg School of Medicine, 
North Western University, USA (expert/research in Rwanda) 
Prof Nikhil Tandon, Dept. of Endocrinology and Metabolism All India Institute of 
Medical Sciences (AIIMS) Ansari Nagar, New Delhi (National Diabetes Register 
ICMR)  
RWANDA  
Diabetic Association: 
Crispin Gishoma, Interim Director, Rwanda Diabetes Association  
Ministry of Health, PAHO and Partners: 
Dr Agnes Binagwaho, Minister of Health, Rwanda (joint meeting) 
Dr Aimee Muhimpund, NCD Focal Point at Rwanda Bio-Medical Centre, MoH 
Chantelle Geru, Country Representative, WHO  
Patrick Wajero, Country Director, Rwanda, OXFAM  
Thur de Kuijer, Associate Country Director, Uganda/Rwanda, OXFAM 
Jason Baker, Director, Marjorie’s Fund 
Christian Strong, Team Type One  
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 Dr Gene Bukhman, Senior Health and Policy Adviser NCDs, Partners in Health, 
Director of Global Programs in NCD and Social Change, Harvard Medical School, 
Senior Technical Adviser for NCD to Rwandan Ministry of Health. 
Clinicians treating children and young people with T1D: 
Etienne Uwingabire, Senior Nurse, Rwanda Diabetes Association 
Senior Doctor, Nyanza Regional Hospital, (also met with over 30 children and 
young people)  
Children, Young People and families 
 6 young people, 2 female and 4 male between the ages of 18 and 27 years.  
Also visited and met for group discussions:  
Rwandan Diabetic Association (including 30+ children and young people) 
2x District Hospitals (including 30+ children and young people) 
Education Centre (including 25 young people)  
JAMAICA 
DiabetesAssociation:  
Mrs Lurline Less, Director, Diabetes Association of Jamaica (DAJ) 
Dr Errol Morrison, President, DAJ, President, University of Technology of 
Jamaica.  
Sharlene Keens-Nembhard, Manager, DAJ 
Ministry of Health, PAHO and Partners: 
Dr Tamu Davidson Sadler, Acting Director, Chronic Diseases. MoH 
Dr Kam Mung – Disease Prevention and Control Advisor, Jamaica, Bermuda and 
Cayman Islands, PAHO 
Dr Malcolm, Sustainable development, PAHO 
Miss Estee, Disease Prevention and Control, PAHO 
Clinicians treating children and young people with T1D 
Dr Michelle-Ann Richards Dawson, Senior Medical Officer, Bustamante Hospital 
for Children, Kingston 
Professor Marshall Tulloch-Reid, Professor of Epidemiology and Endocrinology, 
Epidemiology Research Unit, University of the West Indies 
Dr Bovette Butler, Senior Registrar Paediatrics, Spanish Town Hospital 
Dr Anona Griffiths, Senior Resident Paediatrics, May Pen Hospital 
Channer Samuels, Dietician, May Pen Hospital 
Dr Ann-Marie Woodham, Paediatrician, St Ann’s Bay Regional Public Hospital   
Patricia Murray, Dietician (Nutritionist), North East Regional Health Authority 
and St Ann’s Bay Regional Public Hospital 
Elisabeth Christie, Pharmacist, St Ann’s Bay Regional Public Hospital 
65 
 
Michelle Artcher, Laboratory Technician, Kingston General Hospital  
Children, Young People and families: 
4 young people, one male and three female between the ages 14 and 17years 
 MEXICO 
Diabetes Associations: 
Federacion Mexicana de Diabetes (FMD) (Mexico City)(Coordinates state diabetes 
associations)  
Gisela Ayala, Director, FMD   
Marcela Vega, President 
Marie Elena Mota, Coordinator, LFAC program  
AMD (Mexican Diabetes Association) Nuevo Leon, Monterrey: 
Alejandra Clariond, President 
Laura Quintanilla, Chair 
Nelly Rodriguez, Director General, Coordinator of LFAC program 
Jessica Salazar Morales, Diabetes Educator, Nutritionist 
Maria Levy, Founder of first diabetes association in Mexico, (Monterrey 1972) 
and first lay President of IDF.  
AMD Sureste, Merida: 
Claudia Duran, President 
Veronica Canul, Director and LFAC Coordinator 
AMD Cancun: 
Dra Lilian Chagoyan, Paediatrician, Cancun Hospital, Founder of AMD Cancun 
Sarai, coordinator of AMD Cancun (see below) 
Note: LFAC support to Cancun was agreed following the visit 
Ministry of Health, PAHO and Partners: 
Dra Gabriela Ortez Solis, Director, Subsection Prevention and Promotion of 
Health, National Centre for prevention and Control of Diseases, Ministry of 
Health 
Dra Diana Carrasco Alcantara, Sub Director Chronic Diseases, Ministry of Health  
Dr Enrique Gil Bellorin,  Advisor in Chronic Diseases and Mental health, Country 
Contact, PAHO (OPS/OMS) 
Xochitl Benitez Cordova, Coordinator of Diabetes Education, BD Medical 
(Manufacturer of syringes/needles) 
Eduardo Becherell Castorena, National Commercial Manager, NIPRO Medical de 
Mexico (Manufacturers of glucometers and strips) 
Alia Huerta Marquez, Manager of Diabetes Division, NIPRO Medical de Mexico 
Sara Valencia, NIPRO 
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Jorge Franchini Gomez, Director of Projects, Farmacias del Ahorro (Fahorro) 
Ximena Suinaga Romero de Terreros, Commercial SubDirector, Farmacias del 
Ahorro   (chain of pharmacies with doctors in attendance- funder and partners 
with FMD) 
 Clinicians treating children and young people with T1D: 
Dra Anna Lilia Rodriguez, Perinatologist, Institute of Perinatology, (INPER)  
Dr Carlos Robles Valdes, President, Sociedad Mexicana de Endocrinologia 
Pediatrica, Institute National de Pediatria (INP)  
Also nurses, nutritionists etc at the AMDs  
Dra Lilian Chagoyan, Paediatrician, Cancun Hospital, Founder of AMD Cancun 
Sarai, coordinator of AMD Cancun 
 Children, Young People and families: 
Monterrey: 
5 children. Three male and two female between the ages of 4 to 14 years 
Merida: 
4 children. One male and three female between the ages of 5 to 15 years 
Cancun: 
2 children. One male and one female between the ages of 7 to 11 years 
 
PHILIPPINES 
Hope WorldWide (coordinates the LFAC program):   
Bervina (Vina) Casabar de Nuevo, LFAC coordinator 
Carol C Arcilla, LFAC nurse and data coordinator (recently appointed) 
Dr Rosa Sy, LFAC instigator and coordinator for Philippines, Paediatrician, past 
president PSEDM (Philippine Society for Endocrinology, Diabetes and 
Metabolism) 
Ministry of Health, WHO, OXFAM and Partners: 
Dr Carmela Granada. Program Director for Diabetes Prevention and Control, 
MOH 
Dr Julie Hall. Country Representative, WHO 
Dr Justin Morgan, Country Director, OXFAM 
Clinicians treating children and young people with T1D: 
ISDFI  - (Institute for Studies on Diabetes Foundation Inc) 
Dr Catindig-Fernando, Director and her team - Dr Francis Pasaporte, Dr Leyden 
Florido,  Nerissa C Llanza, Dr Ronaldo Toledo, Mercedita Marcelino    
PSEDM – (Philippines Society for Endocrinology, Diabetes and Metabolism) 
Dr Jemino – Endocrinologist, President, PSEDM 
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Dr Jeremy Robles – Endocrinologist, Director, PSEDM 
PGH – (Philippines General Hospital) 
Dr Sioksoan Cua, Section on Paediatric Endocrinology, University of the 
Philippines and Philippines General Hospital 
Dr Jackie Lou Soriana, Clinical Fellow, PGH  
Children, Young People and families: 
ISDFI 
5 children. Two male and three female between the ages of 9 to 16 years 
PSEDM 
3 children and young people. Two male and one female between the ages of 10 to 
20 years 
PGH 
3 children. Two male and one female between the ages of 12 to 14 years 
INDIA  
Dream Trust (Coordinator of LFAC program in Nagpur) 
Seema Chalkhore, Manager of Dream Trust and LFAC coordinator 
 Also met with Nutritionist, Nurse, Administrator for Insulin and LFAC, Social 
Worker, Manager 
Ministry of Health, WHO, OXFAM Partners etc: 
Dr SadhanaTayade, Joint Director Health Services, Ministry of Health, Mumbai, 
Maharashtra,   
Dr R.L. Sathe, State  Program Manager, NCD, Ministry of Health, Mumbai 
Dr Pankaj Wagh, State program Coordinator, Ministry of Health, Mumbai 
Dr Rupesh Mahajan, Consultant, Ministry of Health, Mumbai  
Dr Atreyi Ganguli, National Professional Officer, Non Communicable Diseases 
Team, WHO Country Office for India 
Dr Fikyu Tesfaye Tullu, Team Leader, Non Communicable Diseases Team, WHO 
Country Office for India. 
Clinicians treating children and young people with T1D: 
 Dr Sharad Pendsey, Diabetologist and Founder of Dream Trust 
Dr Sanket  Pendsey, Diabetologist, Dream Trust 
Children, Young People and families: 
Met with group of 12+ children and young people supported by LFAC and Dream 
Trust, for collective discussion 
Individual interviews: 
6 young people. One male and five female between the ages of 19 to 40 years 
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Appendix 2  Coverage by IDF-LFAC 
Country IDF atlas 
estimated 
children < 
29 years 
old with 
T1D* 
Country 
respondents 
estimated 
children < 
26 y with 
T1D  
No. of children 
reportedly 
supported 
through the 
IDF-LFAC 
program 
Total health 
expenditure 
per capita. 
PPP Int. $ 
(WHO 
2011) 
Total health 
expenditure 
% of GDP 
(WHO 2011) 
Azerbaijan 400 900 153 520 5.3 
Bangladesh 17,400 5,000 2,030 61 3.7 
Bolivia 200 250 160 264 5.5 
Burundi 600 350 250 54 9.1 
Cambodia 400 - 4 132 6 
Cayman Islands 0 15    
Dominican Republic 200 10,000 350 509 5.5 
DRC 3,000 - 391 26 7.5 
Ecuador 800 3,000 50 635 7.9 
Eritrea 200 2,500 1,050 17 2.9 
Ethiopia 1,200 10,000 2,600 50 4.8 
Fiji 20 45 30 194 4.2 
Ghana 3,600 700 620 85 5.2 
Guatemala 4,800 250 105 327 6.9 
Guyana 0  35 194 5.6 
Haiti 200 25,000 150 76 6.9 
India 135,400 140,000 56 126 3.7 
Jamaica 200 300 278 397 5.2 
Kenya 2,000 1,000 250 72 4.4 
Liberia 600 600 250 88 16.4 
Maldives 40 76 76 510 6.2 
Mali 2,600 300 300 69 6.5 
Mauritania 600 - 50 138 6.1 
Mexico 26,800 - 200 962 6.3 
Nepal 800 1,000 150 61 5.1 
Nigeria 27,600 200 200 128 5.4 
Pakistan 3,200 2,000,000 17 28 10 
Philippines 15,800 - 35 164 4.1 
Republic of Congo 200 100 64 97 3.3 
Rwanda 600 1,023 1,023 120 10.4 
Saint Lucia 20 35  703 7.7 
Solomon Islands 0 < 10 2 200 7.4 
Sri Lanka 2,000 - - 175 3.5 
Sudan 19,600 6,000 2,000 162 7.2 
Tajikistan 400 600 400 129 6 
Tanzania 1,400 1,426 661 100 7.2 
Togo 1,000 120 67 74 7.5 
Uzbekistan 1,200 2,327 400 177 5.6 
Vietnam 1,600 400 100 216 6.8 
Zimbabwe 600 - 396 - - 
*The IDF atlas presents estimated prevalence of T1D for children < 14 years old. 
This number was multiplied to estimate numbers with T1D up to 28 years old.  
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Appendix 3 Rwanda country visit  
8 – 14th May 2014 
 
Introduction 
Rwanda was the first country to host the evaluation team. The trip coincided 
with a visit by a number of other diabetes organizations and experts, some of 
whom worked as partners with IDF-LFAC both in Rwanda and elsewhere. These 
included Trevor Orchard from Pittsburgh University and Deborah Edidin from 
Feinberg School of Medicine, North Western University, who support IDF-LFAC 
with data collection and research; Jason Baker (JB) from Marjorie’s Fund (MF) a 
US based charity that partners with IDF-LFAC in supporting the Diabetes 
Education Centre in Mwulire, south of the capital Kigali; and Christian Strong 
(CS) from Team Type One (TT1), another US charity that raises awareness and 
funds for people living with diabetes. Part of the purpose of their visit was to 
explore new partnerships and to see how their work can be better integrated 
into the national health system.  
The visit was organized by the Rwanda Diabetes Association (RDA), an NGO that 
was founded in 1997 by Francis Gishoma and that is now being led by his son 
Crispin Gishoma. 
Background 
Rwanda is a small, landlocked country in the Great Lakes Region in central 
Africa. Around two thirds of the population live below the poverty line and the 
country is heavily dependent on foreign aid. The country’s President, Paul 
Kagame, is a powerful leader who is striving to turn a land of mainly subsistence 
farmers into a middle-income country by 2020. The country has experienced 
decades of tension between the Tutsis and the Hutus, the two ethnic groups that 
make up the population.  
20 years ago (1994) saw the genocide of around 800,000 Tutsis by the majority 
Hutus. This led to many children becoming orphans and traumatized the 
population that remained. The health effects of the genocide were substantial: 
facilities were destroyed, doctors and nurses were either killed or fled and 
supply chains for drugs collapsed. Some of the young people being supported by 
IDF-LFAC were small children at the time of the atrocities and are still living with 
the memories of what happened to them and their families. There remains a 
‘silence’ in relation to this period of history among most of the population, and 
distrust and fear still exist. However, since that time, the country has made 
considerable progress both economically and in terms of development indicators 
– it is one of a few African countries on track to achieve seven of the eight 
Millennium Development Goals. 
Many children and young people living with T1D face fear and discrimination. 
Traditional healers are still popular and there are some unfounded beliefs 
regarding potential ‘cures’ for T1D. General population awareness and 
acceptance is a long way off.  
Some of the families we spoke to found the burden of a child with T1D too much 
to bear, so entrenched were they in their own state of poverty. One young 
woman we met through the IDF-LFAC program had been diagnosed with T1D 
five years previously. She was working as a cook for a family who provided her 
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with accommodation and food (albeit not necessarily the best food for her 
diabetes). She said of her own family that they “think of me as already a dead 
person”.  
Another problem faced by many Rwandans is food insecurity. When you 
combine this with living with T1D, managing the disease becomes even more of a 
challenge, even if you are fortunate enough to have family support.  
We visited a 26 year old woman who was living in a remote village in a rural area 
with her older brother and extended family. She complained of vision 
complications and had had a toe amputated. She explained that she did not take 
her insulin on a daily basis as she often had no food. Although she knew what 
vegetables she should eat for her diabetes, she said her brother was unwilling to 
give her a small plot of land on which to grow them as he needed it for his own 
vegetables.  
Health 
Rwanda is one of the few countries in Africa that has met the Abuja target of 
allocating at least 15% of its annual budget to health. It has a comprehensive 
health system that focuses on equity, decentralization and the integration of 
services. A community based health insurance scheme known as ‘Mutuelle de 
Santé’ is almost universal and is implemented on a sliding scale with the poorest 
of the poor getting health care for free.  
In terms of health spending, Rwanda’s main priorities are disease prevention 
and control, maternal health, and nutrition. Much more is needed to address 
chronic diseases.  
The Ministry of Health is in the process of developing a NCD/ chronic disease 
strategy, which includes diabetes, but will not include ‘vertical’ programs on 
specific diseases. Its main focus in respect of diabetes will be on T2D as this has 
the greater burden of disease. They want to include inter-sectoral approaches 
which will cover the range of prevention, diagnosis, treatment and care.  
The MoH recognizes the contributions that various partner / NGO organizations 
have made to health. The Minister of Health, Dr Agnes Binagwaho, was very 
interested and supportive of IDF-LFAC and recognized the benefit that was being 
delivered to children in Rwanda, many of whom would otherwise have died. 
(Prior to IDF-LFAC only a handful of children were diagnosed with T1D, many 
died without diagnosis. Over 1000 children are currently living with T1D as a 
result of IDF-LFAC interventions.) 
While we were there, a meeting was organized by the Ministry to better 
understand the activities of different organizations working on T1D. At the end 
of the meeting, the Ministry agreed to set up a coordinating group that would 
meet regularly to share information on overall diabetes care and management 
and data collection.  
The public health service in Rwanda consists of 39 district hospitals and related 
community services.  
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The geography of the country 
means that many of these are 
remote and isolated and cover 
large areas, with poor transport 
links. Services in urban areas 
and Kigali are generally better 
developed and with more and 
better trained and equipped 
doctors available. There is only 
one pediatric endocrinologist in 
the country who is based in 
Kigali. The local district doctors 
and nurses have to cover the 
whole range of all disease 
entities and hence do not have 
expertise in T1D. The plan is to 
train nurses to have expertise in chronic diseases in each district/locality so that 
they can deal with all chronic diseases. T1D would be included in this. Health 
services are not completely free at the point of delivery - payments need to be 
made for consultations at hospital clinics and for medications although this is 
subsidized by the Mutuelle scheme and is waived for the poorest of the poor.  
LFAC Delivery 
LFAC has been active in Rwanda 
since 2004 through its 
partnership with the Rwandan 
Diabetes Association (RDA). It 
provides both supplies, including 
insulin and syringes, some 
glucometers and strips and 
HBa1c machines. It also funds 
staff at the RDA to coordinate 
and run the service.  
There have been and continue to 
be challenges with deliveries, 
Customs and storage, for 
example there has been a 
shortage of syringes over the 
past two years and children and young people have had to buy their own and 
then reuse. Payments have to be made for supplies to clear Customs (5% of 
value), which RDA manages and IDF-LFAC funds.  
The RDA delivers the IDF-LFAC program through 34 of the 39 district hospitals 
and soon they hope to work with all of them. Education on T1D diagnosis, 
treatment and management has been provided to doctors and nurses in these 
hospitals. Visits are carried out every three months, by two RDA/LFAC nurses, to 
all the district hospitals, to follow up on the IDF-LFAC children and YP. These 
visits are becoming more of a challenge now that the number of district hospitals 
has increased. Similarly RDA expressed a need for additional staff such as 
nutritionists, psychologists and nurse educators. 
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In ten years, IDF-LFAC has helped around 1000 children. Eight hundred are 
currently in the program and 157 have ‘aged out’ i.e. they are over the age of 25, 
and no longer receive support from IDF-LFAC. 
The model of delivery adopted by IDF-LFAC in Rwanda – partnering with the 
RDA as a ‘route’ into the system and using the existing health service systems for 
delivery is a good one. Some NGOs have their own model and ‘impose’ it on the 
country. This is likely to be less successful in the long run.  
The RDA, with support from IDF-LFAC and Marjorie’s Fund has established a 
Diabetes Education Centre (DEC) in Mwulire, around 2 hours drive south of 
Kigali. This provides a temporary home for some of the more vulnerable older 
children and young people and helps them learn how to manage living with 
diabetes and to acquire a vocational skill. 130 children and YP have been through 
the center since it started in 2010, and have attended beauty salon workshops 
and acquired skills in farming techniques, hairdressing and tailoring. The aim is 
to ensure that the YP are self-sufficient and hence able to support themselves in 
terms of their insulin and other supplies for T1D which they will need to 
purchase after they have left the IDF-LFAC program. 
We met some YP who had benefited from this educational program, including 
one young man who was now a successful chef; another was working as a 
barber. The approach of ensuring that YP are self-sufficient by the time they are 
25 is critical to the sustainability of the IDF-LFAC program.  
Several countries have differing models for developing YP to be self-sufficient. 
Rwanda has the Diabetes Education Centre, India (Nagpur) has a rehabilitation 
program and educational scholarships, Bangladesh has a focus on developing 
skills to repair mobile phones, and Tanzania has a microcredit approach. These 
four models (and any others available) should be evaluated and lessons learned 
for other countries.  
Partnership working 
Two partner organizations were included on this visit. This was useful to see 
how different diabetes charities could work together and with IDF-LFAC.  
The first was Team Type 1 who, following one of their cycling races in Rwanda, 
had made an offer to the government to provide 900 ‘testing kits’ (glucometers) 
and a million strips. An MOU had been drawn up between TT1 and the Ministry 
of Health to this effect. Distribution was to be handled by RDA. Although IDF-
LFAC had supported and provided some glucometers and strips in the past (from 
a different company) they showed generosity of spirit to welcome this offer, 
agree to divert their own strips and glucometers to another country and 
embrace the partnership. IDF-LFAC demonstrated a degree of pragmatism and 
flexibility to work with others to make the best things happen for the children 
and YP with T1D.  
The second was Marjorie’s Fund who partnered with IDF-LFAC in supporting 
vocational training and diabetes education of children and young people at the 
DEC, to ensure they were able to get employment and be self-sufficient by the 
age of 25. MF recognized the importance of ‘generosity of spirit’ as well as 
available funding in partnership working, and that IDF-LFAC demonstrated these 
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qualities. These opportunities for multiple partnership working provide an 
opportunity to ‘pilot’ and evaluate such joint venture approaches.  
Both partners – MF and TT1 - recognized the amazing work that IDF-LFAC had 
already undertaken and that more than a thousand lives had been saved due to 
the IDF-LFAC program. 
In effect IDF-LFAC will continue to fund staff and supplies (insulin, syringes), 
Marjorie’s Fund will support educational programs and TT1 will provide 
glucometers and strips to enable children and young people to manage their 
T1D. This aims to ensure that the children and young people are not just 
‘surviving but are thriving’.  
Some other NGO organizations are active in Rwanda and are adopting different 
approaches to improving health outcomes in infectious and non-communicable 
diseases. Rather than fund disease specific programs, Partners in Health, for 
example are supporting a ‘whole health system’ approach in three districts of 
Rwanda. This works out at around $15 per capita over a catchment area of 
roughly one million people and means services can be designed to cut across 
diseases and thus be more integrated into the national health system. 
Preliminary discussions around partnership between IDF-LFAC and PIH began 
while we were there, focusing on how the work already done by IDF-LFAC at 
district level can provide a basis for seeding a more integrated team. Thus, the 
focal points that have been trained in T1D care and management could be 
trained in other tasks to do with complex, chronic care and would be employed 
full time. It would be interesting to see how this partnership develops.  
One of the other advantages of working in partnership with other NGOs is that 
they can come together to ‘lobby’ for better services and support from the 
government. This only works if the partners agree to support each other and not 
‘compete’. This approach was successfully seen in practice in Rwanda with the 
Minister of Health, Dr Agnes Binagwaho, where she recognized the importance of 
IDF-LFAC in supporting the RDA in raising awareness of T1D, training health 
care workers and producing culturally appropriate educational materials. 
Data and Register  
LFAC has also had a considerable impact on the RDA’s ability to do record 
keeping and data management. This support has been provided by Dr Trevor 
Orchard, Professor of Epidemiology at Pittsburgh University and Deborah 
Edidin, from Feinberg School of Medicine, North Western University. Students 
linked to Trevor’s program have come out every year to assist in setting up a 
register and do research on T1D, thus enabling the RDA to maintain an up to date 
register of all patients seen in the IDF-LFAC program. An electronic data system 
has been developed. Most other countries are still using paper based systems 
and some of these are variable in quality. Consideration needs to be given as to 
whether the Rwanda developed system is transferable, or if not whether the 
principles could be transferable to other countries to develop their own data 
systems. For example an electronic system was being developed in the 
Philippines that might benefit from learning from Rwanda’s experiences. 
Thanks to IDF-LFAC’s support, the RDA has been able to act as an advocate for 
children and young people with T1D, particularly with the Ministry of Health, as 
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they have the evidence of the burden of disease from the data capture and 
information gathering and research (albeit small in comparison to other chronic 
disease). This is a powerful tool.  
The Minister of Health seemed interested and supportive of the IDF-LFAC 
partnership model and recognized the benefit that was being delivered to 
children in Rwanda, many of whom would otherwise have died. However, she 
was also keen to see how the IDF-LFAC program could be better integrated into 
the national health system.  
Recommendations  
e) LFAC adopts a more flexible model of support and aims to provide what is 
needed in the country. IDF-LFAC undertakes a basic needs assessment 
with a number of key individuals to find what is needed in each country to 
improve diabetes care and management for children and YP.  
f) The model of delivery adopted by IDF-LFAC in Rwanda, using the Diabetic 
Association as a ‘route’ into the system and using the existing health 
service systems for delivery is a good one. Continued/further integration 
within the existing health system is recommended. 
g)  Building on the work already done at the district level, in training HCW 
about T1D, but exploring whether the district ‘focal points’ can be trained 
in wider chronic disease management, as is intended by the MoH, may be 
worth considering in order to ‘mainstream’ the IDF-LFAC program and 
T1D care into the local health services. 
h) LFAC needs to consider whether they need to ‘review’ the needs of the 
country on a regular basis, say every 4 or 5 years, and to develop an 
approach to carry this out.  
i) Further population awareness raising about T1D is still needed. The RDA 
have been active in radio and newspaper interviews etc. Many 
‘misunderstandings’/ beliefs and stigmatization still remain in the 
population and more needs to be done to tackle discrimination. RDA and 
IDF-LFAC should consider what mechanism of awareness raising could be 
put into effect, possibly using new social media approaches, or more 
conventional methods such as churches, radio and TV, volunteers etc. IDF-
LFAC could do more on advocacy training, identifying young leaders who 
could go on to become champions, raising awareness both amongst the 
general population and with MoH. Utilizing potential political champions 
(e.g. MPs with T1D) or local celebrities to speak out about living with T1D 
could be explored.  
j) With the expansion of the IDF-LFAC program to all the district hospitals 
there may need to be additional nurse support to ensure the 3 monthly 
visits and clinic checks can be carried out. Funding for additional staff such 
as psychologists, nutritionists, educators also need to be considered.  
k) Several countries have differing models for developing YP to be self- 
sufficient. Rwanda has the Diabetes Education Centre, India (Nagpur) has 
a ‘rehabilitation’ program and educational scholarships, Bangladesh has a 
program focusing on developing skills to repair mobile phones, and 
Tanzania has a microcredit approach. These four models should be 
evaluated and lessons learned for other countries.  
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l) The approach of ensuring that YP are self-sufficient by the time they are 
25 is critical to the sustainability of the IDF-LFAC program. Mechanisms 
for achieving this need to be supported and propagated.  
m)  IDF-LFAC is willing and able to work in partnership with other NGOs etc. 
in a flexible and pragmatic way. They are generous in spirit and use their 
(combined) resources to best effect. This is a strength of IDF-LFAC and its 
approach and should be continued. In addition, multiple partnership 
working provides an opportunity to ‘pilot’ and evaluate such joint venture 
approaches.  
n) Similarly partnerships with other capacity building organizations or ‘self-
sufficiency’ mechanism such as vocational training should be explored (e.g. 
Oxfam in Rwanda has programs in supporting capacity building in young 
people and in micro financing models, which could link to the Diabetes 
Education Centre.  
o) Consideration needs to be given as to whether the data and register 
system developed in Rwanda is transferable, or if not whether the 
principles could be implemented in other countries to develop their data 
systems. For example an electronic system was being developed in 
Philippines that might benefit from learning about Rwanda’s experiences. 
p) The approach to data system development, i.e. using external academic 
‘experts’ and their teams also needs to be considered for replication. There 
are considerable win wins possible.  
q) The RDA, with IDF-LFAC’s support, has been able to act as an advocate for 
children and young people with T1D, particularly with the Minister of 
Health, as they have gathered the evidence of the burden of disease from 
the data capture and conducted research. This is a powerful tool. This 
should be considered as an approach elsewhere to ensure sustainability.  
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Appendix 4 Jamaica country visit 
21st – 26th July 2014 
 
Context and health services 
Health services in Jamaica are a mix of private and public provision. In the public 
sector, health services are delivered through a network of 
primary/secondary/tertiary care facilities, comprising of 24 hospitals and more 
than 340 health centers. The facilities are managed by four regional health 
authorities and located across the island’s 14 parishes.  
Some institutions provide both private and public services, for example the 
University of the West Indies (UWI) provides both, and often supports those who 
cannot afford more expensive care packages in an informal way. 
NCD is now the leading cause of mortality and morbidity in Jamaica. To help 
address this issue, an NCD Committee was formed in 2012, bringing together 
representatives from relevant line ministries, NGOs and civil society. An NCD 
program is ‘work in progress’ but is focused on adults.  
The government is facing huge challenges in terms of health financing which 
currently stands at between 2-3% of GDP. Two years ago, Jamaica was re-
classified as a lower middle-income country. This reduced the country’s 
eligibility for highly concessional loans and grant assistance. To make matters 
worse, the government has to pay roughly 50% of its income on repaying an IMF 
loan, as well as having to adhere to strict conditions re the hiring of new staff. 
One hospital we visited had been asked to make substantial ‘cuts’, including for 
emergency services.  
In 2003, the Government set up the National Health Fund (NHF) to help 
individuals living with chronic disease access essential medicines. The NHF 
covers 15 chronic diseases, including T1D; with an NHF card, patients living with 
T1D are entitled to get insulin, a glucometer and the first batch of strips, as well 
as HBa1c 4 times a year, provided they use public hospitals and pharmacies. If 
accessed elsewhere there is a co-payment.  
In reality there are many problems in making this happen. Patients have to 
‘register’ in order to have access to the NHF, there appears to be a reluctance by 
some to do so and for others they do not have the necessary documentation, for 
example a ‘tax number’ is needed to register but many families are single parents 
and are surviving in the ‘black’ economy. The public health system also appears 
to be overwhelmed with long queues and waiting times, limited stock and 
intermittent supplies, with insulin sometimes not available. Families end up 
being forced to use the private system and paying for their medication and 
strips. In addition, the patient will often see different clinicians each time and 
some may be not very experienced in T1D. Owing to a shortage of health 
personnel in some of the public hospitals, medical students are sometimes 
servicing the clinics. Hence the ‘government system’ is unpredictable, 
understaffed and often overwhelmed and there is little continuity. In effect it is 
often ‘inaccessible’. 
In Jamaica, pediatric services only deal with children up to age 12. They are then 
transferred to adult services. Some pediatricians, notably in the private sector, 
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‘hold on’ to their patients until they are in their late teens, in order to provide the 
continuity and appropriateness of care needed. In general, however, this means 
children are transferred over with no relationship history with a particular 
doctor and as the system is paper-based, leads to patients getting ‘lost to follow 
up’. In more rural areas, by contrast, with smaller services and a limited number 
of clinicians, there are often better ’connections’ between pediatric and adult 
doctors and so there is less concern about handing the patient over at age 12.  
Due to this early hand over age, there was little focus within the IDF-LFAC 
program on children and young people in late adolescence or early 20s and the 
‘age out’ issues at age 25 did not seem a significant issue. However, there was 
concern that the poorest and most vulnerable families would not be able to 
afford medication. One doctor we met - endocrinologist Dr Marshall Tulloch 
Reid, from the University of the West Indies (UWI), said he paid for medication 
and testing for a number of patients who could not afford them. He is also setting 
up a special adolescent clinic at UWI to help address the particular challenges 
faced by this age group.  
Everyone we spoke to was extremely positive about the IDF-LFAC program. 
Clinicians spoke of improved home testing and monitoring by patients, improved 
consistency both in terms of supplies and in HBa1c testing in health settings and 
better access to medication for resource poor families. The Senior Medical 
Officer at Bustamente Hospital for Children said “LFAC has made us more 
structured – in documenting cases and monitoring - children have their own 
glucometers and they come to the clinic with their log book. Both the dietician 
and the pharmacist have records of the patients so it has improved our own data 
collection of diabetes patients.” The Ministry of Health recognized that the 
presence of IDF-LFAC had raised awareness of T1D and, together with other 
partners, had helped with starting to develop a patient register. 
Thus, IDF-LFAC fills a necessary gap and was generally welcomed and thought to 
be necessary for the next 5 – 10 years at least. There appeared to be little 
prospect of the government system providing more reliable and comprehensive 
services within that timeframe.  
LFAC Delivery 
The ‘context’ and how health services are provided in each country is important 
and the IDF-LFAC team is flexible to accommodate this, whilst remaining focused 
on what it does best i.e. ensure children and young people have access to 
treatment and management of their T1D.  
As elsewhere, IDF-LFAC is delivered/ coordinated/ managed through a national 
body – in this instance the Diabetes Association of Jamaica (DAJ). The DAJ 
implements the IDF-LFAC program through the two main pediatric hospitals in 
Kingston (Bustamante Hospital and UWI) and through public hospitals and 
clinics in a number of different parishes geographically spread across the island, 
i.e. through existing health service delivery mechanisms. Most of the ten centers 
have between 15 and 20 children covered by the IDF-LFAC program but in a few 
places there are more, e.g. Spanish Town has between 35and40. Overall Kingston 
seems fairly well provided with health services but it’s a different story in the 
more isolated rural parishes. 
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Even though access to T1D 
treatment is possible for those 
who cannot afford to pay 
privately (through the NHF), this 
does not appear to work well in 
practice. In theory under the 
NHF, patients living with T1D can 
get insulin and syringes for free, 
plus one glucometer and a few 
strips (with co-payments). The 
patient then has to buy more 
strips. IDF-LFAC fills the gap for 
children and young people by 
providing both insulin and 
glucometers and strips etc. 
However the glucometers that 
IDF-LFAC provided are a different brand to the government ones and use 
different strips. This has created the potential for confusion.  
As IDF-LFAC’s implementing partner in Jamaica, the DAJ is responsible for 
dealing with the mechanics and custom transactions of the delivery of supplies 
and their distribution to the ten centers supported by IDF-LFAC. The quantities 
delivered are based on a simple ‘list’ of children provided by the pharmacist 
from the relevant hospital/clinic. Some of the ‘systems’ for maintaining such 
records seem somewhat ad hoc. Both the delivery driver and the nurse 
coordinator at DAJ have good relationships with the clinics but overall 
coordination and record keeping of the program needs to be improved. 
Clinicians spoke of limited communication, feedback and follow up about the 
IDF-LFAC program from DAJ staff and little information sharing. “We need an 
administrator who comes and checks on things,” said the Senior Medical Officer 
at Bustamente Hospital.  
More capacity building/training is needed. Some nurses have been educated in 
T1D (funded by the NHF and coordinated by Professor Tulloch Reid at UWI) but 
they have only attended short courses (1 and ½ days) so their depth of 
knowledge is minimal. Also, there appears to be little rationale as to who is 
selected to attend these courses. Often when they return to their hospital base 
they are working in A&E or theatres or on other wards but not on the pediatric 
wards so they are not available to ‘educate’ the children and YP and their 
families. Some agree to do so but this is ad hoc and not organized in any formal 
way.  
Whilst children and YP living with T1D are seen by a clinician and by the nurse 
manager/coordinator at DAJ, additional psychological support is needed for the 
more vulnerable children. This is especially noticeable as there aren’t enough 
nurse educators who have the right training.  
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More education and training is needed both for children, YP and their families 
and for professionals. There is a need for more appropriate teaching/educational 
materials. Jamaica is not, apparently, a ‘reading’ nation and hence videos, 
cartoons, comics, or picture books would be more suitable. The ‘Bumblebee’ 
video was enjoyed and welcomed, but as some children do not have access to 
DVD players, computers or the internet it would be good to diversify the 
materials into formats that can be easily accessed. These can be adapted from 
IDF-LFAC’s educational materials and made relevant and appropriate to a 
Jamaican audience.  
One popular activity run by the DAJ is an annual ‘Diabetes Camp’. The main aim 
is to educate children and YP about their diabetes and its management. It also 
provides an opportunity for those living with T1D to meet each other and share 
experiences. The camps last a week and are run by a psychologist and are not 
cheap. However, children who can’t afford to pay for the fees are helped 
financially either by staff at the DAJ, or by sponsorship from elsewhere.  
There is also another diabetes camp “Yellowbird” (PHOTO) which used to be run 
by the DAJ but is now run separately, some children had attended both, some 
children had not attended either.  
Many of the children and young people and their families were unaware that the 
IDF-LFAC support will end at age 25. This could be for a number of reasons. 
When children and YP are transferred to 
‘adult’ services at age 12, many 
disappear into the system and are lost to 
follow up after that time. Some of the 
doctors involved in the IDF-LFAC 
program did not know that the support 
ends after the age of 25 and recognized 
that much more advocacy and 
awareness raising both about the IDF-
LFAC program and about T1D was 
needed amongst the senior management 
in health services (e.g. district and 
regional medical officers) across the 
island.  
Data and Register 
There was a paucity of information 
about the children receiving support 
from IDF-LFAC. The amount of insulin 
and supplies was based on a somewhat ad hoc set of ‘lists’ from the 10 health 
centers/clinics.  
DAJ did not seem to recognize their role in data collection and tracking supplies 
and in ‘requiring’ this from the delivery clinics. Indeed some of the clinicians 
were either unaware of the need for annual returns on each child or had not 
been asked for them. This is not much to ask in return for IDF-LFAC support. 
Where data is collected, it is recognized by clinicians as helpful in stimulating 
‘better’ record keeping, and it provides useful information on the pattern of the 
disease over time and on the burden of disease. DAJ and IDF-LFAC should 
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consider how they can achieve better records and use the ‘leverage’ of the 
support from IDF-LFAC to achieve this. 
A national (paper based) diabetes register was started with initial support from 
various partners, which was acknowledged by the Ministry of Health. However it 
appears the project ran out of funds in December 2013 and is not being 
progressed. It would seem worth considering whether further support to this 
venture would be beneficial.  
Recommendations 
r) The overall management, coordination and record keeping of the IDF-
LFAC program in Jamaica needs to be improved. DAJ and IDF-LFAC should 
consider how they can achieve better data collection and record keeping 
and use ‘leverage’ of the support from IDF-LFAC to achieve this as quid pro 
quo. An external ‘expert’ (Dr Larry Deeb) is been identified to visit Jamaica 
and identify how to address this issue.  
s) More capacity building/training is needed, particularly for nurse 
educators, many of whom only have very limited training. Those who have 
been trained should be enabled to give support to children and their 
families, rather than, as at present, when the trained ‘educators’ are 
working in other fields in the hospital and are not available to pediatric 
wards. Appropriate psychological support is also needed for some 
children.  
t)  Educational materials need to be adapted for Jamaica in order to be 
culturally appropriate e.g. as pictures/ comics/ cartoons etc. 
u) Diabetes camps are well received and valuable to the children. However 
consideration should be given as to whether something more 
systematic/ substantial could be done for all the children and YP with T1D. 
v) Further support from IDF-LFAC for the national register to be developed 
should be considered. This could be generated from expert volunteers 
(similar to what has happened in Rwanda) who could work on improving 
data collection and establishing a proper register. 
w) LFAC to undertake a review of what support is needed in the country. Is it 
really insulin or would the educational aspects be more important? It may 
be that different support is needed in Kingston than in more rural 
areas/parishes.  
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Appendix 5  Mexico Country Visit  
October26th – November 3rd 2014.  
Context and Health services:  
Mexico is an upper middle-income country with a reasonably robust yet 
fragmented health service. It has the second largest economy in Latin America 
and has a population of around 116 million. Despite this, prosperity remains a 
dream for many Mexicans and the socio-economic gap between the rich and poor 
remains wide.  
In terms of health financing, the majority of the population is covered by one of 
several insurance schemes with the private sector playing a significant role in 
the supply and financing of health-care services.  
The main insurance schemes include:  
• ISSSTE (for government and public sector workers) 
• IMSS (for most of the working population) 
• Seguro Popular (for those in low paid jobs or not covered by the other 
insurance schemes)  
• Private (small sector) 
• 5. Others (covering the military and oil industry workers)  
 
Decisions about what is available through these various insurance schemes 
appear to be made both at ‘federal’ and at ‘state’ level.  
In respect of Type 1 diabetes (T1D), access to insulin is routinely covered by the 
various insurance schemes, but the type of insulin may vary from scheme to 
scheme and place to place. Glucometers and strips to test blood glucose levels 
and other equipment (e.g. syringes/ lancets) are usually not available through 
the public insurance schemes, and patients often have to buy them.  
However, concern was repeatedly expressed about the unreliability of 
government-supplied insulin both in terms of quantity (intermittently 
unavailable), variety (specialist types prescribed to children were not provided) 
and quality. There was a perception that the ‘Chinese’ manufactured cheap 
insulin that was provided made control of T1D more difficult to maintain. 
A national strategy on diabetes and obesity was developed in 2013, with strong 
political support from the President, but this focuses mainly on Type 2 diabetes 
(T2D) in adults, and there is little or no attention to T1D in children and young 
people. Children’s health services remain more focused on infectious diseases 
than on chronic conditions.  
The country is relatively rich and some people (but not all) said that there was 
no reason why the government (through the public insurance schemes etc.) 
shouldn’t provide all that was necessary (i.e. including glucometers and strips) 
within a few years’ time. However many thought this was unlikely in the ‘near 
future’.  
LFAC has not been seen as providing any ‘leverage’ or influence to encourage the 
government to better support children with T1D. However, several people we 
spoke to understood the ‘potential’ to influence the political agenda and that this 
could be achieved through some of the leading clinicians. 
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Federacion Mexicana de Diabetes: 
The Federacion Mexicana de Diabetes (FMD) was set up in 1988 and acts as an 
umbrella body for diabetic associations in the country. They acted as our ‘host’ 
and their coordinator travelled with us on all the visits. Diabetic associations 
have been set up either in individual states and municipalities and function 
independently. Some are affiliated to the Federacion and some are not. The first 
diabetic association was set up in 1972, in Monterrey, by Maria Levy. She has 
been active in diabetes care for many years and is a past president of the IDF 
(she was the first woman and first ‘patient’ president). She was diagnosed with 
T1D at the age of eight. She was instrumental in recognizing the need for insulin 
for children with T1D, in developing countries and the instigation of what 
became the IDF-LFAC program. 
Local/ State Diabetic Associations: 
Visits were made to diabetic associations and related services in each of 
following places: 
• Mexico City 
• Monterrey 
• Merida 
• Cancun 
Diabetes associations provide education and support to children with diabetes 
(mainly type 1) and their families and they also support the general population 
with type 2 diabetes. Most associations have nutritionists, educators and 
podiatrists, many of whom work on a voluntary basis.  
The state and municipality diabetes associations are run by passionate lay 
individuals, often parents/mothers of a child with T1D. They fund raise locally to 
support their work, and often rely on 
‘benefactors’ (e.g. ‘donations’ of 
premises or transport). They are often 
able to ‘tap into’ the local affluent 
population. 
Not all states have diabetic associations 
and it is often the poorer states, 
potentially with more ‘need’, who do not 
have them, or have very small 
associations with little capacity. 
The associations providing IDF-LFAC 
support (four at present and hopefully 
two more - Cancun and Acapulco - soon) 
are those that have ‘capacity’ to manage 
the IDF-LFAC program rather than 
where the greatest ‘need’ (poverty) is in 
the country. In the poorest regions there 
are not viable diabetic associations. 
There is recognition that IDF-LFAC 
support is not based on a comprehensive 
‘needs assessment’. It does, however, 
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support the most underprivileged children in the states/centers where its 
programs are running. We suggested to the FMD should consider whether they 
could ‘stimulate’ diabetes associations or increase capacity in poorer states/ 
areas.  
The FMD has been innovative in developing fund raising mechanisms. One such 
scheme involved companies paying for certain ‘diabetic’ foods to be ‘approved’ 
by the FMD e.g. “Sugar free mini Obleas”  
Discussions were also held with clinicians, partners and beneficiaries of IDF-
LFAC including: 
• specialist hospitals/endocrinologists who provide the clinical services to 
children and young people with T1D 
• BD – a company that manufactures needles and syringes and provides some 
information and training to diabetes ‘educators’ 
• NIPRO – the company that provides glucometers and strips for children, via 
IDF-LFAC 
• Farmacias del Ahorro – a pharmacy chain that provides financial support to 
FMD and medical consultation services in their pharmacies. 
• Children and young people and their families 
LFAC delivery 
LFAC has been providing support to Mexico since 2012, so it is one of their 
newest country programs. Support consists of providing NIPRO glucometers and 
strips (to test blood glucose) and educational materials for children and their 
families via the diabetic associations.  
FMD felt that they had an upper limit of 200 children that could be supported by 
IDF-LFAC. Whilst IDF-LFAC claim that there is no upper limit, there may be a ‘de 
facto’ limit to the support IDF-LFAC can offer depending on resources available. 
The support here is not for basic insulin etc. provision but for more sophisticated 
management of T1D. 
The number of IDF-LFAC supported children is divided between the diabetic 
associations involved:  
• Monterrey – 65  
• Guadalajara – 50 
• Merida – 25 
• Guadajuanto – 50  
• Total = 190 
When we visited, Cancun did not have IDF-LFAC support but were hoping to get 
it once the required paperwork had been put together for approval. Since then, 
IDF-LFAC has confirmed that both Cancun and Acapulco are now on the 
program.  
The main aim of the diabetic associations is to provide children and families with 
the knowledge and ability to be able to manage their diabetes and live ‘normal’ 
lives. This revolves around frequent blood glucose testing and modifying diet 
and insulin to achieve ‘control’. The children have HbA1c tests regularly (every 
three months, usually at the diabetic association) and the aim is to get the results 
below eight.  
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LFAC provides support for ‘managing’ T1D (glucometers and strips) that would 
not otherwise be available unless the families paid for them themselves (basic 
care including insulin is provided by the government). Therefore, IDF-LFAC’s 
support means the system can 
provide ‘better ‘ service and 
improved management and 
control of T1D rather than 
attending to basic needs.  
There is a strong focus on 
educating the child and family 
to manage their diabetes and 
on ‘co responsibility’. This 
means the child and family 
need to ‘sign up’ to fortnightly 
educational sessions (and 
cooking classes etc.) at the 
diabetes association, and in 
return they receive a 
glucometer and strips. If they fail to attend they are ‘struck off’ the program. 
Whilst this has its value we questioned whether there is a risk that the most 
‘vulnerable’ children (e.g. from dysfunctional families or without family support 
etc.) may be abandoned. They recognized the point we were making. In practice 
there is evidence that informally they do support children in these 
circumstances, including diabetic association staff personally supporting 
children with travel money to encourage them to attend the diabetic association 
clinics.  
It is worth considering 
whether the co-responsibility 
model (that uses IDF-LFAC 
support as a ‘leverage’ 
mechanism) could be 
transferred to another 
country program.  
Each diabetes association has 
a ‘waiting list’ of children who 
could be on the IDF-LFAC 
program. Clarification is 
therefore needed re the 
maximum number of children 
that IDF-LFAC can support.  
In some more rural areas 
where health services are 
‘thin on the ground’ there are some government run mobile services “Caravan”). 
This might provide a mechanism for children from more deprived backgrounds 
to be reached. These services often support the rural deprived populations of 
Mayan origin.  
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Summer camps have been run for some time and are clearly appreciated by the 
children and young people. These are sponsored by local businesses or 
individuals so children and families do not have to pay, or may make a small 
contribution. As in other countries, these provide an excellent opportunity for 
children to learn about diabetes and its management, but also to meet other 
children and YP with T1D, often for the first time. 
As IDF-LFAC has only recently been active in Mexico, none of the young people 
are close to 26 years old so issues relating to ‘graduating’ from the IDF-LFAC 
program have not arisen. Most children and YP are in education, training or jobs 
by their late teens so this may not be an issue. In at least one of the diabetes 
associations the children are only expected to be supported until the age of 18.  
Data and Register: 
There is consistently good record keeping and data feedback to IDF-LFAC. The 
Ministry of Health aims to produce a national ‘diabetes register’. This would 
cover adults at first and eventually will also include children. Currently incidence 
and prevalence figures are unknown.  
Recommendations: 
1. The Federacion (FMD) and IDF-LFAC should consider whether they could 
‘stimulate’ diabetes associations to be developed or increase capacity in poorer 
states and more deprived areas, where underprivileged children with T1D are 
not currently receiving IDF-LFAC support and where services may be poor. 
Support from either Lilley Mexico or from rich entrepreneurs (e.g. Telecom 
millionaires) should also be considered by FMD.  
2. The ‘co-responsibility’ model that uses IDF-LFAC support as a ‘leverage’ 
mechanism to ensure engagement of children with T1D and their families 
appears to be effective. Consideration should be given as to whether this 
approach is transferrable elsewhere. 
3. There needs to be clarification about the ‘upper limit’ number of children and 
potentially whether more children may be able to be supported within the 
current IDF-LFAC ‘envelope’ of support.  
4. FMD and Diabetes Associations should consider whether they can ‘piggyback’ 
on the rural ‘caravan’ that provides health services to reach more deprived 
children.  
5. Given Mexico’s economic position, the ‘government’ should be able to provide 
better support to children and young people with T1D. Consideration should be 
given as to how IDF-LFAC, or IDF regional office can work with other local 
leaders and the FMD to encourage the government to do so, using information 
from IDF-LFAC delivery on the burden of disease. 
6. The lack of a country wide ‘needs assessment’ prior to the start of the IDF-LFAC 
program is demonstrable. Both FMD and IDF-LFAC recognize that they are not 
meeting the needs of the poorest. Consideration needs to be given to the ‘needs 
assessment’ process and how IDF-LFAC can better base its program support 
where most needed.  
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Appendix 6  Philippines Country Visit 
10th-17th December 2014 
Context and government health system:  
The Philippines is a low-middle income country in the South East Asian region, 
comprising over 7100 islands and a population of 94 million.  
Given its geographic location in the Western Pacific, the country experiences 
typhoons, earthquakes and volcanic eruptions on a regular basis, making it one 
of the most disaster-prone areas in the world. Much of the country is 
mountainous and the population, made up of more than 180 ethnic groups is 
dispersed over a wide area. In the south, conflict breaks out intermittently. 
In terms of health, the Philippines faces what is termed the ‘double burden of 
disease’ where both infectious diseases and non-communicable diseases are 
leading causes of mortality and morbidity. Despite these challenging conditions, 
over the last 40 years, indicators of health status have improved dramatically 
with infant mortality dropping by two thirds and life expectancy increasing to 
over 70 years. However, considerable inequities in health care access and 
outcomes remain. Life expectancy in richer provinces is more than 10 years 
longer than in poorer ones. 
The country has a complicated, heavily decentralized and fragmented health 
system. Over time a dual system of public and private provision has evolved with 
both operating on a fee for service basis (the latter is subsidized through the 
national health insurance agency PhilHealth). Public services are used by the 
poor and the not so poor; the private sector is used by around 30% of the 
population who can afford fee for service payments. In terms of health financing, 
around one third of health services are paid for by the government, more than 
50% from out of pocket payments and the rest is a combination of private 
sources and social insurance.  
In the private sector, individuals are covered either by private health insurance 
(paid for by employers) or having to pay themselves. PhilHealth, which 
previously only covered the working population, is open to all (without 
contribution) and is free to the poor and, since 2014, the elderly (60+). However 
it covers only a proportion of hospital costs (around 20%) and does not cover 
outpatient fees. The ‘poorest of the poor’ (i.e. approximately the bottom 10%) 
are ‘enrolled’ by local government, but this is variable from place to place. Some 
underprivileged patients in this category have been given local ‘grants’ (often 
just one off funding) but it appears that decisions are made more by ‘who you 
know’ than any strict criteria. Conflicts of interest in all levels of government are 
common.  
Only some hospitals are ‘accredited’ to deliver PhilHealth. From 2015, insulin is 
supposed to be available in outpatient clinics as well as ‘in’ hospital. (NB there 
are elections in 2016 so there may be other changes to the health system as a 
result). The Pediatric General Hospital in Manila is open to everyone. Some 
‘private’ hospitals offer charitable support to the poor.  
The main urban areas are better supplied with doctors and health services. This 
is especially true of subspecialties such as endocrinologists, diabetologists and 
pediatric endocrinologists. There is considerable migration of Philippine health 
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care workers to other countries, including UK. It was reported that some 
Philippine trained doctors are currently migrating to UK and elsewhere to work 
as nurses. This is an added drain on staffing in the Philippines.  
Nationally and through Ministry of Health discussions, the sort of ‘support’ 
provided by IDF-LFAC and others is seen as acceptable as long as they do not try 
to dictate or influence policy and there is no conflict of interest. There is a 
recognition that the government is not able to provide all health services needed 
although universal coverage is a desired end stage.  
LFAC support: 
LFAC currently supports 35 children (p.a.) in three centers in the capital Manila: 
1. PSEDM (Philippines Society for Endocrinology, Diabetes and Metabolism) 
2. ISDFI (Institute for Studies on Diabetes Foundation Inc)  
3. PGH (Philippines General Hospital) 
 
Some of the children receive 
partial support (e.g. only 
insulin) and some full 
support (e.g. insulin, meters, 
strips +/- syringes). One 
hundred and ten children in 
total have been supported by 
IDF-LFAC since 2001. The 
centers apply criteria such as 
the economic situation of 
children and their families, to 
identify who should receive 
assistance.  
HOPE WorldWide (Hope 
WW) coordinates the overall 
IDF-LFAC program. Dr Rosa 
Sy initiated the support from 
IDF-LFAC (2001) when she was President of the PSEDM, following discussions 
with Graham Ogle. IDF-LFAC provides funding for local purchase of insulin and 
supplies. Dr RS has negotiated a good price for insulin etc. from the 
manufacturers.  
Originally the three centers took the decision that the doctors would maintain 
records/ provide data to IDF-LFAC etc., and in this way the available IDF-LFAC 
funding could be used to buy insulin to support more children. However this 
approach did not work very well and so now they have appointed a nutritionist 
to coordinate and collate the data.  
‘Conditionality’ is a strongly held theme. In all three centers they expect the 
children to learn how to manage their T1D, to attend clinics and to show 
improvement in their HbA1c results. If not, then children are removed from the 
IDF-LFAC program and the ‘place’ goes to someone else.  
Additional support for needy children is provided by a number of other charities 
e.g. ‘Adopt a Diabetic Child’ and from PHARMA (pharmaceutical industries) and 
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also from local government but it is patchy, so the doctors ‘box and cox’ as to 
who gets what from which program. This flexible system seems to work 
reasonably well.  
There are 20 pediatric 
endocrinologists across the 
Philippines, mainly based in 
urban areas (Manila) and 200 – 
300 adult endocrinologists. Each 
of the IDF-LFAC- supported 
centers provides education to 
their alumni. In general, 
diabetologists have good 
contacts with other 
diabetologists etc. so they do not 
see the need for any ‘peer’ 
support from other countries via 
IDF-LFAC. 
PSEDM is a ‘professional association’ for endocrinologists/ diabetologists. They 
recognize that their role includes building relationships with and ‘lobbying’ 
government for more resources for diabetes. They do not expect IDF-LFAC to do 
this. IDF-LFAC has not tried to influence Ministry of Health policies. 
Internal ‘leadership’ support is seen as important. For example ISDFI has a 
program to support rural and family doctors to be able to take local leadership 
over diabetes.  
PGEDM is starting, at the request of IDF-LFAC, to provide support for a few 
children outside Manila e.g. in Cebu (one of the central islands) through their 
trained alumni. But there are challenges in providing the insulin and to organize 
transport etc. It remains much easier to concentrate in Manila, but these are not 
necessarily the most needy children.  
Camps for children that teach them how to manage their T1D are popular among 
children and their families. Each center runs their own camps, usually supported 
by volunteers and sponsors etc. However there is no follow up with the children 
afterwards and no mechanism for them to stay in touch with each other.  
Where there is contact between families and children with T1D, (e.g. by chance 
in clinics and through ‘camps’) this is taken up with enthusiasm. Parents also 
expressed a wish to be ‘in touch’ with other parents of children with T1D.  
Social context 
Diabetes associations or clubs do not appear to exist. Patient empowerment and 
peer support for any disease is not common and may not be within the Filipino 
culture.  
It was suggested that diabetic clubs/associations may be able to be stimulated 
via HopeWW or via the church which has a strong influence in the country.  
Data and information 
The incidence and prevalence of T1D in children and young people is unknown. 
Surveys that have been carried out have been for adults. It is generally 
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considered likely that most children with T1D across the Philippines are 
diagnosed and treated even if they have to pay. However, given that there are 
few skilled staff and limited supplies in the rural and more remote island areas, if 
there are children diagnosed with T1D, they are unlikely to do well.  
HOPE WW provides IDF-LFAC with data annually (with the exception of 2013). 
With the new appointment, HopeWW were about to collate the 2014 data 
following our visit. PSEDM has recently set up a database for children with T1D, 
which includes all the relevant clinical and other data. This could potentially be 
used for overall data collation, but at present is only starting to function within 
PSEDM. Consideration should be given by HOPE WW and PSEDM together with 
IDF-LFAC as to the most cost effective way to maintain data collection. 
In 2008, a modified version of the RAPIA needs assessment was undertaken by 
Michiyo Higuchi (Higuchi 2010) and David Beran (Beran and Higuchi 2013). 
Unfortunately, those we met were unaware of this initiative/research and did 
not recollect being part of the process, although the methodology might imply 
that they should have been. The RAPIA approach provides a comprehensive 
needs assessment on both T1D and T2D but does not focus on children and YP. 
However, where it is available, it would provide extremely useful data on the 
status of provision and care for people living with T1D info and could be used to 
inform the needs assessment undertaken by IDF-LFAC.  
Recommendations: 
1. Having ‘conditions’ attached to IDF-LFAC care and support appears to function 
well as it develops a culture of reciprocity where children and young people 
‘agree’ to learn how to manage their T1D and show improvement. This approach 
should be considered in other countries. 
2. There are clear benefits when children and YP living with T1D are put in touch 
with each other. Similarly parents would welcome peer support. More could be 
done to build these relationships beyond the camp setting. This could be 
facilitated by HOPE WW or possibly through the churches. Lessons learned from 
other countries could help inform this development.  
3. PSEDM may benefit from hearing about other countries who have set up their 
own databases before setting up their own. The database could potentially be 
used for the whole IDF-LFAC program in the Philippines and not only the PSEDM 
part. This also needs to be reviewed in relation to the IDF-LFAC database. HOPE 
WW and PSEDM together with IDF-LFAC need to consider the most cost effective 
way to maintain data collection, and ensure there is not duplication of effort. 
4. Further investigation into the modified RAPIA need assessment that was carried 
out in the Philippines may be beneficial in identifying ‘need’ more robustly and 
thus ensure support is given to the most vulnerable.  
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Appendix 7 India (Nagpur) Country Visit 
3-11 January 2015. 
Context:  
Nagpur is a large city in the state of Maharashtra right in the center of India. 
India is the world’s largest democracy, the second most populous country after 
China and a multi-lingual federal state. It has a national Non Communicable 
Disease (NCD) strategy which includes diabetes, (mostly T2D), obesity, cardio 
vascular disease (CVD) and stroke. Whilst this is a national program it is the 
responsibility of the individual states to decide on priority areas, how resources 
are spent and then to implement. States hold the health and health care 
responsibility. There are effectively no health insurance schemes. Everybody 
pays to see a doctor and for hospital visits. A tiny proportion - 1 – 2 % of the 
population, have private health insurance. 
Government health system: 
A government health system exists but it is intended for those who cannot afford 
private payments, and is mainly focused on hospital care. The structure of this 
government system includes local community ‘district’ services and cascades up 
through to district/area hospitals. Children with T1D may be diagnosed through 
this system but are usually referred to the local district hospital, as the 
community level is unlikely to have the expertise. The state (Maharashtra) 
Ministry of Health said that insulin is available through this system. However this 
was not the experience of many of the children and families we spoke to. 
In the past, insulin was available both in hospitals but also in outpatient clinics, 
but patients would only be given enough for 15 days (sometimes one month) 
and the patient would then have to return and re attend the outpatient clinic. 
There were long waiting times and often insulin was not available, as it had run 
out.  
In general, although the state government is supposed to provide insulin for 
people with T1D, patients either have to pay for their own or, if they can’t afford 
it, rely on charities and NGOs to provide assistance. This is done on an ad hoc 
basis, with no mechanism to organize this in any coordinated way. It is likely that 
there are similar arrangements in other parts of India, but no systematic 
information is available. These charitable arrangements are often dependent on 
the local doctors’ attitude/philanthropy etc.  
LFAC supports nine centers across India covering approximately 1500 children 
and young people. 
LFAC delivery in Nagpur: 
The LFAC program is integrated into the work of Dream Trust (DT), a charity 
that was set up in 1995 by Dr Sharad Pendsey, a diabetologist, and his wife, 
following the deaths of two girls diagnosed with T1D. DT’s work focused on 
primarily girls who were underprivileged and had no access to or could not 
afford to pay for insulin. (Dr SP and Dr GO met at a conference where SP 
presented a paper on DT and the support provided to underprivileged children.) 
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DT provides a package of treatment and care, similar to that provided to private 
patients, (although private patients may be able to afford more modern 
technology such as insulin pumps etc.) 
The LFAC and DT clinics take place two days a week, the rest of the time is for 
private patients. The clinic team is made up of nurses, educators, administrators, 
and social workers and all are available to all patients. Patients who need care 
are given it, and either supported by LFAC or by DT / sponsorship etc. There is 
also a further trust set up - the Pendsey Trust, which similarly raises funds for 
diabetes treatment.  
Children and young people (YP) are usually ‘referred’ to DT, either by another 
physician/ diabetologist (often soon after first diagnosis) who knows of DT 
support to poorer patients or by word of mouth. DT also advertises its activities 
in local newspapers and these are a source of self-referral.  
DT raises funds in various ways including support from the UK, Austria and 
elsewhere and sponsorship. (www.dreamtrust.org) 
LFAC has supported DT 
since 2002. They started off 
by helping 15 children, now 
45 children and YP are 
supported by LFAC each 
year. LFAC does not provide 
actual supplies, but gives 
funding and DT orders 
insulin and other supplies 
locally. Funding provides 
for a full package of support 
including insulin, 
glucometers and strips and 
syringes. The children and 
YP are seen every three 
months at the DT clinic and 
given supplies for 3 months (more frequently as necessary, during initial 
stabilization period etc.). Children and YP are asked to bring back empty vials 
and syringes (to ensure they are not ‘selling’ insulin or syringes).  
The clinic has good systems in place to record who receives what insulin etc. 
Insulin is ordered weekly from a local distributer and arrives the day prior to the 
LFAC and DT clinic. The clinics are well organized and a backup supply of insulin 
is also kept at the clinic in case they need more on any particular day.  
Whilst the majority of supplies is standard insulin, some insulin pens are 
provided for children to use in school. This is because many schools are reluctant 
to let children bring in syringes and so children were missing their afternoon 
insulin dose.  
Previously the US charity ‘Insulin for Life’ provided insulin to DT, but there were 
problems with customs and so LFAC stepped in and provided funding for the 
local purchase of supplies. DT also uses the LFAC educational materials and some 
are being translated into local languages. 
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Dr SP is well known as a diabetic ‘educator’ and is an expert on diabetic foot. He 
has published papers and books, and delivers educational workshops for other 
clinicians throughout India. His son, Dr Sanket Pendsey, also a diabetologist, 
works in the same practice. 
Dr SP has devised a terracotta ‘pot’ with a ‘cooling’ chamber (using the 
mechanism of water evaporation as a cooling effect) and lid, which can act as a 
‘cool box’ for insulin if the patient has no access to a fridge.  
Social context: 
Girls and women with T1D face considerable prejudice in Nagpur. Although 
illegal, female infanticide and feticide is still practiced in some states, such that 
the women to men ratio may be 750:1000. It is also illegal to ascertain the sex of 
the fetus (to try to prevent abortions of female fetuses). Marriage for women is 
the norm, possibly in late teens or early twenties. 70% marriages are still 
arranged and the preference is to stay within the same caste. 
Many women with T1D are rejected for marriage, although there appears to be 
no such prejudice against men.T1D in women is therefore often kept secret.  
This leads to the need for women to be self-sufficient. 
Extended support: 
A number of innovative ways to extend support to children and YP with T1D 
have been set up including paying for travel expenses, educational scholarships, 
vocational training, bicycles, sewing machines, and ‘rehabilitation’ to enable 
young people to set up their own businesses and attain self-sufficiency.  
LFAC provided special grant funding in 2013 and 2014 for these endeavors, most 
of it going to LFAC patients but some to those of DT (with agreement from GO), 
particularly for some ‘graduates’ of LFAC aged over 26. 
The grants work in the following ways:  
Travel: Money is given to support the child/ YP (and one parent if a child) to 
travel to the DT /LFAC clinic. Bus/travel receipt/ticket is required and the 
money signed for. (Photo) DT covers quite a large geography and travel may take 
up to 6 hours from distant rural areas. Most children have to travel between two 
to three hours.  
Education: Grants are given to children and YP to continue their schooling as 
education is seen by DT as the key to eradicating poverty and being self-
sufficient. Receipts for books, educational expenses and uniforms need to be 
produced and signed for and support from the principal or head teacher is 
required. The grants are usually between 1000 – 3000 rupees (£10 - £30).  
Bicycles are also provided for some children in order to reduce the school drop-
out rate, especially for girls in rural areas who may need to travel long distances 
to get to school.  
‘Rehabilitation’: This focuses on older YP, some of whom may be ‘graduates’ of 
LFAC and over the age of 25. The idea is to support the YP to start a business so 
that they can be self-sufficient. DT has provided sewing machines, bicycles to 
enable the selling of goods in a particular area, a buffalo to make cheese, yoghurt 
or ghee to sell, help in setting up a stationery and general store in a rural village, 
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or a sari and jewelry shop. 
Funding may be provided for 
initial stock and set up costs etc. 
The individual has to make a 
proposal to the “rehabilitation 
advisory group”, an external 
group of business people, who 
will help with support and ensure 
a viable business plan. 
Since some rehabilitation did not 
work very well, they have now 
introduced ‘vocational training’ 
including workshops on how to 
set up a business and mentoring 
from the advisory group 
members to ensure successful 
projects are supported.  
Treatment of other medical 
conditions: Some YP have 
developed complications or other 
medical conditions. These may be 
treated through support from DT/LFAC. One example is of a young woman (aged 
19) who developed cataracts. These were removed using support from DT, and 
from a supportive ophthalmologist friend of Dr S.P. The girl had to pay a small 
amount and DT funded the rest. DT believe that a contribution from the patient 
is important for them to recognize the costs and appreciate the support they are 
being given.  
Data and Register: 
The DT and LFAC clinic keep good records and make annual returns to LFAC. It is 
a paper system and they would welcome any opportunity to develop an 
electronic database. 
They are flexible as to how children move in and out of LFAC and DT support, 
and this seems to work well.  
A National register (ICMR) of children and YP (less than 25 years of age) is being 
set up by the All India Institute of Medical Sciences (led by Professor Nikhil 
Tandon). It covers children diagnosed since 2006 and backdated to 2000. The 
first report is due to be published soon and covers 5540 children from 5 centers 
across India. It looks at treatment and follow up/ complications etc. It will be 
‘representative’ but not provide overall incidence/ prevalence. This register will 
contribute to the global mapping study that LFAC and ISPAD are setting up.  
Recommendations: 
1. Lessons can be learned from a ‘can do’ attitude that identifies when children and 
young people (especially girls) are in need of support for their T1D and provides 
that support, covering costs flexibly from LFAC, DT, Pendsey Trust and 
sponsorship. LFAC is a substantial part of the overall DT funding. 
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2.  Good ‘systems’ are in place for record keeping and monitoring spend and 
ensuring any expenditure is valid with receipts etc. required. Models could be 
transferred elsewhere e.g. for travel and educational grants. 
3. The extended support systems for education, vocational training, and 
rehabilitation act as a stepping stone to self-sufficiency and are worth modeling 
elsewhere. DT recognizes this and has put systems in place that help ensure 
their success. The fact that those benefitting from the grant have to contribute in 
some way and account for expenditure prevents a culture of dependency and 
encourages self-reliance. Relatively small amounts of funding from LFAC have 
achieved major success 
4. The model of a ‘nominal financial contribution’ from patient/family for some 
special treatments (e.g. Cataract removal) should be considered elsewhere as a 
mechanism of engagement and ownership. 
5. Learning from other electronic database systems such as the one developed in 
Rwanda or the one being implemented in the Philippines could be used to help 
DT build their own.  
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Appendix 8 Survey questionnaire to diabetes associations 
 
 (This questionnaire was used for the e-mail survey and during country visits) 
 
This is a questionnaire to find out more about the International Diabetes Federation’s ‘Life 
for a Child’ (LFAC) programme and their work in support of children and young people who 
have Type 1 Diabetes in partner countries. It is part of an evaluation conducted by the 
London School of Hygiene and Tropical Medicine for the Helmsley Charitable Trust, one of 
LFAC’s major donors. The aim of the evaluation is to assess LFAC’s organizational structure, 
programme impact and potential to catalyse long term sustainable improvements to Type 1 
Diabetes delivery systems in its partner countries.  
This questionnaire will be sent to all countries that LFAC supports. We would appreciate if 
someone from your organization can answer the questions, giving as much detail as possible. 
If possible, please fill out the questionnaire online at the link 
https://www.surveymonkey.com/s/29B3YYX 
It should take around 45 minutes to complete.  
Where we state children and young people we refer to people less than (<) 26 years old. 
Taking part in the evaluation is entirely voluntary. Your comments will be confidential and 
will not be attributed to you in the final report or presentations, but we may want to use 
quotes anonymously and we plan to list all the people surveyed, unless you tell us not to 
include your name/organization. 
If it is not possible to do it online, please answer the questions below and then send the 
completed form to LFACsurvey@lshtm.ac.uk 
Please feel free to add any additional comments about the impact of the programme at the 
end. Your contributions are much appreciated and can help inform improvements for the 
future.  
To answer the questions below, click on the grey square and start writing, boxes will expand 
to fit text. For questions with a ‘yes/no/don’t know’ answer, check the relevant box by 
clicking on the grey square. 
*************************************************** 
NAME:       
DATE:       
COUNTRY:       
ORGANIZATION:       
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Your role in the organization:       
What year did you start working with LFAC?       
LFAC Type 1 Diabetes Programme - Country Questionnaire  
1. Children and young people reached 
a. To the best of your knowledge, how many children and young people (under 26 
years old) in your country are currently living with Type 1 Diabetes? (Please give 
an estimate/approximate number if you do not have a precise number) 
 
 
 
b. How many children and young people with Type 1 Diabetes are supported 
through the LFAC programme? 
 
 
c. Briefly describe how the LFAC programme works in your country.  
 
d. Briefly describe any barriers experienced in reaching and supporting children 
with Type 1 Diabetes? Please consider both urban and rural areas.  
e. Are there other organizations besides LFAC providing support to children and 
young people living with Type 1 Diabetes in your country?  
  
YES  NO  DON’T KNOW  
If yes, please state which organizations and briefly describe what support they 
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provide? 
f. Does LFAC partner with other organizations to deliver support for children and 
young people with Type 1 Diabetes in your country?  
YES  NO   
 
If yes, please name the organizations involved and briefly describe the 
partnership.  
 
g. For the children not supported by the LFAC programme - Are they adequately 
supported by other organization(s)? 
 
YES – Some of them   YES – All of them    NO  
 
If YES (All or Some of them), by whom? (e.g.. government/other NGO/ paying 
themselves) 
 
h. Do you believe most children and young people with Type 1 Diabetes in your 
country are being diagnosed and given support today?  
YES  NO  DON’T KNOW  
i. In the list below, please tick the support provided by LFAC:  
 
 Check if 
YES 
Insulin  
Blood glucose monitoring (meters and strips)  
Syringes  
HbA1c testing equipment  
Educational materials for children/families in relevant language(s)  
Training of health professionals  
Support from Diabetes experts from other countries  
Other (please specify)       
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j. What are the three main difficulties in ensuring all children and young people 
with Type 1 Diabetes (under 26 years old) receive the care and treatment they 
need? 
1.       
2.        
3.       
2. Procurement and supply of Type 1 Diabetes medicines and supplies 
a. Does your government provide any Type 1 Diabetes medicines, supplies or 
training to support children and young people (under 26 years old)?  
YES  NO   
 If yes, please fill out of the table below:  
 Yes No Is it 
available 
to all 
children 
and 
young 
people? 
 
Is it free for 
all children 
and young 
people? 
 
 
 
 
Additional 
comments (such 
as co-payments 
or population 
coverage) 
Yes No Yes No 
Insulin               
Blood glucose monitoring (meters 
and strips) 
            
Syringes             
HbA1c testing equipment              
Educational materials for 
children/families 
            
Training for children and families              
Specialist diabetes training for 
health professionals 
            
b. Since LFAC started its programme in your country, has any aspect of government 
provision of Type 1 diabetes support to children and young people changed?  
       YES  NO  DON’T KNOW  
If yes, how has it changed? 
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c. Do all medicines and supplies provided by LFAC reach the intended beneficiaries 
(children and young people)?  
 
YES  NO  DON’T KNOW  
If no, please explain why not?  
d. Do children and young people in the LFAC programme get their medicines and 
supplies free of charge? 
 
YES  NO   
If no, please explain why not: 
 
e. Are medicine and supplies stored appropriately so they do not go off or expire 
before they reach the intended beneficiaries?  
YES  NO  DON’T KNOW  
 
If no, please explain why not? 
 
 
 
3. Data collection 
a. Do you have data on the children and young people supported through the LFAC 
programme?  
YES  NO   
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b. Does this data include:  
Yes No 
Age   
Sex (male/female)   
Address/Village   
Education   
Diabetes Management and Control   
Diabetes Complications   
Other medical conditions   
Other (please specify)…        
 
c. Do you fill in an LFAC data sheet for each child each year?  
 
YES  NO   
 
d. Do you have data that can be used to understand the diabetes-related health 
status, including morbidity and mortality of participants: 
Yes No 
When they start the LFAC programme   
During the LFAC programme   
At the end when they leave the LFAC 
programme (at 26 years old) 
  
After they have left the LFAC programme   
 
e. Is this data shared with LFAC?  
YES  NO   
 
f. Has the LFAC programme in your country had an impact on data collection on 
Type 1 Diabetes in children and young people?  
 
YES  NO   
 
4. Training 
a. Has LFAC provided training for any of the following:  
 Yes No Don’t know 
Health Professional    
Children/Young People    
Families    
Others (please specify)  
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b. If yes, has the training improved any of the following: 
 Yes No Don’t 
know 
Clinical services     
Changes to insulin regimes    
Patient outcomes    
Improved HbA1c    
Patients’ self-help/management of their own conditions    
Patients’ better glucose control    
Reduction in severe episodes such as DKA requiring 
hospitalization 
   
Reduced mortality from diabetes in children and young people    
Increase in regular reviews to prevent complications e.g. eye 
examinations, foot examinations 
   
A reduction in complications    
Delays in onset of complications    
Wider awareness of diabetes    
Yours or other partners (e.g. health professionals) skills in 
advocacy1/lobbying for support from the government 
   
Others: (please specify)      
 
 
Please give examples:  
 
                                                             
1 Advocacy includes speaking out publicly in support of people living with Type 1 Diabetes to 
promote or support change (for example in government policy). 
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c. Do you think there is a need for more training for any of the below? 
 
 Yes No 
Health Professionals    
Patients   
Families   
Others   
 
Please briefly describe what type of additional training is needed: 
 
 
 
d. Does your country have National diabetes care guidelines accessible to all 
primary care clinicians? 
YES  NO  DON’T KNOW  
 
 
5. Impact of LFAC  
a. Has the LFAC programme improved any of the following for children and 
young people with Type 1 Diabetes:  
 
 Yes No Don’t 
know 
Numbers being correctly 
diagnosed 
 
 
 
 
 
 
Diabetes management and 
control 
 
 
 
 
 
 
Wider geographical coverage in 
diagnosis, treatment and care 
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Staff training  
 
 
 
 
 
General awareness in the wider 
population about Type 1 
Diabetes 
 
 
 
 
 
 
Other (please 
specify) 
 
      
 
If yes to any above, please give brief examples of how it has improved?:  
 
b. In your opinion, please describe what difference (negative and positive) LFAC has 
made in your country towards the care and treatment of children and young people 
living with Type 1 Diabetes? 
 
6. Strategy and Operations 
 
a. Who initiated discussions about receiving LFAC support in your country? 
(Please check one box) 
 
 
National Diabetes Organization 
 
 
Senior Medical Professionals  
 
Ministry of Health  
 
Patient(s) with Type 1 Diabetes  
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Other (please specify)  
      
 
 
b. Who was involved in establishing the LFAC programme in your country  
(please check all appropriate boxes)  
 
 
National Diabetes Organization 
 
 
Senior Medical Professionals  
 
Ministry of Health  
 
Patient(s) with Type 1 Diabetes or their families  
 
Other (please specify)  
      
 
 
c. Was the LFAC programme design based on a formal assessment of need?  
YES  NO  DON’T KNOW  
If yes, please explain briefly how it was done.  
 
d.  Does your organization have a formal written agreement with your 
government on the provision of Type 1 Diabetes care and management 
in children and young people? 
YES  NO  DON’T KNOW  
 
If yes, please send a copy to LFACsurvey@lshtm.ac.uk 
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e. What impact do import taxes and customs duties and procedures have 
on LFAC programmes in your country?  
 
 Yes No Don’t know 
Taxes and duties have to be paid  
 
 
 
 
 
Delays in delivery of medicines 
and supplies 
 
 
 
 
 
 
Medicines and supplies going 
out of date 
 
 
 
 
 
 
Other (please specify)   
      
 
f. If yes to any of the above, how can this be improved? Please describe 
briefly. 
 
 
g. How do you rate your working relationship with LFAC? 
 Please check box 
Excellent  
 
Good  
 
Average  
 
Poor  
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h. How could this be improved? Please describe briefly.  
 
 
i. Could the care and treatment of children and young people with 
diabetes provided by LFAC programme be better integrated into national 
health services in your country?  
YES  NO   
 
If yes, please describe in what way? 
 
7. Sustainability/long term impact/advocacy 
 
a. How long do you expect LFAC to continue to support treatment and care 
for children and young people with Type 1 Diabetes in your country?  
(Please click and choose from the drop-down menu) 
 
One year 
b. When do you expect your government to take over this responsibility? 
(Please click and choose from the drop-down menu) 
 
One year  
  If more than 10 years what is needed for the government to take over 
sooner?  
c. Which of the following has LFAC supported in your country? 
Awareness raising in the community / Information campaigns on 
Type 1 Diabetes 
YES  NO  DON’T KNOW  
   If yes, 
how?  
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Advocacy with government to raise diabetes higher on the policy 
agenda in the country 
YES  NO  DON’T KNOW  
   If yes, 
how?  
 
Advocacy with civil society, professional organizations or others to 
raise diabetes higher on the policy agenda in the country 
YES  NO  DON’T KNOW  
If yes, 
how? 
 
 
Encouraging government to take on the responsibility of care for its 
own Type 1 Diabetes patients  
YES  NO  DON’T KNOW  
If yes, 
how? 
 
 
 
Vocational training for children and young people to be able to be 
self-sufficient in managing their diabetes after leaving the 
programme  
YES  NO  DON’T KNOW  
If yes, 
how? 
 
 
 
Work with pharmaceutical companies to provide medicines and 
supplies for Type 1 Diabetes at reduced costs  
YES  NO  DON’T KNOW  
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If yes, 
how? 
 
 
Research on Type 1 Diabetes in your country  
YES  NO  DON’T KNOW  
If yes, 
how? 
 
 
 
 
d. Has LFAC made a difference to the government’s prioritization of 
providing care to people with Type 1 Diabetes?  
YES  NO  DON’T KNOW  
e. Has LFAC ever participated in conversations about diabetes-related 
policy and health budgeting with relevant health decision-makers in your 
country? 
YES  NO  DON’T KNOW  
f. What do you think LFAC could do to help the government take over 
responsibility for treating these children? 
g. Do you work in partnership with other countries, providing or 
exchanging support or training? 
       YES  NO   
  If yes, please describe:  
h. Would you welcome a country to country peer support programme / like 
to work with other countries?  
      
      
Other, please specify:       
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YES  NO   
8. After LFAC 
a. When young people leave the LFAC programme at 26 years old, what support do 
they receive in terms of insulin, glucose testing, medical care and diabetes 
check-ups and from whom?  
 Support? From whom? Does young person 
have to pay? 
Yes No Yes No 
Insulin           
Glucose testing           
Medical care           
Diabetes check -ups           
 
b. Please briefly describe the main issues facing people more than (>) 26 years old 
when they leave the LFAC programme.  
c. Has LFAC prepared you to support people with Type 1 Diabetes after the age of 
26? 
YES  NO   
If yes, how?  
Do you have any other comments on the LFAC programme in your country? 
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Appendix 8b Survey questions/frameworks (5) used on country visits 
for particular groups of interviewees.  
1.  Questions for Ministry of Health staff  
 
Date: 
Name: 
Position: 
Interviewers: 
 
                  1.What are the overall funding mechanisms for health care in your 
country? 
2 What are your priorities in terms of health spending? 
3 Funding for diabetes 
a. Does the Ministry of Health have funds for the treatment and 
care of Type 1 Diabetes? If so, how much? If not, why not? 
b. Does the Ministry of Health receive funds from donors for Type 1 
Diabetes? If so how much and from whom? 
c. How are these funds used? 
d. Do you get diabetes care/ support from other national or 
international organizations? If yes, please list names and briefly 
describe what and how they get support 
4 Prevalence of Diabetes type 1 in your country 
a. Do you know how many people have Type 1 Diabetes in your 
country? If yes, how many? 
b. Do you know how many children and young people (YP) have 
Type 1 Diabetes? 
c. Do you have national guidelines for Type 1 Diabetes? If yes, could 
we see them? If not, why not? 
d. In what ways do you support people with Type 1 Diabetes? 
5 Knowledge and opinion of the LFAC programme 
a. What do you know about the Life For A Child programme? 
b. What is your opinion of the presence of LFAC’s support for 
children and YP in your country? (positive and negative) 
6 Impact of LFAC programme 
a. What impact has the LFAC support had on the geographical 
coverage of children and young people’s diabetes care in 
your country?  
b. What impact has LFAC had on the number of children being 
correctly diagnosed?  
c. What impact has LFAC had on the numbers of children getting 
the medical support they need compared to before?  
d. What impact has LFAC had on the numbers of staff being trained 
in diabetes care?  
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e. Is the LFAC support and equipment enough to reach all children 
and youth with Type 1 Diabetes? If no, please describe what 
there is additional need for? 
 
f. How would children and young people access treatment and care 
for Type 1 Diabetes if LFAC was not there? 
7 Sustainability  
a. Has LFAC helped the development of long-term sustainable 
improvements to T1D care delivery systems in your country?  
i. Yes 
ii. No 
iii. Partly 
iv. Not sure 
If yes, how? If no, why not? 
b. How do you think sustainability of Type 1 diabetes care can be 
improved? 
8 Influence on health budgeting, policy and advocacy  
Has LFAC engaged with you in policy and advocacy discussions at the 
national level? If so, please describe what the discussions were about and if 
there was any result.  
9 What are the main challenges facing children and young people < 
26 years old with diabetes in your country today and in the future? 
10 When participants leave the LFAC programme at 26 years old, do 
they get any support from the government?  
i. If yes, sometimes or partly please explain how this works: 
ii. If no, please briefly describe any main issues facing young 
people when they leave the programme.  
11 What additional support do you think would best help you improve 
the care and treatment of children and young people with Type 1 
diabetes in your country? 
12 Do you have any other comments on the LFAC Type 1 Diabetes 
support programme in your country? 
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2. Questions for Experts/Volunteers  
 
 
Name: 
Title/Position: 
Organization: 
Date: 
Interviewer: 
 
***************************************************************************** 
INTRODUCTION 
1. What do you know about the LFAC programme? 
2. What have you done for LFAC? 
3. How did you come to partner with LFAC? (where relevant) 
4. Where have you volunteered with LFAC? (where relevant) 
 
A: LFAC ORGANIZATIONAL STRUCTURE 
5. What do you think about the LFAC programme? (service delivery, partnering with 
local diabetes associations, use of volunteers etc.) 
 
6. What are LFAC’s strengths and weaknesses? 
 
 
B: OPTIMAL STRATEGIC FRAMEWORK 
7. Currently LFAC’s approach is wide and shallow (many countries, limited 
engagement) rather than narrow and deep. Is this the right strategy to take?  
 
8. Do you think the delivery of LFAC programmes Is adequately integrated into 
national health systems? How could this be improved?  
 
9. Are there other models that you know of that provide support, care and treatment 
for people with Type 1 Diabetes that are more effective? If so, what and have they 
been evaluated? 
 
 
10. What do you think about LFAC’s close relationship with pharmaceutical companies? 
What impact do you think that has on their programmes? 
 
 
C: CHANGES TO POLICIES THAT COULD IMPROVE QUALITY, QUANTITY, 
EFFECTIVENESS OR EFFICIENCY 
 
11. LFAC relies on volunteer experts to conduct site visits and trainings and serve as 
mentors. How effective and sustainable is this? Is this enough? 
12. How does LFAC train/prepare volunteers to ensure consistency in appropriate 
clinical standards?  
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D: IMPACTS ON COUNTRIES, SYSTEMS AND CHILDREN 
 
13. Has LFAC’s presence in partner countries led to the ability to collect more accurate 
incidence/prevalence data for T1D in these countries? If so, where and how? 
14. What impact has LFAC had on the organization of youth diabetes care and the 
geographical extent of care in the countries supported? 
 
E: LONG TERM SUSTAINABILITY 
 
15. How does LFAC catalyse long term sustainable improvements in T1D care delivery 
systems? How can LFAC make its programmes more sustainable? 
16.  Has LFAC made a difference in governments’ prioritization of providing care to 
people with T1D? If yes, please give examples.  
17. How does LFAC engage in policy and advocacy discussion at national level? Could 
this be improved? How? 
18. How effective is LFAC in influencing national decisions and or policies on care and 
treatment for children and young people with Type 1 diabetes? If yes how? If no, 
how could this be improved? 
19. Do you think LFAC should move towards integrating more into national health 
systems and priorities (e.g. NCD or complex, chronic care programmes)? If so, why? 
If not,why not? 
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3. Questions for Partner Organizations  
 
Name: 
Title: 
Organization: 
Date: 
Interviewer: 
 
***************************************************************************** 
 
A. Programmes in country 
 
1. What does your organization do here re T1 Diabetes care?  
2. How long have you worked here? 
3. Who do you work with? (government, National NGO, regional networks, other 
countries etc.) 
B. LFAC 
 
1. Have you heard of Life for a Child?  
If yes, what do you know about it?  
2. Do you partner with Life for a Child? If yes, how? 
3. What are the pros and cons of Life for a Child? 
4. How can Life for a Child be improved? 
5. How do you coordinate your activities with those of Life for a Child and other 
organizations providing care and treatment for patients with Type 1 Diabetes? 
6. How could this be improved? 
7. How sustainable is the Life for a Child model?  
8. How effective is LFAC in influencing national decisions and or policies on care 
and treatment for children and young people with Type 1 diabetes? If yes how? 
If no, how could this be improved? 
9. How soon do you think the government can take over the responsibility of 
providing care and treatment for children and young people with T1D? 
 
10. What steps could be taken to improve long-term sustainability of diabetes care 
and treatment? 
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4. Questions for Children and Families  
 
Date:  
Name: 
Male/female: (delete as appropriate) 
Age: 
Name of village/town/city: 
Interviewer: 
******************************************************* 
 
1. How old were you/was your child when first diagnosed?  
 
2. Had you heard about diabetes before you/your child was diagnosed? 
 
3. Have you/your child had any complications from your diabetes? If so, 
what? 
 
4. What is the hardest thing about living with diabetes? 
 
5. How does diabetes affect your everyday life? 
(e.g. schooling, family, work, visit friends, others) 
 
6. What support do you currently receive? 
From whom? (e.g. LFAC) 
 
7. Do you have to pay for any Diabetes medicines or treatment?  
If yes, how much? (indicate cost next to relevant item on list) 
 
 Free of charge? (Yes or 
No) 
Cost 
Insulin   
blood glucose monitor    
blood glucose test strips   
Syringes   
education sessions   
health checks   
8. How often do you/your child go to the clinic?  
9. Is anything stopping you/your child going to the clinic? If yes, what? (Use 
prompts below as guide) 
- travel distance/time 
- travel cost 
- cost of attending clinic 
o fee  
o loss of earnings 
- other? 
10. When did you have your last medical visit to check your diabetes?  
11. What did they check? 
e.g. HbA1c, weight, height, feet, vision, urine, blood, blood pressure  
 
12. Where do you get your insulin? 
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13. Do you ever have difficulties in getting insulin? If yes, what? 
 
14. Where do you store your insulin?  
 
15. Do you/your child always take your insulin when you need to? If no why 
not? 
 
16. Do you test your /your child’s glucose levels? If yes, how many times a day? 
If not, why not? 
 
17. Do you have enough syringes and glucose test strips to manage your 
diabetes? 
 
18. Where and how have you found out more about Diabetes? 
 
19. Are you in contact with other young people who have Diabetes? If yes, is 
this helpful? If not, would you like to be?  
 
20. If there were three things that could help you manage your diabetes better, 
what would they be? 
 
a. _________________________________________________________________ 
 
b. _________________________________________________________________ 
 
c. _________________________________________________________________ 
 
21. Have you had any help on how you will look after yourself and manage 
your diabetes when you turn 26? If yes, what? 
 
22. Do you have any other comments on your diabetes care and support 
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5.  Questions for health centers/clinics  
 
 
Name: __________________________________________________________________ 
Clinic/Health Centre: ______________________________________________________ 
Location: ________________________________________________________________ 
Interviewer: _____________________________________________________________ 
Date: ___________________________ 
 
  
1.     Children and young people reached 
a.  How many children and young people (YP) with Type 1 Diabetes are 
registered with your centre/clinic? ______ 
 
b. How many of these have you seen/supported in the past year? _________ 
c. Please briefly describe what type of care and support you provide? 
 
d. How many of the children and YP that you see live in the city, and how many 
live in more remote, rural areas? City:_______________ Remote/rural 
areas:______________ 
 
e. How do you reach and provide support to children in more remote areas / 
rural areas?  
 
f. What kind of support do you receive from the LFAC programme? Please tick 
the relevant option and say what percentage this is of the total: 
i. Insulin       _____% 
ii.  Blood glucose monitoring (meters and strips)  _____% 
iii. Syringes       _____% 
iv. HbA1C testing equipment     _____% 
v. Educational materials for children/families  _____% 
vi. Training of health professionals     _____% 
vii. Other: _____________________________________    _____% 
 
g. Is this support enough?    Yes   No 
h. If no, please describe what else you need (use list below as prompts) 
i. Insulin 
ii.  Blood glucose monitoring equipment (meters and strips) 
iii. Syringes 
iv. HbA1C testing equipment 
v. Educational materials for children/families 
vi. Training for children and families  
vii. Other: ______________________________________________________ 
 
i. Do you get support from any other national or international organizations re 
diabetes care and treatment? If yes, please state which organizations and 
briefly describe what support they provide. 
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j. Please describe any difficulties experienced in reaching and supporting 
children and young people with Type 1 Diabetes (<26 years old)? Please 
consider both urban and rural areas.  
 
2. Procurement and supply 
a. Do any children or YP with Type 1 diabetes have to pay for their own 
treatment?   
Yes  No  Don’t know 
 
b. If yes, please describe (For what? How much?): 
 
c. Does the government provide any medical supplies or other support to 
children and YP with Type 1 Diabetes?      
   
 Yes  No  Don’t know 
d. If yes, please list what: 
 
e. How is your health centre/clinic supplied with (who from and how?):  
i. Insulin 
ii. Syringes 
iii. Bloody glucose monitoring (meters and strips) 
iv. HbA1C testing equipment 
v. Educational materials 
vi. Training for children and families 
vii. Specialist diabetes training for health professionals 
 
f. Since LFAC started its programme, has any aspect of government provision 
of Type 1 diabetes support to children and young people changed?  
Yes   No Don’t know 
 
g. If yes, how has it changed? 
 
3. Data collection 
a. Do you collect data on the children and young people (<26 years old) 
supported through the LFAC programme?  Yes No Don’t know  
 
b. Does this data include basic data such as;  
i. Age      Yes  No 
ii. Sex (Male/Female)    Yes  No 
iii. Address/village     Yes  No 
iv. Education     Yes  No 
v. Diabetes management and control  Yes  No 
vi. Diabetes complications    Yes  No 
vii. Other medical conditions    Yes  No 
 
c. Is the data used to monitor progress and risk of complications in:  
i. Individual children?    Yes  No  
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ii. Groups?      Yes  No 
 
d. Is this data shared with LFAC? Yes No  
 
e. Has the LFAC programme in your country had an impact on data collection 
on Type 1 Diabetes in children and young people? Yes   No  Don’t know 
 
f.  Do you continue to see the same patients once they are over 26 years old 
and no longer supported by LFAC?   Yes   No  Don’t know 
 
g. If yes, do you continue to record data on morbidity and mortality on all 
diabetes patients? Yes   No  Don’t know 
  
4. Training 
 
a. Have you received any training from LFAC? Yes No Don’t know 
If yes, please describe type of training received and who it was for? 
What has been the impact of the training? (Use prompts below as a guide) 
i. clinical services  
ii. changes to insulin regimes 
iii. patient outcomes 
iv. improved HbA1c 
v. patients self-help/management of their own conditions 
vi. better glucose control 
vii. reduction in severe episodes such as DKA requiring hospitalization 
viii. reduced mortality from diabetes in children and young people 
ix. increase in regular reviews to prevent complications e.g. eye 
examinations, foot examinations 
x. a reduction in complications 
b. Is there a need for more training? Yes  No Don’t know 
If yes, briefly describe what type of training is needed and for whom? 
 
5. Impact of LFAC 
a. Has the LFAC programme improved any of the following for children and 
young people with Type 1 Diabetes? Prompt: 
i. Numbers correctly diagnosed: 
ii. Diabetes management and control: 
iii. Wider geographical coverage in diagnosis, treatment and care: 
iv. Staff training:  
v. General awareness of diabetes in the wider populations about Type 
1 Diabetes: 
vi. Other? 
If yes, please give brief examples of how it has improved? 
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b. In your opinion, what difference (positive and negative) LFAC has made 
towards the care and treatment of children and young people living with 
Type 1 Diabetes? 
6. Sustainability/ long term impact  
a. Has LFAC helped the development of long-term sustainable improvements to 
Type 1 Diabetes care for children and young people?   Yes  No 
 Don’t know 
b.  If yes, please describe briefly how? 
c. How long do you expect LFAC to continue to support treatment and care for 
children and young people with Type 1 Diabetes in your country? 
One year/Three years/Fives years/Ten years or more 
d. When do you expect the government to take over this responsibility? 
One year/Three years/Fives years/Ten years/Not in the foreseeable future 
 
7. After LFAC 
a. When young people leave the LFAC programme at 26 years old, what 
support do they receive in terms of insulin, glucose testing, medical care and 
diabetes check-ups and from whom?    
b. If yes, is this free of charge or is there a cost to the individual?  
c. Please briefly describe the main issues facing young people >26 years old 
when they leave the LFAC programme: 
d. Do you have any other comments on the LFAC programme in your country? 
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Appendix 9 Consent form 
London School of Hygiene and Tropical Medicine 
(University of London) 
 
 
 
15-17 Tavistock Place 
London WC1H 9SH             Switchboard: +44 (0) 20  7636 8636 
 
 
European Centre on Health of Societies in Transition  Tel:+44 (0)20  7927 
2229 
Professor Martin McKee CBE MB BCh MD MSc DSc FRCP FRCPI FRCPE FFPH 
FMedSci  
        E-mail:martin.mckee@lshtm.ac.uk 
 
 
Dear colleague, 
This is a questionnaire survey aimed at evaluating the Life for a Child’s (LFAC) 
support for children and young people with Type 1 Diabetes Mellitus. This 
include its impact on health systems and policies as well as the children and 
young people supported through the programme. This survey is being 
undertaken by the London School of Hygiene and Tropical Medicine, at the 
request of the Leona M. and Harry B. Helmsley Charitable Trust, one of the main 
supporters of LFAC. The survey will be sent to all countries that LFAC support. 
The goal of the evaluation is to support LFAC as it goes forward, ensuring that it 
is sustainable in the long term and is able to respond to changing needs. Taking 
part in the evaluation is entirely voluntary. Your comments will be confidential 
and will not be attributed to you in the final report or presentations unless you 
agree to being quoted. We might include the name of your organizations in a list 
in the final report. If you don’t want the name of your organization to appear in 
the final list, please let us know. Your contributions are much appreciated and 
can help inform improvements for the future.  
 
Please contact Dr. Louise Sigfrid on e-mail: louise.sigfrid@lshtm.ac.uk if you have 
any further questions. 
Yours sincerely, 
 
 
Professor Martin McKee 
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Evaluation of Life for a Child Programme 
            
 
1. I confirm that I have read and understand the information about this evaluation 
given to me in writing or in person. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to not answer 
all the questions or withdraw at any time without giving any reason. 
 
3. I understand that the information given by me, may be used in future reports, 
articles or presentations. This information will be anonymous unless I have agreed to 
being quoted. 
 
4. I understand that my name or the name of my organization will be included as a 
general list of people interviewed in reports, articles or presentations.  
 
5. If you do not want your name to appear in the general list please tick this box:  
 
6. I give permission for photographs taken of me and my family to be used for 
reports, presentations, publications and on the London School of Hygiene and 
Tropical Medicine website for the purpose of presenting the results from this 
evaluation:  
 
7. I agree to take part in the above evaluation. 
 
 
 
 
_______________________________________ _________ 
Name of Participant  Date  
 
Organization_____________________________ 
 
 
Signature________________________________ 
 
 
 
_________________________ ________________ ________________ 
Interviewer Date  Signature 
 
 
  
EXPENDITURE AND IN-KIND SUPPORT IN 2014 (in USD) 
 
Total Cash Expenditure      $1,412,134 
 
Made up of:  
 Direct country support     $992,579 (70.3%) 
 Program Development, Monitoring and Administration $419,555 (29.7%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In-Kind support 
Insulin     $3,156,230  
Blood glucose meters and strips  $2,986,566 
Syringes    $236,600 
Other     $7,500 
Total     $6,386,896 
 
Leverage of funds expended to total (including in-kind) $7,779,030 to $1,412,134 = 5.5 : 1. 
 
Camps (Diabetes), $9,256, 1%
Research, $46,937, 5%
Diabetes Education, $51,320, 
5%
HbA1c, $211,941, 21%
Insulin, $157,542, 16%
Strips & Meters, $406,237, 41%
Other Overseas Support, 
$71,319, 7%
Syringes, $9,328, 1%
Training and Assessments, 
$28,698, 3%
Direct country support
(992,579 USD)
“Other Overseas Support “ 
consists of 
 In country coordination 
and transport 
 Customs clearances 
 Vocational training 
 Equipment 
 Direct patient assistance 
 Complications screening 
 Capacity building 
 Other - various 
Approximately 80% of insulin cost 
was warehousing and shipping 
Approximately 20% of strips & meters cost 
was warehousing and shipping 
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